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L ist  of A bbreviations
ADP adenosine diphosphate
ATP adenosine triphosphate
BN blue native
bp base pair
BLAST basic local alignment search tool
cDNA complementary DNA
CI -  CV complex I -  complex V
CoQ coenzyme Q or ubiquinone
CO(X) cytochrome c oxidase
CS citrate synthase
CSF cerebrospinal fluid
cyt cytochrome
DNA deoxyribonucleic acid
dNTP deoxynucleoside triphosphate
ECG electrocardiogram
EEG electroencephalogram
EST expressed sequence tag
FCS fetal calf serum
gDNA genomic DNA
GDP guanosine diphosphate
GTP guanosine triphosphate
HSP heavy strand promoter / hereditary spastic paraplegia / 
heat shock protein
IGA in-gel activity
kDa kilo Dalton
LSP light strand promoter
LSU large subunit
MELAS mitochondrial myopathy, encephalopathy, 
lactic acidosis and stroke-like episodes
MERRF myoclonic epilepsy with ragged-red fibers
MLASA mitochondrial myopathy and sideroblastic anemia
MLPA multiplex ligation-dependent probe amplification
MRI magnetic resonance imaging
mRNA messenger RNA
MRP mitochondrial ribosomal protein
mt mitochondrial
mtDNA mitochondrial DNA
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List of abbreviations
NAD(H) nicotinamide adenine dinucleotide (reduced)
ND NADH dehydrogenase or NADH CoQ oxidoreductase
nDNA nuclear DNA
NTP nucleoside triphosphate
ORF open reading frame
OXPHOS oxidative phosphorylation
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCR polymerase chain reaction
PSI-BLAST position specific iterative BLAST
RNA ribonucleic acid
RP ribosomal protein
rRNA ribosomal RNA
RT-PCR reverse transcriptase PCR
SD standard deviation
SDS sodium dodecyl sulphate
SNP single nucleotide polymorphism
SSU small subunit
TIM translocase of the inner mitochondrial membrane
TOM translocase of the outer mitochondrial membrane
tRNA transfer RNA
VEP visual evoked potential
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If you want to see a rainbow, you 
have got to put up with the rain. 
Dolly Parton
C hapter  1
General introduction and outline 
of this thesis
H
Energy is fundamental to life. For all our actions, from running to sleeping, and for 
the myriad of processes occurring in and outside our cells every second, energy 
is required. This energy is derived from food, mainly from carbohydrates and fat, 
and is generated in the form of adenosine triphosphate (ATP) during the following 
processes: glycolysis (i.e., the breakdown of glucose into pyruvate), the Krebs 
or citric acid cycle (i.e., breakdown of acetyl coenzyme A, which is synthesized 
from pyruvate, fatty acids or in lesser amounts from amino acids), and oxidative 
phosphorylation (Figure 1). Glycolysis takes place in the cell's cytoplasm, also in the 
absence of oxygen, whereas both the Krebs cycle and oxidative phosphorylation 
are aerobic processes occurring in the mitochondrion. Oxidative phosphorylation 
is by far the largest contributor to the ATP supply.
M it o c h o n d r ia
Mitochondria, often called the powerhouses of the cell, are semiautonomous 
organelles present in varying numbers per cell, depending on the tissue type: 
from zero mitochondria in red blood cells to over a thousand in cells with high 
energy demands. Mitochondrial morphology ranges from small bean-shaped 
structures to highly branched tubular networks due to constant remodeling by 
fusion and fission. Reminiscent of its endosymbiotic origin, i.e., that it evolved 
from a bacterium that was engulfed by a host cell over a billion years ago, the 
mitochondrion is surrounded by a double membrane and has its own, circular 
genome. The outer mitochondrial membrane separates the cytosol of the cell from 
the intermembrane space, and the highly invaginated inner membrane envelops 
the mitochondrial matrix, which contains the mitochondrial genome and enzymes 
of the Krebs cycle, among others. Most genes from the prokaryotic genome have 
been lost or have been transferred to the nucleus of the eukaryotic cell during 
evolution. In human cells, nearly all genes that are required for mitochondrial 
functioning reside in the nuclear genome (nDNA); mitochondrial DNA (mtDNA) 
merely contains 37 genes, coding for rRNAs, tRNAs and several constituents of 
the oxidative phosphorylation (OXPHOS) system.
OXPHOS SYSTEM
The respiratory or electron transport chain is composed of four enzymatic 
complexes and two electron carriers, ubiquinone and cytochrome c, and together 
with a fifth complex it makes up the OXPHOS system (Figure 1).1 The five 
complexes of the OXPHOS system are multiprotein structures, consisting of 89 
proteins in total, and constitute the only metabolic pathway that is under dual 
genetic control. The OXPHOS system is embedded in the inner mitochondrial 
membrane and executes the final biochemical steps in energy production. NADH
B  Chapter 1
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and succinate, produced during glycolysis, fatty acid oxidation and the Krebs cycle, 
are oxidized by complex I and complex II, respectively, of the OXPHOS system. The 
hereby liberated electrons are transferred via the electron carriers and complex
III to complex IV, where they are delivered to the final electron acceptor oxygen, 
reducing it to water. The energy released during electron transport is utilized 
by complexes I, III and IV to translocate protons across the mitochondrial inner 
membrane, generating an electrochemical proton gradient. This gradient serves 
as the driving force for the backflow of protons from the intermembrane space to 
the matrix compartment via complex V, ATP synthase. Complex V harnesses the 
free energy to phosphorylate ADP, using inorganic phosphate (Pi), to form ATP.
CYTOSOL
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Figure 1. The mitochondrial oxidative phosphorylation system. Schematic representation of oxidative 
phosphorylation and other metabolic processes, adapted from ref. 2. Thick arrows represent the 
direction of electron movement and dotted arrows indicate the proton flux. For each OXPHOS 
complex, the number of subunits encoded by the nDNA or mtDNA is depicted at the top. The 
import complexes needed for translocation of nDNA-encoded proteins across the outer and inner 
mitochondrial membranes are not shown. Abbreviations: OMM, outer mitochondrial membrane; IS, 
intermembrane space; IMM, inner mitochondrial membrane; CI-V, complex I-V; Ub, ubiquinone; CytC, 
cytochrome c.
M it o c h o n d r ia l  d is o r d e r s
Due to the mitochondrion's central role in cell metabolism, impairment in 
mitochondrial function is associated with a wide range of human disorders. 
The term 'mitochondrial disorder' generally refers to diseases resulting from 
defects in the OXPHOS system, which constitute the majority of disorders caused
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by mitochondrial dysfunction. Since the first description of a patient suffering 
from a mitochondrial disorder by Luft et al in 1962,3 mitochondrial disorders 
have turned out to be the most frequent group of inborn errors of metabolism 
with an estimated incidence of 1 in 5000 live births.4 Because of the complexity 
of the OXPHOS system -  i.e., its bigenomic control, its structural organization 
and difference herein between tissues -  and its intricate regulation, defects in 
a multitude of structures involved in OXPHOS system functioning can lead to 
disorders with extremely heterogeneous clinical manifestations.5,6 Mitochondrial 
diseases vary in their age of onset (from birth to adulthood), course (from static 
to rapidly progressive), and number and type of tissues affected (from any single 
organ to multisystemic). Typically, multiple tissues with high energy demands 
such as brain, skeletal muscle and heart are involved and although symptoms 
can be mild, children commonly show a severe and progressive phenotype that 
often leads to early death. Furthermore, similar clinical manifestations can be 
caused by distinct genetic and biochemical defects and, conversely, the exact 
same mutation or OXPHOS disturbance can result in different symptomatology 
in different patients. The myriad of phenotypes and the fact that no single clinical 
feature is specific complicates clinical diagnosis of mitochondrial disorders. 
Also treatment is a challenge since no cure has been found as yet, except for 
specific cases such as ubiquinone (coenzyme Q) supplementation in ubiquinone 
biosynthesis defects.7,8 Until research into new therapeutic strategies -  some of 
them quite promising -  bear fruit, symptom relief is the only hope for the majority 
of patients. Fortunately, various symptomatic treatment options are available 
and can be very effective. Preventing mitochondrial disorders through genetic 
counseling and prenatal diagnosis is particularly important given the lack of a 
cure. Due to the dual genetic origin (nDNA and mtDNA) of the OXPHOS system, 
autosomal recessive and dominant, X-linked and maternal modes of inheritance 
can occur, in addition to sporadic (de novo) mutations. Prenatal diagnosis is 
largely based on biochemical measurements, which are reliable in only a limited 
number of cases.9 With the progress in our understanding of the molecular bases 
of mitochondrial disease, more specific and accurate prenatal diagnosis at the 
molecular level should become increasingly feasible.
O b j e c t iv e s , a p p r o a c h  a n d  o u t l in e  o f  t h is  t h e s is
Despite substantial advances in elucidation of the genes and pathogenic 
mechanisms responsible for mitochondrial disorders,10,11 in the majority of patients 
the genetic defect cannot be identified. Consequently, further research into the 
genetic origin of mitochondrial disease is called for. Biochemically, mitochondrial 
defects are classified based on the enzyme(s) affected and whether one or more 
OXPHOS complexes are involved -  isolated or combined deficiencies, respectively.
Ü  Chapter 1
14
General introduction and outline of this thesis
Nearly 30% of all OXPHOS deficiencies in fresh muscle biopsies analyzed at the 
Nijmegen Center for Mitochondrial Disorders consist of combined deficiencies.12 
Whenever de activities of multiple enzymes are diminished, the molecular cause is 
not likely to be found in genes encoding building blocks of the OXPHOS system. 
In these cases, the defect is suspected to affect processes indirectly involved 
in the formation of the OXPHOS system: mtDNA maintenance, mitochondrial 
transcription or translation including posttranscriptional or -translational 
processes, transport of proteins across mitochondrial membranes, mitochondrial 
membrane biogenesis, and assembly of the OXPHOS system.
The main objective of the research presented in this thesis was to 
expand our knowledge of the underlying molecular causes of combined OXPHOS 
system defects. We focused our investigations on deficiencies of complexes I, III 
and IV, aiming to find novel nuclear gene defects. To date, numerous mutations 
associated with combined OXPHOS deficiencies have been reported, most in 
mtDNA but the number of nDNA mutations is increasing rapidly, yet many cases 
remain unresolved. Gaining more insight into the localization of the genetic 
defects in such patients will not only contribute to a thorough understanding of 
the OXPHOS system and processes related to its functioning, but will also improve 
possibilities of pre- and postnatal diagnosis and hopefully therapy in the future.
The general approach that was used in the present study is the following. 
First of all, patients with decreased enzyme activities of the complexes I, III and IV 
in fibroblasts and/or muscle tissue were included in the study. Normal complex II 
activity was a prerequisite for selection. This is because our research was primarily 
directed toward discovering molecular causes of mitochondrial translation defects 
and complex II, being composed of subunits encoded solely by the nuclear 
genome, should not be affected by impairments in mitochondrial translation. The 
activity of complex V was often not known and therefore not included as a criterion. 
Secondly, mutations in the mtDNA were excluded by sequencing the entire 
mitochondrial genome in fibroblast DNA of the 33 patients who were selected. 
Subsequently, nuclear genes were screened for mutations: 1) genes known to be 
implicated in combined complex I, III and IV deficiencies, namely genes coding 
for polymerase gamma, mitochondrial translation factors mtEFTs, mtEFTu and 
mtEFG1, and mitochondrial ribosomal proteins (MRPs) MRPS16 and MRPS22; 2) 
candidate genes for combined OXPHOS defects, namely genes encoding the 6 
remaining mitochondrial translation factors, 7 more MRPs, 2 potential mtDNA 
maintenance proteins, mitochondrial inner membrane transport protein OXA1L, 
and 7 mitochondrial transcription factors. Additionally, the rate of mitochondrial 
protein synthesis was determined in 18 out of a total of 33 patients. The results 
were used either to direct mutational analysis or to indicate the pathogenicity of 
a mutation. Furthermore, homozygosity mapping was performed for 7 patients.
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This aided in the detection of the genetic defect in 1 patient (see chapter 8), but 
was uninformative in the other cases because of the lack of DNA from family 
members, resulting in large homozygous regions and consequently still many 
candidate genes.
Due to the multitude of proteins (in)directly involved in mitochondrial 
translation in particular and the biogenesis of the OXPHOS system in general, 
selection of genes for mutational screening in patients with combined OXPHOS 
deficiencies is not an easy task. Chapter 2 of this thesis gives an overview of 
mitochondrial protein synthesis and other processes required for a functional 
OXPHOS system, highlighting proteins involved in the biogenesis or maintenance 
of multiple OXPHOS complexes and implicated in mitochondrial disorders. 
MtDNA sequencing in our patient cohort revealed two novel mitochondrial tRNA 
mutations responsible for progressive multisystemic diseases. These mutations 
and their functional consequences are described in chapter 3. The next two 
chapters deal with mutations in the nuclear genes coding for mitochondrial 
translation elongation factors mtEFTs (chapter 4) and mtEFG1 (chapter 5). 
These studies emphasize the heterogeneity and complexity of mitochondrial 
disorders. Chapter 4 reports a striking difference in clinical presentation of an 
identical genetic defect in two unrelated patients, and chapter 5 demonstrates 
the importance of a thorough biochemical analysis of fibroblasts in addition 
to muscle tissue as OXPHOS enzyme deficiencies are not always manifested 
in muscle tissue. Chapter 4 concerns a different patient cohort than the one 
described above; assistance was provided in the research during a traineeship 
and in the publication during the current PhD. In chapter 6, we investigated the 
evolution of the mitochondrial ribosomal proteome in a diverse set of eukaryotic 
species using extensive homology searches with the aim to 1) gain insight into 
the evolutionary history of MRPs and 2) aid prioritization of MRPs as candidates 
for their involvement in combined OXPHOS defects. This comparative genomics 
analysis revealed two new human MRPs. These two MRPs, together with two 
other candidate genes that were selected based on their potential function in 
mtDNA maintenance, were screened for mutations in our group of patients with 
OXPHOS complex I, III and IV deficiencies. Chapter 7 contains the results of 
this study, i.e. many non-pathogenic sequence variations. The second mutation 
in MRPS22 and its pathogenic role in the patient's mitochondrial disorder is 
reported in chapter 8. This finding underscores that candidate genes should not 
be prioritized based solely on their evolutionary conservation because proteins 
lacking bacterial homologs, such as MRPS22, have been shown to be implicated 
in mitochondrial disorders. Finally, chapter 9 reflects on all results obtained and 
discusses directions for future research with respect to combined complex I, III 
and IV OXPHOS deficiencies.
Ü  Chapter 1
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A b s t r a c t
Mitochondrial disorders are a heterogeneous group of often multi-systemic and 
early fatal diseases, which are amongst the most common inherited human diseases. 
These disorders are caused by defects in the oxidative phosphorylation (OXPHOS) 
system, which comprises five multi-subunit enzyme complexes encoded by both 
the nuclear and the mitochondrial genomes. Due to the multitude of proteins and 
intricacy of the processes required for a properly functioning OXPHOS system, 
identifying the genetic defect that underlies an OXPHOS deficiency is not an 
easy task, especially in the case of combined OXPHOS defects. In the present 
communication we give an extensive overview of the proteins and processes 
(in)directly involved in mitochondrial translation and the biogenesis of the 
OXPHOS system and their roles in combined OXPHOS deficiencies. This knowledge 
is important for further research into the genetic causes, with the ultimate goal 
to effectively prevent and cure these complex and often devastating disorders.
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1. I n t r o d u c t io n
Mitochondria are essential organelles that are present in virtually all eukaryotic 
cells. They originated from an ancestral alpha-proteobacterial endosymbiont.1 
The primary function of the mitochondrion is ATP production via the oxidative 
phosphorylation (OXPHOS) pathway. Additionally, mitochondria have been 
found to perform crucial roles in many other metabolic, regulatory and 
developmental processes. Mitochondrial dysfunction can therefore result 
in a variety of diseases, including common multi-factorial disorders such 
as diabetes23 and Parkinson's disease.4 Furthermore, mitochondria are 
implicated in the normal aging process.5,6 The term mitochondrial disorder 
usually refers to diseases that are caused by disturbances in the OXPHOS 
system. This is a heterogeneous group of often multisystemic and early fatal 
diseases, which are amongst the most common inherited human diseases.7
The OXPHOS system is embedded in the mitochondrial inner membrane and 
consists of five multiprotein enzyme complexes (I-V) and two electron carriers.8 
The main function of the system is the coordinated transport of electrons and 
protons, resulting in the production of ATP. The great complexity of the OXPHOS 
system, which comprises almost 90 proteins encoded by both the nuclear and the 
mitochondrial genomes, explains the heterogeneity in clinical phenotypes that 
are associated with genetic defects in oxidative phosphorylation. Approximately 
67% of the OXPHOS disorders diagnosed at our centre consist of isolated enzyme 
deficiencies, whereas in 33% of the cases multiple enzyme complexes show 
lowered activities.9 Due to the dual genetic control, the defect can be located 
on the nuclear (n) as well as the mitochondrial (mt) DNA. Isolated OXPHOS 
deficiencies are generally caused by mutations in structural genes (encoding 
subunits of the OXPHOS system) or in genes encoding proteins involved 
in the assembly of a specific OXPHOS enzyme complex.1011 For combined 
deficiencies the situation is more complicated. Most mutations associated with 
combined OXPHOS defects have been reported in mtDNA-encoded transfer 
(t) and ribosomal (r) RNAs.12 Additionally, nDNA-encoded proteins required for 
the replication and integrity of mtDNA, such as polymerase y  and thymidine 
kinase, are implicated in combined deficiencies.13 Recently, mutations in nine 
different nuclear gene products involved in mitochondrial protein synthesis 
were reported: elongation factors mtEFG1, mtEFTs and mtEFTu, small ribosomal 
subunit proteins MRPS16 and MRPS22, aspartyl- and arginyl-tRNA synthetases, 
and tRNA-modifying enzymes PUS1 and TRMU.14-25 These findings defined a new 
class of gene defects underlying combined OXPHOS disorders. In general, when 
multiple OXPHOS enzymes are affected, the genetic defect is presumed not to 
be located in genes encoding OXPHOS subunits, but rather in genes needed for
Chapter
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mtDNA maintenance, mitochondrial transcription or translation including post- 
transcriptional or -translational processes, import of nDNA-encoded proteins into 
the mitochondrion or mitochondrial membrane biogenesis. Given the number of 
proteins involved in these processes, a comprehensive overview of the processes 
and proteins that could be implicated in combined OXPHOS deficiencies is 
important for further research into the cause of these complex diseases.
This review will focus on the mammalian mitochondrial translation and its 
role in mitochondrial disorders. However, other processes implicated in combined 
OXPHOS deficiencies, in particular combined OXPHOS deficiencies with normal 
complex II activities, and indirectly related to mitochondrial translation will also 
be outlined. We will first describe which processes are required before protein 
synthesis can take place in the mammalian mitochondrion and which components 
are needed for these processes. Second, the current state of knowledge of the 
mitochondrial translation machinery and the mechanism of translation, including 
regulation and functions of translation factors beyond protein synthesis, will 
be discussed. Third, we will cover post-translational processes with a functional 
OXPHOS system as end result. Fourth, we will give a non-exhaustive overview of 
the mutations that have been reported to impair mitochondrial protein synthesis 
and result in OXPHOS deficiencies. And finally, prospects of research into the 
pathogenesis of mitochondrial disorders will be mentioned.
2. R e q u ire m e n ts  b e fo re  m ito c h o n d r ia l  t r a n s la t io n  c a n  ta k e  p lace
For translation in the mitochondrion to be able to take place, a number of 
conditions have to be fulfilled. First of all, mtDNA has to be present, maintained, 
replicated and transcribed. Additionally, nuclear-encoded proteins required for 
the proper functioning of the mitochondrion have to be imported from the cell 
cytoplasm. These processes will now be discussed successively. Figure 1 gives 
an overview of the major processes (in)directly involved in the biogenesis of the 
OXPHOS system and covered in this review.
2.1. Human mtDNA
The mitochondrial genome is a double-stranded, circular molecule of 16,659 base 
pairs. It is a highly compact genome that lacks introns and contains only one 
major non-coding region (the displacement or D-loop) and 37 genes, which code 
for 22 tRNAs, 2 rRNAs and 13 polypeptide subunits of the OXPHOS complexes I, 
III, IV and V.26 These genes are located on both strands of the mtDNA molecule, 
the heavy (H) and light (L) strand. MtDNA has a mutation rate 10-20 times that of 
nDNA,27-29 which is thought to be caused by the lack of protective histones, slightly 
limited DNA repair and proximity to damaging reactive oxygen species (ROS)
22
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generated at the inner membrane. The unique features of mitochondrial genetics 
are essential for understanding the etiology and pathogenesis of mitochondrial 
disorders:30 (a) mtDNA is maternally inherited; (b) cells typically contain hundreds 
of mitochondria and thousands of mtDNA molecules (polyplasmy); (c) mutations 
can affect all mtDNA copies in an individual (homoplasmy) or only some copies 
resulting in the coexistence of two or more mtDNA genotypes within a single 
cell, organ or individual (heteroplasmy); (d) in case of heteroplasmy, a minimum 
percentage of mutated mtDNAs has to be present in a cell for the OXPHOS system 
to malfunction (threshold effect) and this threshold level varies widely between 
different tissues; (e) during mitosis both normal and mutant mtDNA are randomly 
distributed to the daughter cells, which can result in changing mutational loads 
during the life of the patient and different mutational loads in different cells and 
tissues (mitotic segregation).
Figure 1. Schematic overview of the processes involved in mitochondrial translation and the 
biogenesis of the OXPHOS system. Before translation can take place in the mitochondrion, the mtDNA 
needs to be maintained, replicated and transcribed and numerous nDNA-encoded proteins have to 
be imported into the mitochondrion for these processes and for mitochondrial translation itself (see 
Figure 2 for more details on mitochondrial translation and its components depicted here). For the 
formation of the OXPHOS system, the nDNA- and mtDNA-encoded subunits need to be synthesized, 
imported, inserted into the inner membrane and assembled into enzyme complexes. The 13 mRNAs 
depicted refer to 9 monocistronic and 2 dicistronic transcripts. Proteins implicated in mitochondrial 
disorders are mentioned in brackets (also see Table 1). C I-CV = complex I-V  of the OXPHOS system; 
TIM and TOM = translocase of the inner and outer mitochondrial membranes.
MRPS16+S22, PUS1, TRMU, DARS2, RARS2)
Mt translation (mtEFG1, mtEFTs, mtEFTu,
MtDNA transcription
Mt protein processing and quality control (SPG7)
(TAZ, OPA1, MFN2, DNM1L)
(TYMP, RRM2B)
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2.2. Maintenance and replication of mtDNA
Unlike nDNA, which replicates only once during cell division, mtDNA is continuously 
replicated, independent of the cell cycle and also in non-dividing cells such as 
skeletal muscle fibers and central neurons.31 Replication is generally thought to 
take place via a strand-asynchronous mechanism involving two unidirectional, 
independent origins.3233 Synthesis starts at the origin of H-strand replication 
(OH) in the D-loop and proceeds along the parental L-strand to produce a full 
daughter H-strand. When the second origin (OL) at two-thirds of the way around 
the genome is reached, DNA synthesis of the L-strand initiates in the opposite 
direction. Recently, however, a bidirectional mode of mtDNA replication has been 
proposed.3435 This second mechanism involves a coupled leading- and lagging- 
strand synthesis and is reported to exist along with the strand-asynchronous 
mechanism.
MtDNA replication is achieved by a number of nuclear-encoded proteins. 
First of all, the only DNA polymerase present in mammalian mitochondria: 
polymerase y. Polymerase y is a heterotrimer consisting of a catalytic subunit 
with proof-reading ability (POLG) and two identical accessory subunits (POLG2) 
that bind DNA and increase the processivity of POLG. Second, Twinkle is a 5' 
to 3' DNA helicase that unwinds double-stranded mtDNA and thereby plays a 
role in mtDNA maintenance and regulation of mtDNA copy number. Third, the 
mitochondrial single-stranded binding protein (mtSSB) is thought to maintain the 
integrity of single-stranded regions of DNA at replication forks and to stimulate 
the activity of Twinkle and polymerase y. Additionally, several topoisomerases 
regulate supercoiling of mtDNA. Furthermore, mtDNA ligase III is involved in 
replication as well as repair of the mitochondrial genome. For replication initiation, 
RNA primers are needed. An as yet unidentified mtDNA primase likely provides 
the RNA primer for L-strand synthesis, whereas the mitochondrial transcription 
machinery is involved in RNA primer formation for H-strand synthesis (see 
Section 2.3). RNase mitochondrial RNA processing endonuclease (RNase MRP) 
and endonuclease G are implicated in processing of the precursor RNA primers 
for H-strand replication. Last, RNase H1 has been proposed to be involved in 
replication of the mitochondrial genome by removal of the RNA primers. Ligase 
III, RNase MRP and RNase H1 are not specific mitochondrial proteins; they are 
also located in the cell nucleus. For a more detailed description of mitochondrial 
replication see a review by Graziewicz et al.36
Furthermore, various other proteins are indirectly involved in the maintenance 
of mtDNA either through protecting the mitochondrial genome, repairing mtDNA 
damage, or supplying nucleotide pools. Firstly, the protection of the mitochondrial 
genome. MtDNA is packaged into protein-DNA complexes called nucleoids, 
which are believed to be the units of mtDNA transmission and inheritance.37,38
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Among the nucleoid components are proteins involved in the maintenance, 
replication and/or transcription of mtDNA, such as mtSSB, Twinkle, POLG and 
TFAM (mitochondrial transcription factor A). Secondly, mtDNA repair is crucial to 
avoid accumulation of damage to the rapidly replicating mitochondrial genome. 
Mitochondria possess multiple repair mechanisms, but these are beyond the 
scope of this review (detailed descriptions of mtDNA repair have been published 
previously).3940 Thirdly, a proper balance of the mitochondrial (deoxy)nucleoside 
triphosphate ((d)NTP) pools, accomplished by mitochondrial transport proteins and 
salvage pathway enzymes, is also essential for mtDNA maintenance and replication 
(for an overview of mitochondrial dNTP metabolism and all proteins involved see 
reference 41). Shortage and/or imbalance of the dNTP pool could affect the efficiency 
and accuracy of mitochondrial replication. Additionally, disturbances of the NTP 
pool may interfere with replication by affecting the synthesis of the RNA primers 
necessary for replication initiation. This could subsequently lead to deletions in the 
mtDNA or depletion (i.e., reduced copy number) of the mitochondrial genome. A 
number of mitochondrial disorders are caused by defects in the mitochondrial dNTP 
metabolism due to mutations in the following nine nuclear genes: DGUOK, TK2, 
TYMP, SLC25A4, SLC25A3, SUCLG1, SUCLA2, RRM2B, and MPV17 (for reviews see 
references134243).Mitochondrial deoxyguanosine kinase (DGUOK) and thymidine 
kinase (TK2) catalyze the first step in the salvage pathways of pyrimidine and 
purine deoxynucleosides, respectively. In the salvage pathway, deoxynucleosides 
are activated by stepwise phosphorylation leading to formation of the dNTPs. The 
cytoplasmic enzyme thymidine phosphorylase (TYMP) catalyzes the reversible 
phosphorylation of thymidine and thereby regulates the availability of thymidine 
for DNA synthesis. Additionally, adenine nucleotide translocators (ANT) are 
needed to regulate the concentration of adenine nucleotides by exchanging ATP 
for ADP in and out of the mitochondrial matrix; SLC25A4 (ANT1) is the heart and 
skeletal muscle specific isoform. The mitochondrial phosphate carrier SLC25A3 
transports inorganic phosphate into the mitochondrial matrix. SUCLG1 and 
SUCLA2 encode the a- and ß-subunits of the Krebs cycle enzyme succinate-CoA 
ligase (SUCL). Defects in these genes could lead to mtDNA depletion through 
decreased activity of the mitochondrial nucleotide diphosphate kinase (NDPK), 
which functions in the last step of the mitochondrial dNTP salvage pathway and 
associates with SUCL. The p53R2 subunit (encoded by RRM2B) of the cytosolic 
enzyme ribonucleotide reductase is required for de novo deoxyribonucleotide 
synthesis in nonproliferating cells, thereby supplying dNTPs for nDNA repair and 
mtDNA synthesis. Finally, the mitochondrial inner membrane protein MPV17 
is also involved in dNTP metabolism, with defects causing mtDNA depletion; 
the exact function of MPV17 remains to be elucidated, however. In addition 
to disturbed homeostasis of mitochondrial dNTP pools, mtDNA instability can
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naturally be caused by mutations in genes affecting mtDNA replication directly. 
Mutations have been reported in POLG, POLG2, and C10orf2 (Twinkle), with POLG 
being the most important contributor.13
2.3. Transcription of m tDnA
Transcription originates from three promoters: two H strand promoters (HSP1 
and HSP2) and one L strand promoter (LSP). The HSP1 and LSP are located in the 
D-loop, whereas HSP2 is located downstream of HSP1 close to the 5' end of the 
12S rRNA gene. Transcription from both the HSP2 and LSP generates polycistronic 
molecules covering nearly the entire H or L strand, corresponding to 12 protein- 
coding genes, 14 tRNA genes and 2 rRNA genes (HSP2) or 1 protein-coding gene 
and 8 tRNA genes (LSP). Additionally, transcription from the LSP produces the RNA 
primers necessary for initiating mtDNA replication of the H-strand. Transcripts 
derived from HSP1, on the other hand, contain mainly the 12S and 16S rRNAs. The 
basic human mitochondrial transcription machinery consists of three components: 
mtRNA polymerase (POLRMT), TFAM and either mitochondrial transcription factor 
B1 (TFB1M) or B2 (TFB2M). Promoter recognition and transcription initiation require 
the simultaneous presence of these three factors, however, the precise contribution 
of each has not yet been fully determined.4445 Termination of transcription appears 
to be regulated by multiple termination factors, but the exact mechanism and 
all factors involved still need to be elucidated.4546 Termination sites have been 
identified for transcription from HSP1 and HSP2; the two proteins binding to 
the HSP2 termination site await identification. Even though the mitochondrial 
transcription termination factor MTERF1 (or MTERF) has been shown to bind the 
HSP1 termination site (at the 3' end of the 16S rRNA gene) and be required for 
HSP1 transcription termination in vitro, it seems to block L strand transcription 
more effectively than transcription from the H strand; the precise function of 
the protein in vivo is unclear. Recently, MTERF1 was found to be essential for 
transcription initiation in vitro, which led to the hypothesis that MTERF1 regulates 
and promotes transcription at HSP1 by forming a loop between the MTERF1 
initiation and termination binding sites. This way it helps favor a higher synthesis 
rate of rRNAs compared to mRNAs from the H strand. Furthermore, MTERF1 
appears to modulate mtDNA replication pausing; its dual role could be important 
for coordination of replication and transcription.47 Three homologs of MTERF1 
and thus potential mitochondrial transcription termination factors have been 
identified: MTERF2 (or MTERFD3 or MTERFL), MTERF3 (or MTERFD1) and MTERF4 
(or MTERFD2).48 MTERF2 is proposed to regulate cell growth through modulation 
of mitochondrial transcription.49 MTERF2 shows the opposite expression pattern 
in response to serum compared to MTERF1, suggesting that they have divergent 
roles. Additionally, MTERF2 was found to be present in nucleoids, displaying non
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sequence-specific DNA-binding activity.50 Contrastingly, Wenz et al demonstrated 
specific binding of MTERF2 to the HSP promoter region.51 Furthermore, MTERF2 
knock-out resulted in decreased mitochondrial transcription and mRNA levels. 
MTERF3, on the other hand, has been shown in mouse in vivo and in human in vitro 
to function as a negative regulator of transcription initiation through interaction 
with the mtDNA promoter region.52 Moreover, MTERF3 knock-down in Drosophila 
led to a decreased rate of mitochondrial protein synthesis, possibly through down- 
regulation of TFB1M (see Section 3.3 for more information on TFB1M's function in 
translation).4653 In summary, the current view is as follows: MTERF1 through 3 share 
a common binding site in the D-loop; both MTERF1 and 2 promote transcription 
initiation, whereas MTERF3 inhibits it; all three factors are needed to maintain 
optimal transcript levels and thereby ensure proper functioning of the OXPHOS 
system. The role of MTERF4 has not been investigated in detail, however, it appears 
to bind mtDNA in the D-loop region and form a stable homodimer with a putative 
RNA methyltransferase.54
Processing of the polycistronic primary transcripts is thought to require four 
enzymes. The tRNA genes mark most of the junctions between mitochondrial 
protein-coding and rRNA genes. According to the tRNA punctuation model, 
the secondary structures of the tRNA sequences provide the signals for 
endonucleolytic excision of the tRNAs, yielding most of the tRNAs, mRNAs and 
rRNAs.55 This initial processing step is performed by the mitochondrial RNase 
P (5'-end endonucleolytic cleavage) and tRNase Z (3'-end cleavage) enzymes. 
Maturation of the excised tRNAs is completed by addition of a CCA triplet to 
their 3'-end, which is catalyzed by an ATP(CTP):tRNA nucleotidyltransferase. After 
post-transcriptional modification and correct folding of the tRNAs, the amino 
acid can be attached to the CCA triplet by the corresponding aminoacyl-tRNA 
synthetase. The tRNA acceptor stem and the anticodon play important roles for 
the recognition of the tRNA by the appropriate synthetase. During or immediately 
after cleavage of the tRNAs, the rRNAs and mRNAs are polyadenylated by a 
mitochondrial poly(A) polymerase. This post-transcriptional modification creates 
the stop codons for some mRNAs and may also be necessary for stabilization of 
some RNAs (for a review see Montoya et al).56 In this way, 9 monocistronic and 2 
dicistronic mRNA transcripts are formed. Another important post-transcriptional 
process is RNA degradation, which is required to control RNA levels and 
eliminate processing by-products and aberrant transcripts.57 Nevertheless, the 
players involved and the exact mechanism have yet to be revealed. SUV3 and 
polynucleotide phosphorylase are possible candidates.5859
Until now, no mutations causing mitochondrial disease have been reported in 
genes coding for proteins involved in mitochondrial transcription. Nonetheless, a 
mutation in the MTERF1 binding site (in the tRNALeu(UUR) gene) is associated with the
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mitochondrial disorder MELAS (mitochondrial myopathy, encephalopathy, lactic 
acidosis and stroke-like episodes). This mutation reduces the binding affinity for 
MTERF1 and results in a drastic impairment of transcription termination in vitro, 
however, in vivo the transcription termination defect could not be confirmed.6061 
Furthermore, TFB1M modifies the phenotypic expression of the deafness- 
associated 1555A>G mtDNA mutation (see Section 3.3). Additionally, post- 
transcriptional modification of tRNAs is disturbed in patients with mitochondrial 
myopathy and sideroblastic anemia (MLASA) due to a mutation in pseudouridylate 
synthase PUS1.1417 PUS1 converts uridine into pseudouridine in cytosolic as well 
as mitochondrial tRNAs. Recently, mutations in TRMU, a mitochondria-specific 
enzyme that is required for the 2-thiolation on the wobble position of the tRNA 
anticodon, were detected in patients with acute liver failure in infancy.24 Previously, 
TRMU was identified as another nuclear modifier gene for the mitochondrial 12S 
rRNA mutation 1555A>G.62 See Section 5.2 for more details on defects in the 
latter two genes.
2.4. Import of nDnA encoded proteins
Most mitochondrial proteins, including all proteins involved in mitochondrial 
translation, are encoded in the nucleus and therefore have to be transported 
to and imported into the mitochondrion. Cytosolic chaperones, such as heat 
shock proteins Hsp70 and Hsp90, guide the precursor proteins to translocation 
channel receptors on the mitochondrial surface, keep the proteins unfolded 
to prevent aggregation and enable entrance into the translocation channels. 
Alternatively, preproteins seem also to be imported into mitochondria in a co- 
translational manner.63-67 These proteins, produced on ribosomes bound to the 
outer mitochondrial membrane, are almost exclusively of prokaryotic origin.6869 
The cytoplasmic and mitochondrial translation machineries are suggested to 
be localized in close proximity on either side of the mitochondrial membranes, 
thereby allowing efficient assembly of the OXPHOS system.70 Import and sorting 
of nDNA-encoded proteins into mitochondria is achieved by translocases in 
the outer and inner mitochondrial membrane.71,72 The translocase of the outer 
mitochondrial membrane (TOM complex) forms the entrance for basically 
all nuclear-encoded mitochondrial proteins. After passing through the TOM 
complex, the preproteins can follow various routes depending on their targeting 
signals: (1) outer membrane proteins are integrated into the membrane by 
the sorting and assembly machinery (SAM complex); (2) translocation to the 
intermembrane space is mediated by the TIM23 complex (translocase of the inner 
mitochondrial membrane) or by components in the intermembrane space; (3) 
matrix proteins reach their destination through the TIM23 channel; (4) for inner 
membrane proteins there are three pathways, (a) insertion by the TIM22 complex,
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(b) lateral integration after arrest at the TIM23 complex, and (c) import into the 
matrix via TIM23 followed by export to the inner membrane (see Section 4.2 
for more information on the export to the inner membrane). After translocation, 
mitochondrial targeting sequences are removed proteolytically and the proteins 
fold into their functional structures.
Two syndromes have been related to defects in mitochondrial import. 
Mutations in the gene for the translocase subunit TIMM8A (or DDP1) have 
been reported to result in the deafness dystonia syndrome or Mohr-Tranebjaerg 
syndrome (MTS).7374 TIMM8A is part of a small alternative TIM complex that is 
involved in the import of TIMM23, an essential constituent of the TIM23 complex, 
and a few other proteins.71 Remarkably, no impairment of the OXPHOS system 
has been observed.7375 The exact mechanism by which TIMM8A mutations 
affect mitochondrial function remains to be clarified. Dilated cardiomyopathy 
with ataxia (DCMA) is caused by a mutation in DNAJC19, which is thought to 
be a homolog of yeast Tim14.76 Tim14 is an essential component of the TIM23 
complex,77 suggesting that the underlying disease mechanism is defective import 
of nDNA-encoded proteins into the mitochondrion. However, this has not been 
verified yet.
3 . M it o c h o n d r ia l  t r a n s l a t io n
Although most of the proteins present in mitochondria are encoded by the 
nDNA, a few are encoded by the mtDNA and are synthesized by the separate 
mitochondrial translation system. The human mitochondrial genome codes 
for 22 tRNAs, 2 rRNAs and 13 polypeptide subunits of the enzyme complexes 
I, III, IV and V.26 Whereas the components and mechanisms of translation are 
well characterized for bacterial and eukaryotic cytoplasmic systems, far less is 
known about mitochondrial protein synthesis due to the lack of a proper in vitro 
mitochondrial translation system. For a review on mammalian mitochondrial 
protein synthesis, insertion and disorders associated with these processes see 
Pérez-Martínez et al.78
The mitochondrial translation more closely resembles its prokaryotic than its 
eukaryotic cytoplasmic counterpart. However, the protein-synthesizing system 
of mitochondria has a number of interesting characteristics not observed in 
prokaryotes or the eukaryotic cell cytoplasm. First of all, mitochondria use a 
genetic code that has several distinct differences from the universal code.79 For 
example, human mitochondria use the universal arginine codons AGG and AGA, in 
addition to UAA and UAG, for termination. Furthermore, UGA serves as a codon for 
tryptophan rather than as a stop codon. Additionally, AUA has been reassigned to 
Met rather than serving as an Ile codon. Secondly, also the mitochondrial mRNAs 
have unusual features: they contain no or very few 5' untranslated nucleotides,80
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are uncapped,81 and contain a poly(A) tail that immediately follows or even 
forms part of the stop codon.55 The small subunit of mitochondrial ribosomes 
(mitoribosomes) appears to bind these mRNAs tightly in a sequence-independent 
manner and in the absence of initiation factors or initiation tRNA,82 unlike the 
prokaryotic83 and eukaryotic cytoplasmic84 systems. Thirdly, mitochondria use a 
simplified decoding mechanism that allows translation of all codons with only 
22 tRNAs instead of the 31 predicted by Crick's wobble hypothesis.2685 Fourthly, 
mammalian mitochondria use a single tRNAMet for both the initiation and 
elongation phases (depending on the presence or absence of a formyl group, 
resp.), whereas not only in the prokaryotic and eukaryotic cytoplasmic translation 
systems but also in the mitochondria of most lower eukaryotes two specialized 
tRNAMet species exist.86
In this section, we will cover in subsequent paragraphs the components of 
the protein synthesis machinery, the translation process steps, its regulation, and 
additional roles of mitochondrial translation proteins outside the translation process.
3.1. The mitochondrial translation machinery
The basic mitochondrial translation machinery comprises mtDNA-encoded 
rRNAs and tRNAs as well as many proteins coded for by the nuclear genome: 
(1) initiation, elongation and termination translation factors; (2) mitochondrial 
ribosomal proteins (MRPs); (3) mitochondrial aminoacyl-tRNA synthetases and 
methionyl-tRNA transformylase. These components will be described in more 
detail successively.
First of all, the translation factors. The exact functions of the mitochondrial 
translation factors will be discussed in Section 3.2. Bacterial translation initiation 
involves three factors: IF1, IF2, and IF3. Whereas IF1 and IF2 are considered to 
be universal and essential initiation factors, IF3 orthologs have not been found 
in archaea or the cytoplasm of eukaryotes.87,88 Surprisingly, the mitochondrial 
translation machinery consists of two initiation factors orthologous to prokaryotic 
IF289 and IF390 and despite extensive searches, no IF1 ortholog has been detected.91 
Recently, mitochondrial IF2 (mtIF2) was demonstrated to perform functions of 
both bacterial IF1 and IF2; a conserved 37 amino acid insertion in mtIF2 seems 
to have assumed the role of IF1, facilitating the bond between mtIF2 and the 
mitoribosome and the formation of the initiation complex.92 All three prokaryotic 
elongation factors have also been found in human mitochondria: mtEFTu, mtEFTs 
and mtEFG.93-95 In contrast to most bacteria, which have merely one EFG protein 
that acts during both the elongation and termination phases of the translation 
process, mitochondria contain two EFG homologs, mtEFG1 and mtEFG2,93 that are 
35% identical.91 The importance of mtEFG1 for mitochondrial protein synthesis 
has been demonstrated by mtEFG1 defects in patients with a mitochondrial
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disorder152225 and its translocation activity was shown in vitro.96 Even though 
expression levels of mtEFG2 are greatest in skeletal muscle, heart and liver,93 
three tissues with high metabolic energy rates, the functional significance of 
mtEFG2 for mitochondrial translation is not entirely clear. Notably, deletion of 
the mtEFG2 ortholog in yeast (MEF2) does not lead to impaired mitochondrial 
protein synthesis and respiratory defects, as is the case for MEF1, the mtEFG1 
yeast ortholog.97 Moreover, complementation of mtEFG1 defects through 
overexpression of mtEFG2 could not be attained,1525 indicating that mtEFG2 
might not play a role in the translocation step of mitochondrial translation. 
This was recently confirmed by Tsuboi et al, who demonstrated that mtEFG1 
specifically catalyzes translocation, whereas mtEFG2 has an essential function 
in ribosome recycling and lacks translocation activity.98 Thus the dual role of 
prokaryotic EFG is distributed between mtEFG1 and mtEFG2. Bacteria contain four 
factors responsible for translation termination: the three release factors RF1-3 
and the ribosome recycling factor RRF.99 The release factors are divided into two 
classes, with class I factors (RF1 and RF2) promoting codon-specific hydrolysis 
of peptidyl-tRNA and class II factors (RF3) lacking specificity but stimulating the 
activity of class I factors and their dissociation from the ribosome. Bacteria utilize 
three stop codons; both class I release factors recognize UAA, whereas UAG and 
UGA are decoded only by RF1 or RF2, respectively. In the eukaryotic cytosol two 
release factors, RF1 and RF3 orthologs, are required for the termination step with 
just one class I factor recognizing all three stop codons.100 A factor equivalent to 
bacterial RRF appears to be absent. The termination process in mitochondria, 
on the other hand, has not yet been fully elucidated. Two release factors, mtRF1 
and mtRF1a (or HMRF1L), and a recycling factor (mtRRF) have been identified 
and partly characterized.101-104 Being involved in ribosome recycling instead of the 
elongation phase, mtEFG2 should be added to this list and be renamed mtRRF2.96 
MtRF1 was proposed to be a member of the class I release factors based on 
bioinformatic analyses,103 but recently this factor failed to exhibit release factor 
activity in vitro and in vivo.101102 Nonetheless, the newly identified release factor 
mtRF1a was shown to terminate translation at UAA and UAG codons, analogous 
to bacterial RF1. Thus the question whether a mitochondrial release factor exists 
that recognizes the other two mitochondrial stop codons, AGG and AGA, which 
are found in just two of the mitochondrial transcripts, remains unresolved. The 
fact that release activity was not observed for mtRF1 could be attributed to the 
use of bacterial and yeast systems that naturally do not terminate with these 
codons.102 Therefore, the possibility remains that mtRF1 is indeed a mitochondrial 
release factor. Alternatively, AGA and AGG might not be used as stop codons 
since there is no experimental data supporting this and remarkably, in rat and 
mouse mitochondria the codons AGA and AGG are unassigned and UAA appears
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to be the single stop codon utilized.105106 The terminal AGA and AGG codons 
could be edited post-transcriptionally, creating UAG stop codons, which could 
then be decoded by mtRF1a.101 Whether mitochondria contain a class II factor 
equivalent to bacterial RF3 is unclear.
Secondly, the mitoribosomes that are made up of rRNAs and MRPs and 
comprise two subunits, the small (SSU or 28S) and the large (LSU or 39S) subunit. 
The human mitoribosome consists of 2 rRNAs (12S and 16S) and around 81 
MRPs.107 Mammalian mitoribosomes differ markedly from bacterial, cytosolic and 
even from other mitochondrial ribosomes.108 They lack nearly half the rRNA present 
in bacterial ribosomes, resulting in a sedimentation coefficient of 55S compared 
with 70S in bacteria. Nevertheless, mitoribosomes contain a correspondingly higher 
protein content due to enlargement of proteins and recruitment of numerous extra 
proteins, causing a greater molecular mass and size than bacterial ribosomes. Most 
of these enlarged and supernumerary proteins do not seem to compensate for the 
missing rRNA segments since they occupy new positions in the mitoribosome,109 
suggesting that they perform mitochondria-specific functions.
Third, the mitochondrial tRNAs. In general, human mitochondrial tRNAs 
deviate from the canonical tRNAs, but still fold into mostly classical cloverleaf 
secondary structures and presumably also into L-shaped tertiary structures.110 
Mitochondrial tRNAs are shorter than bacterial or eukaryotic cytoplasmic tRNAs, 
have large variations in the size of the D- and T-loops, and lack multiple conserved 
nucleotides that are involved in classical tertiary interactions creating the L-shape, 
which possibly results in a weaker tertiary structure. Post-transcriptional base 
modification appears to be more important for the proper tertiary structure and 
functioning of mitochondrial tRNAs compared with cytosolic tRNAs.111 Certain 
mitochondrial tRNAs will consequently be completely non-functional when they 
lack the post-transcriptional modification resulting in an aberrant structure.112 
Furthermore, modifications can improve tRNA specificity and its recognition 
by mRNA codons and to a lesser extent by aminoacyl-tRNA synthetases.113114 
In total, 19 mitochondrial aminoacyl-tRNA synthetases have been identified, of 
which two are encoded by the same gene as the cytosolic enzyme.115 Only the 
gene for mitochondrial glutaminyl-tRNA synthetase has not been found yet. 
After aminoacylation, the tRNAMet needs to be formylated by methionyl-tRNA 
transformylase to initiate mitochondrial translation.
Although the core components of the mitochondrial translation machinery 
have been identified, many more factors are likely to be involved, directly 
or indirectly, and have yet to be discovered. Recently, Davies et al showed 
that pentatricopeptide repeat domain protein 3 (PTCD3) associates with the 
mitoribosomal SSU and is necessary for mitochondrial protein synthesis.116 The 
precise function of PTCD3 remains to be clarified, however.
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3.2. The mitochondrial translation process
The basic model of protein synthesis is derived from studies in bacteria (see 
references87,99 117 for reviews on the processes involved in protein synthesis). Our 
understanding of the mechanisms of mitochondrial translation is based on this 
model and additional studies in mitochondria.
Protein synthesis is divided into three phases: initiation, elongation 
and termination. The exact starting mechanism of the translation process 
in mitochondria is poorly understood. Due to the unusual characteristics of 
mitochondrial mRNAs, neither the Shine-Dalgarno sequence observed in 
prokaryotes nor the 7-methylguanlyate cap structure found in the eukaryotic cell 
cytoplasm can facilitate ribosome binding and direct the ribosome to the start 
codon. It is thought that the mRNA entry gate on the SSU of the mitoribosome has 
evolved in such way that it recognizes the unique mitochondrial mRNAs with their 
unstructured 5' sequences.109118 Many questions remain concerning the precise 
sequence of events during the initiation phase in mammalian mitochondria. In the 
current model, mitochondrial translation factor mtIF3 catalyzes the dissociation 
of the mitoribosome into its two component subunits (Figure 2, step 1), which 
may be an active rather than a passive process, thereby permitting the assembly 
of the initiation complex while preventing premature binding of the LSU.90119 
Possibly, complete subunit dissociation is not essential for initiation of translation, 
however, the subunit interface must become accessible for fMet-tRNAMet and 
mRNA binding. It has been postulated that the first step in initiation complex 
formation is sequence-independent binding of mRNA to the SSU (Figure 2, step 
2).82120 MtIF3 is thought to assist the mRNA to bind the SSU so that the start 
codon (AUG) is correctly positioned at the peptidyl (P) site of the mitoribosome. 
Both fMet-tRNA and mtIF2 can bind weakly to the SSU in the absence of mRNA 
and mtIF3 is hypothesized to prevent or correct the premature binding of these 
components.119 The binding of fMet-tRNAMet to the SSU requires mtIF2, which is 
markedly enhanced by GTP (Figure 2, step 3).121122 Recombining of the LSU with 
the SSU (Figure 2, step 4) probably stimulates the dissociation of mtIF3 (Figure 2, 
step 5).123 Additionally, GTP hydrolysis on mtIF2 is triggered by the LSU, leading 
to its release from the complex (Figure 2, step 6). The initiation phase is now 
complete and translation can proceed with the elongation phase.
The basic steps in the elongation phase are the same in bacteria and 
mitochondria, however, the equilibrium dissociation constants for interactions 
between mtEFTu and its ligands differ considerably between the prokaryotic 
and mitochondrial systems.124,125 The relative ratios of the elongation factors 
are important for efficient translation.21,25 126 These ratios differ between tissues 
and can be adapted in response to dysfunction of one of the elongation 
factors.25 Elongation factor mtEFTu forms a ternary complex with GTP and an
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Figure 2. Diagram of human mitochondrial protein synthesis. The three phases of mitochondrial 
translation -  initiation, elongation and termination -  and all translation factors involved are represented 
in this figure. See Section 3.2 in the text for a detailed description of all steps (numbered in boxes) of 
the mitochondrial translation process. Initiation, elongation and termination factors are represented 
by green, purple and red ovals, respectively. GTP and GDP are shown in yellow and beige circles, 
respectively.
aminoacylated tRNA (Figure 2, step 7). It is proposed to be critical for translational 
accuracy through surveillance of aminoacyl-tRNAs for misacylation.127 MtEFTu 
protects the tRNA from hydrolysis and, after a proofreading step, carries it to the 
mitoribosomal aminoacyl or acceptor (A) site for the decoding of mRNA by codon- 
anticodon interactions on the SSU (Figure 2, step 10). When the codon-anticodon 
recognition occurs, GTP hydrolysis on mtEFTu is stimulated by the mitoribosome, 
resulting in the release of mtEFTu-GDP (Figure 2, step 8). The nucleotide exchange
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protein mtEFTs converts mtEFTu-GDP in active mtEFTu-GTP (Figure 2, step 9). 
Following the release from mtEFTu, the 3' end of the aminoacyl-tRNA moves 
into the peptidyl transferase center of the LSU where peptide bond formation is 
catalyzed, adding one amino acid to the growing peptide (Figure 2, step 11). The 
elongation factor mtEFG1 with bound GTP catalyzes the translocation step by 
conformational changes in both mtEFG1 and the mitoribosome, during which the 
A and P site tRNAs move to the P and exit (E) sites of the mitoribosome and mRNA 
is advanced by one codon (Figure 2, step 12). Subsequently, the tRNA leaves 
the mitoribosome via the E site (Figure 2, step 13) and a new elongation cycle 
can start (Figure 2, step 14). Whether the mitoribosome contains an actual E site 
is uncertain. The bovine mitoribosomal structure and a comparative analysis of 
ribosome sequences revealed that the mitoribosomal E site deviates substantially 
from the prokaryotic and eukaryotic cytosolic situations.109128 129 Based on these 
findings, the E site has been suggested to be very weak or even absent in the 
mitoribosome. Moreover, the mitoribosomal polypeptide exit tunnel is markedly 
different, allowing premature exposure of the nascent polypeptide to the 
mitochondrial matrix or membrane before reaching the conventional exit site.109 
Whether all or some nascent polypeptide chains emerge prematurely from the 
peculiar mitoribosomal exit tunnel is currently unknown.
The third and last step in protein synthesis, termination, begins when a stop 
codon (UAA, UAG, AGA or AGG) is encountered in the A site. A mitochondrial 
release factor, mtRF1a or possibly also mtRF1 or an as yet unidentified protein, 
recognizes the stop codon (Figure 2, step 15) and causes the protein that is 
attached to the last tRNA molecule in the P site to be released (Figure 2, step 16). 
The ester bond between the tRNA and the nascent polypeptide is hydrolyzed, 
presumably by the peptidyl transferase center on the LSU triggered by the release 
factor, and this process is catalyzed by GTP. After release of the newly synthesized 
protein, mtRRF and mtEFG2-GTP together enable the mitoribosomal subunits, 
tRNA and mRNA to dissociate from each other (Figure 2, step 17), making the 
components available for a new round of protein synthesis. GTP hydrolysis is 
required for the release of mtRRF and mtEFG2-GDP from the LSU (Figure 2, step 
18).96
3.3. Regulation of mitochondrial translation
In yeast, nuclear-encoded, gene-specific activation factors are required for 
mitochondrial translation initiation.130131 Currently, translational activation factors 
have been found for (nearly) all eight yeast mtDNA-encoded proteins and synthesis 
of some proteins, for example Cox3, depends on multiple activation factors.130-132 
These activators bind to the 5' untranslated leader (5'-UTL) sequences of the 
mRNA, probably to assist in positioning the mitoribosomes over the initiation
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codon. All translational activator proteins studied so far are integral membrane 
proteins or bound to the mitochondrial inner membrane, suggesting that they are 
also involved in tethering mitochondrial translation to the inner membrane. This 
way they can promote cotranslational insertion of newly synthesized proteins and 
subsequent assembly into the OXPHOS complexes. Thus the yeast mitochondrial 
translational activators regulate not only the levels of mitochondrially synthesized 
gene products, but also the location of mitochondrial translation.
The mechanisms of human mitochondrial translation regulation are poorly 
understood. Human mitochondrial mRNAs lack 5'-UTL sequences and until 
recently no clear evidence was found for the existence of mRNA-specific 
translation activators, which suggests that modulation of mitochondrial protein 
synthesis in humans involves other strategies than in yeast.133 Genome-wide 
linkage analysis and chromosome transfer in a patient presenting with Leigh 
syndrome due to an isolated complex IV deficiency resulted in the identification 
of a human translational activator of the complex IV subunit COXI: CCDC44 or 
TACO1.134 A homozygous base insertion, creating a premature stop codon, led 
to severely decreased levels of TACO1 in patient fibroblasts. Consequently, only 
a small amount of COXI was synthesized despite normal concentrations of the 
COXI transcript, compromising complex IV assembly and activity. Remarkably, 
deletion of the TACO1 ortholog in yeast produced no respiration or mitochondrial 
translation defect. In contrast to the human situation, TACO1 is apparently not 
essential for respiration in yeast.
Furthermore, another potential translational activator for COXI has been 
identified in humans: a member of the pentatricopeptide (PPR) family, leucine- 
rich PPR-motif containing protein (LRPPRC, also known as LRP130). The PPR 
motif has been found in proteins that interact with RNA, such as POLRMT, which 
contains two PPR motifs in the amino-terminal domain (ATD).135 LRPPRC has been 
postulated to be a homolog of Pet309,136 the yeast mitochondrial translational 
activator for COX1.137 Mutations in LRPPRC lead to the neurodegenerative disorder 
Leigh Syndrome French-Canadian type (LSFC), with a deficiency of complex IV of 
the OXPHOS system.136 LRPPRC appears to play a role in the translation and/or 
stability of COXI and COXIII mRNAs, similar to yeast Pet309.138 In addition to its 
role as translational activator, Pet309 might be involved in coupling mitochondrial 
transcription to translation through interaction with Nam1,139 a protein that is 
postulated to stabilize and direct mRNAs to the mitochondrial inner membrane 
for translation140 and that binds to the ATD of yeast mtRNA polymerase.135 
LRPPRC has been suggested to function together with heterogeneous nuclear 
ribonucleoprotein K (hnRNP K) and POLRMT in coupling the mitochondrial 
transcription and translation machineries in a manner analogous to the 
yeast system.141 However, the situation is more complex than depicted here,
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encompassing additional proteins for which homology between yeast and human 
has not been identified yet. Moreover, LRPPRC binds not only mitochondrial but 
also nuclear mRNAs, indicating that it could be involved in coordinating nuclear 
and mitochondrial gene expression.142
Nolden et al proposed a negative-feedback loop mechanism for regulation 
of mitochondrial translation.143 The ATP-dependent m-AAA protease plays an 
important role in quality control of mitochondrial inner membrane proteins. One 
of the substrates of this enzyme is the ribosomal protein MRPL32. Processing of 
MRPL32 by the m-AAA protease results in a tight association of MRPL32 with 
the inner membrane and allows completion of mitoribosome assembly in close 
proximity to the inner membrane. Maturation of MRPL32 seems to be required 
for mitochondrial translation since synthesis of mtDNA-encoded proteins 
was substantially impaired in cells lacking the m-AAA protease. Regulation of 
translation via the m-AAA protease could for instance take place when nuclear 
and mitochondrial gene expression are unbalanced. Excess respiratory subunits 
and other nonnative substrates of the m-AAA protease may then accumulate 
and compete with MRPL32 for binding to the protease. This will hamper MRPL32 
processing, ribosome assembly, and finally mitochondrial translation. Accordingly, 
the amount of respiratory subunits available to the m-AAA protease decreases 
and MRPL32 processing increases again. The importance of this regulation 
process has been demonstrated by loss-of-function mutations in paraplegin, a 
subunit of the human m-AAA protease, which result in the neurodegenerative 
disorder hereditary spastic paraplegia.144
Possibly, TFB1M and TFB2M are involved in a retrograde pathway regulating 
mitochondrial biogenesis and function.145 146 Overexpression of TFB2M resulted in 
increased TFB1M levels and consequently an increase in mitochondrial biogenesis. 
In addition to their transcriptional stimulatory activity, TFB1M and TFB2M have 
rRNA methyltransferase activity. Thus these factors are indirectly involved in 
mitochondrial protein synthesis via their ability to methylate the mitochondrial 
12S rRNA, which is important for mitoribosome activity. TFB1M has been identified 
as a nuclear modifier of the 1555A>G mutation in the 12S rRNA gene that causes 
nonsyndromic or aminoglycoside antibiotic-induced deafness.147 Presumably, 
altered or lack of methylation due to malfunctioning TFB1M can diminish the 
effect of the 1555A>G mutation on mitoribosome conformation. In vivo studies 
in mice revealed that TFB1M is an essential rRNA methyltransferase, needed for 
stability of the mitoribosomal SSU, that does not directly modulate transcription, 
whereas TFB2M is suggested to have transcriptional activation as its primary 
function.148 Therefore, differential expression of these two factors could modulate 
not only transcription, but also replication (via the transcription factor activity) and 
translation (via the rRNA methyltransferase activity), and in this manner ensure a
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balance between the amounts of mitochondrial transcripts and fully assembled
mitoribosomes.145,148
Mitochondria are under general nuclear control through transcription factors, 
such as nuclear respiratory factors 1 and 2 (NRF-1 and -2).149 These factors 
coordinate the expression of the nuclear and mitochondrial gene products required 
for oxidative phosphorylation and other essential mitochondrial functions. They 
act directly on nuclear genes coding for OXPHOS subunits as well as various 
nuclear genes encoding proteins involved in mtDNA replication, mitochondrial 
transcription or translation, by which they exert indirect control over expression of 
mitochondrial genes. Transcription factor CREB (cAMP response element-binding 
protein) promotes transcription of mitochondrial (in addition to nuclear) genes 
after its import into the mitochondrion directly.150
3.4. Functions of the mitochondrial translation machinery beyond translation
Initiation factor mtIF2 might be involved in mitochondrial mRNA degradation 
and apoptosis. The endoribonuclease RNase L is an important player in apoptosis 
induced by interferons (IFNs).151 After binding its IFN-induced activator, RNase 
L degrades single-stranded RNAs, leading to inhibition of protein synthesis. 
RNase L was shown to interact with mtIF2 and thereby modulate the stability 
of mitochondrial mRNAs, which appears to be essential for IFNa-induced 
apoptosis.152 RNase L is brought into association with the mitochondrial mRNA 
during their translation through interaction with mtIF2. In the presence of IFNa, 
RNase L becomes activated and degrades mRNA, which can eventually result in 
apoptosis. An excess level of mtIF2 could hold RNase L away from the mRNAs, 
preventing their degradation and thus also inhibiting IFNa-induced apoptosis.
In addition to its function in the elongation phase of the mitochondrial 
translation, mtEFTu has been reported to act as a chaperone.153 It plays a role in 
protein quality control in mitochondria, as has been found for its cytosolic and 
prokaryotic counterparts. MtEFTu interacts with unfolded proteins, especially with 
misfolded, newly synthesized polypeptides, and is hypothesized to recruit these 
proteins to a mitochondrial protease complex for their degradation. This protease 
complex presumably consists of the homologs of the bacterial GroEL/ES (Hsp60 
class) chaperone and ClpA/ClpP protease systems, with which EFTu can interact 
via the heat shock protein Hsp31.154
Recently, human mitochondrial ribosomal protein MRPL12 was demonstrated 
to bind to POLRMT, which enhances transcription.155 Free MRPL12, that is MRPL12 
not incorporated in the mitoribosome, appears to interact with POLRMT and 
consequently might coordinate the rate of mitochondrial transcription with the 
rate of mitoribosomal biogenesis. When the import rate of MRPs is exceeding 
the rate of mtDNA-encoded rRNA expression, free MRPL12 will accumulate and
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associate with POLRMT. Subsequently, the rate of mtDNA transcription increases, 
which rebalances the system.
Furthermore, mitochondrial ribosomal proteins MRPS29 and MRPS30 seem 
to be bifunctional proteins.156 These two proteins are the proapoptotic proteins 
death-associated protein 3 (DAP3) and programmed cell death protein 9 (PDCD9 
or p52), respectively. Whether MRPS29 and/or MRPS30 are released from the 
mitoribosome and exported to the cytosol during apoptosis or whether they 
carry out their proapoptotic role while still associated with the mitoribosome 
is unknown. Possibly, inner membrane-associated mitoribosomes affect the 
mitochondrial permeability transition pores via MRPS29 and MRPS30 and thereby 
induce apoptosis.
4 . P o s t -t r a n s l a t io n a l  p r o c e s s e s  r e q u ir e d  f o r  f u n c t io n a l  
o x p h o s  c o m p l e x e s
After translation has taken place, the mtDNA-encoded and imported nDNA- 
encoded proteins need to be incorporated into the inner membrane to form a 
functional OXPHOS system. Mitochondria contain chaperones, proteases and 
assembly factors for particular OXPHOS complexes to aid in this process.
4.1. Quality control by chaperones and proteases
The entire chaperone system represents a mechanism for quality control that 
determines the fate of all mitochondrial proteins: proteolytic degradation or 
folding and assembly. Chaperones from the Hsp60 and Hsp70 class bind to and 
stabilize (partially) unfolded or newly synthesized or imported proteins, thereby 
preventing their aggregation and facilitating their proper folding.157 Hsp100/Clp 
family chaperones are involved in the re-solubilization of protein aggregates and 
unfolding of misfolded proteins, resulting in either refolding by other chaperones 
or degradation by proteases. Excess or non-native proteins are degraded into 
peptides by ATP-dependent proteases and subsequently into amino acids by 
oligopeptidases.158 Mammalian mitochondria have three major ATP-dependent 
proteases: Lon, Clp-like, and other AAA proteases. Both Lon protease and 
proteins from the Clp family are located in the matrix and contain proteolytic 
as well as chaperone activities. Two membrane-bound ATP-dependent AAA- 
proteases, active on the intermembrane space side (i-AAA) or on the matrix 
side (m-AAA), are responsible for quality control of inner membrane proteins. 
Additionally, as mentioned in Section 3.3, they regulate mitochondrial biogenesis 
through selective processing of mitochondrial proteins, for example MRPL32. The 
significance of these AAA proteases is demonstrated by the severe defects due to 
dysfunction of one of the AAA proteases found in several species. The prohibitin 
complex, consisting of Phb1 and Phb2 and also located in the inner membrane, is
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thought to act as a chaperone that stabilizes mitochondrially synthesized OXPHOS 
subunits against degradation by AAA proteases.159,160 While the exact functions 
of the prohibitin complex remain poorly understood, its role in mitochondrial 
biogenesis and metabolism has been corroborated by numerous findings, such 
as different prohibitin expression levels depending on metabolic demand and 
lack of prohibitin leading to reduced mitochondrial membrane potential and 
instability of mtDNA-encoded OXPHOS subunits.160
4.2. Protein insertion into the inner membrane
A subset of mitochondrial inner membrane proteins that are synthesized in the 
cytosol are imported into the mitochondrial matrix prior to their export to the 
inner membrane; all other nuclear-encoded proteins are integrated directly into 
the inner membrane during import into the mitochondrion (also see Section 
2.4). All proteins synthesized by the human mitochondrial translation system are 
destined for the inner membrane and become inserted through the same export 
machinery as used by nDNA-encoded proteins. At least half of the mitoribosomes 
are associated with the inner membrane161 and it has been proposed that only 
membrane-bound mitoribosomes are translationally active.143 It appears that 
mitochondrial gene products become inserted into the inner membrane as they are 
undergoing synthesis on mitoribosomes, that is in a co-translational fashion.162-166 
However, the relative contributions of co- and post-translational insertion and 
the exact mechanisms are unknown. The inner membrane protein Oxa1 plays 
an important role in insertion of both mitochondrial- and nuclear-encoded 
proteins from the mitochondrial matrix into the inner membrane.167,168 Recently, 
the interaction of Oxa1 with the mitoribosome was concluded to involve at least 
the two yeast LSU proteins Mrp20 and Mrpl40, orthologs of bacterial ribosomal 
proteins L23 and L24 respectively, which are located close to the polypeptide 
exit tunnel.169170 Furthermore, mitoribosomal protein MRPL45 was postulated 
to function in the co-translational insertion of mtDNA-encoded proteins into 
the inner membrane.107 The yeast ortholog of MRPL45, Mba1, associates with 
the inner membrane and is involved in protein insertion into the membrane in 
a concerted action with Oxa1, possibly by positioning the mitoribosomal exit 
tunnel at the right location for insertion.164,171 Nonetheless, mitoribosomes remain 
partially anchored to the mitochondrial inner membrane in absence of MRPL45 
and Oxa1, indicating that additional factors are involved in the membrane 
association.164 One of these factors could be LETM1, leucine zipper EF-hand- 
containing transmembrane protein 1, located in the chromosomal region that is 
deleted in patients suffering from Wolf-Hirschhorn syndrome.172 It is the homolog 
of yeast inner membrane protein Mdm38, which has been proposed to function 
in an Oxa1-independent transport pathway across the inner membrane.173 LETM1
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was found to associate with MRPL36 and could thereby anchor the mitoribosome 
to the inner membrane.174 Overexpression of LETM1 resulted in inhibition of 
mitochondrial biogenesis and ATP production. Conversely, LETM1 knockdown 
caused mitochondrial swelling, loss of tubular networks and disassembly of 
OXPHOS complexes I, III, and IV.175 Much of the exact functions of LETM1 remain 
to be clarified, however, such as its role in cell viability and tumorigenesis, in 
addition to its potential interaction with the mitoribosome.174-176
Coupling mitochondrial protein synthesis to insertion of the protein into the 
inner membrane will be advantageous for the efficient formation of OXPHOS 
complexes. As mentioned previously, transcription seems to be coupled to the 
translation system as well. A similar process called transertion, the coupled 
transcription-translation-insertion of proteins into and through membranes, is 
found in bacteria.177,178 Linking of these processes generates hyperstructures, which 
are assemblies of different types of (macro)molecules that form an organizational 
level intermediate between genes/proteins and whole cells.179 Thus the mtDNA, 
transcription and translation machineries may be dynamically connected to the 
inner membrane into hyperstructures at assembly sites for the OXPHOS system.
4.3. Assembly of OXPHOS complexes
Each OXPHOS complex has a specific assembly pathway, which involves 
chaperones that are not part of the functional complex but are implicated in 
its formation: the assembly factors. Up till now, 22 assembly factors have been 
identified and the list is still growing (see reference180 for an overview, including 
defects in assembly): eleven for complex I (NDUFA12L or B17.2L,181 NDUFAF1 or 
CIA30,82 NDUFAF2,181183 NDUFAF3 or C3ORF60,184 NDUFAF4 or C6ORF66,185 Ecsit,186 
C8ORF38,187 C20ORF7,188189 and possibly the CIA84 ortholog PTCD1,190 AIF191 and 
IND1),192 one for complex II (SDHAF1),193 one for complex III (BCS1L),194 six for 
complex IV (SURF1, COX10, COX15, SCO1, SCO2, and supposedly LRPPRC),138195 
and four for complex V (ATP11, ATP12,196 and possibly ATP23197 and OXA1L).198 
Naturally, structural proteins can have additional functions in the assembly of the 
particular OXPHOS complex.
The organization of the OXPHOS system is more intricate than separately 
assembled complexes that are arranged in sequence in the inner mitochondrial 
membrane. Two models for the organization of the mitochondrial respiratory chain 
have been proposed: (1) the "fluid-state" or "random collision" model, which has 
been the preferred description, where all OXPHOS complexes diffuse individually 
in the membrane and electron transfer depends on the random collision of the 
complexes and electron carriers; (2) the "solid-state" model, which was proposed 
over 50 years ago and has recently received more attention, where the complexes 
together form large supramolecular structures termed supercomplexes or
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respirasomes.199,200 The most plausible scenario, however, is a combination of 
these two models: the "plasticity" model.201 In this model, single complexes ("fluid- 
state" model) and different types of supercomplexes ("solid-state" model) coexist 
in the inner membrane. Complex I, for instance, is mainly found in association 
with complex III in various supercomplexes that additionally contain the electron 
carriers coenzyme Q and cytochrome c, complex IV, and sometimes complex II 
or V, and are able to respire. On the other hand, most of the complexes II and
IV are present as individual entities. How the supercomplexes are assembled is 
currently not known, but the significance of this arrangement for the stability of 
the different complexes is certain. This is emphasized by the finding that primary 
defects in, for example, complex III can lead to secondary instability of another 
complex, such as complex I, through improper supercomplex formation.202 More 
often, though, a mutation results merely in an isolated deficiency of the particular 
complex. Recently, defects in Tafazzin, a protein required for the metabolism of 
the inner membrane phospholipid cardiolipin, was shown to affect complex I/ 
III2/IV supercomplex stability.203 The cardiolipin deficiency resulted in weakened 
interactions between complexes I, III, and IV, unstable supercomplexes, and 
decreased levels and activities of the complexes themselves, ultimately causing 
Barth syndrome. Thus combined OXPHOS deficiencies can also be caused by 
defects in the assembly of supercomplexes.
For proper assembly of the OXPHOS system, mitochondrial fusion and fission 
events are crucial since they control mitochondrial morphology and thereby also 
mitochondrial function. Disruption of fusion or fission primarily affects two key 
functions of mitochondria: respiration and regulation of apoptosis.204,205 Defects 
in fusion proteins MFN2 (mitofusin 2) and OPA1 (optic atrophy 1), for instance, 
cause a reduction in membrane potential and OXPHOS enzyme activities and 
are associated with the neurodegenerative diseases Charcot-Marie-Tooth type 
2A and dominant optic atrophy, respectively. Additionally, down-regulating the 
expression of DNML1 (dynamin 1-like, also called DRP1 or DLP1), a protein involved 
in mitochondrial and peroxisomal fission, led to loss of mtDNA and a decrease 
in mitochondrial respiration.206 In a patient with a DNML1 deficiency, however, no 
mitochondrial morphology abnormalities or impairment in respiratory function 
could be detected, despite elevated lactate levels.206,207
5. M u t a t io n s  t h a t  im p a ir  m it o c h o n d r ia l  t r a n s l a t io n  
a n d  r e s u l t  in  m it o c h o n d r ia l  d is o r d e r s
Given the multitude of proteins and complexity of the processes that are required 
for a properly functioning OXPHOS system, it is not surprising that in many 
patients with a mitochondrial disorder the underlying molecular genetic defect
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has not yet been identified. Nonetheless, since the discovery of the first mtDNA 
mutations associated with mitochondrial disorders in 19 8 8,208,209 numerous 
mutations in mtDNA and nDNA have been reported and the list is still expanding 
(for an overview see e.g., reference43). In each of the previous sections we have 
briefly mentioned the relevant genes implicated in mitochondrial disorders, with 
the exception of genes of the mitochondrial translation process. Here we will 
discuss in more detail the mutations found in this class of genes. Table 1 gives an 
overview of the genes implicated in combined OXPHOS deficiencies. These genes 
are also depicted in Figure 1.
5.1. MtDNA mutations
As already stated in the introduction, the majority of mutations associated with 
combined OXPHOS deficiencies and a mitochondrial translation defect are 
located in the mitochondrial genome. Approximately 150 mutations, of which a 
large percentage awaits proper determination of their pathological significance 
(see reference210 for a scoring system), have been reported in mitochondrial tRNA 
genes and a few in rRNA genes.12 It is beyond the scope of this review to discuss 
these mutations in detail; overviews of mitochondrial tRNA mutations and their 
molecular and clinical consequences have been published before.210-212
The tRNALeu(UUR) gene forms a hotspot for pathogenic mutations with nearly 
30 different mutations, but in all tRNA genes, mutations have been detected now. 
A pathogenic tRNA gene mutation is expected to lead to a combined OXPHOS 
defect through a decreased rate of mitochondrial protein synthesis. The exact 
complexes that show a deficiency differ for each mutation, partly depending on 
which tRNA is affected and the percentages of the corresponding amino acid 
in the different OXPHOS subunits. The pathogenic mechanisms involved in the 
translation defect due to a tRNA mutation are numerous and frequently multiple 
events are involved; potential effects are: impaired transcription termination, 
impaired tRNA maturation, defective post-transcriptional modification of the 
tRNA, effect on tRNA structure (e.g., global structural weakness or conformational 
alteration), decreased tRNA stability (found for all mutations investigated), 
reduced aminoacylation, decreased binding to translation factor mtEFTu or 
the mitoribosome, and disturbed codon reading.211 However, cases are known 
where mitochondrial translation was not or only slightly affected despite clear 
impairment of the OXPHOS system.e.g., references220,221 Possibly, this is due to 
toxic effects of premature translation products generated by the absence of the 
correctly functioning tRNA.222 These peptides could interfere with the assembly of 
the OXPHOS complexes or exert their toxic effect through interactions with other 
(non)mitochondrial components, while a quantitative deficit in mitochondrial 
protein synthesis cannot be detected.
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Table 1. Genes involved in the biogenesis or maintenance of multiple OXPHOS complexes 
and implicated in mitochondrial disorders
Affected process Gene Protein (function) References
Combined OXPHOS deficiencies with normal complex II activities0
MtDNA replication POLG Polymerase y catalytic subunit [13,213]
POLG2 Polymerase y accessory subunit [13,214]
C10orf2 Twinkle (mtDNA helicase) [13]
DGUOK Deoxyguanosine kinase [13]
TK2 Thymidine kinase 2 [13]
TYMP Endothelial cell growth factor 1
(thymidine phosphorylase) [13]
Nucleotide synthesis SLC25A4 Adenine nucleotide translocator 1 [13]
and transport SLC25A3 Solute carrier family 25 member [43,215]c
3 (phosphate transporter)
SUCLG1 Succinate-CoA ligase a-subunit [43,216]
SUCLA2 Succinate-CoA ligase ß-subunit [13,216]
RRM2B Ribonucleotide reductase M2 B [13,217]
MPV17 Mt inner membrane protein [13]
22 mitochondrial tRNA genes [12]
2 mitochondrial rRNA genes [12]
GFM1 Mt translation elongation factor G1 [15]
TSFM Mt translation elongation factor Ts [21]
TUFM Mt translation elongation factor Tu [22]
Mt translation MRPS16 Mt ribosomal protein S16 [18]
MRPS22 Mt ribosomal protein S22 [19]
PUS1 Pseudouridine synthase 1 [14]
TRMU tRNA 5-methylaminomethyl- [24]
2-thiouridylate methyltransferase
DARS2 Mt aspartyl-tRNA synthetase 2 [20]c
RARS2 Mt arginyl-tRNA synthetase 2 [16]
Other combined OXPHOS deficienciesb
TIMM8A Translocase of inner mt membrane 8 [74]c
Mt protein import homolog A (small TIM complex subunit)
DNAJC19 DnaJ homolog, subfamily C, member 19 [76]
(TIM23 complex subunit)
TAZ Tafazzin (cardiolipin metabolism) [203,218]
Mt membrane biogenesis OPA1 Optic atrophy 1 (mt fusion) [205]
and maintenance MFN2 Mitofusin 2 (mt fusion) [205]
DNM1L Dynamin 1-like [207]c
(mt and peroxisomal fission)
Mt protein processing SPG7 Spastic paraplegia 7 or paraplegin [144,219]
and quality control (m-AAA protease subunit)
" Based on the function of the affected proteins, a combined complex I, III, IV and V deficiency would be 
expected, however, not always do all these enzyme complexes display decreased activities. 
b All OXPHOS complexes are expected to malfunction based on the function of the affected proteins; 
nonetheless, large variations have been found in the exact OXPHOS complexes involved. 
c The OXPHOS complexes showed normal activities.
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The best-studied mitochondrial tRNA mutations are 3243A>G in tRNALeu(UUR) 
(MT-TL1) and 8344A>G in tRNALys (MT-TK). The 3243A>G mutation is one of 
the most common mutations and causes a range of clinical phenotypes, of 
which MELAS is the most prevalent.223 There is controversy over the pathogenic 
mechanism of the 3243A>G mutation: both loss-of-function (due to poor 
aminoacylation, reduced stability or lack of wobble-base U hypermodification) 
and gain-of-function (due to lack of the hypermodification) of the mutant tRNA 
have been proposed.224 The post-transcriptional taurine modification at the 
anticodon wobble position is needed to restrict decoding to leucine UUR codons. 
Loss of this modification leads to varying degrees of mitochondrial translation 
malfunctioning in different cellular backgrounds through a combination of a 
decoding defect of UUG (and UUA) codons (loss-of-function) and amino acid 
misincorporation (gain-of-function).126,225 Additionally, the 3243A>G mutation 
was shown to diminish 16S rRNA transcription termination and alter processing 
of the primary transcript,61,226 but these effects are likely to contribute less to 
the disease etiology than the previously mentioned mechanisms. The 8344A>G 
mutation is associated with MERRF (myoclonic epilepsy with ragged-red fibers). 
It has also been reported to affect aminoacylation and taurine modification of 
the wobble-base U, the latter which abolishes codon-anticodon pairing on the 
mitoribosomes for both tRNALys codons.225,227 This generates a marked decrease in 
mitochondrial protein synthesis that is most pronounced in proteins with a high 
lysine content and is believed to result from premature translation termination.
Most rRNA mutations have been reported in the 12S rRNA gene (MT-RNR1) 
and all of these are associated with nonsyndromic sensorineural hearing loss 
or aminoglycoside-induced deafness, with the 1555A>G mutation forming one 
of the most common causes.12,228 This mutation is located in the decoding site 
of the mitoribosomal SSU and results in a secondary rRNA structure that more 
closely resembles the corresponding region of the bacterial 16S rRNA, impairing 
mitochondrial protein synthesis and facilitating interaction with aminoglycoside 
antibiotics, which again exacerbates the translation defect. The mutation alone 
does not lead to disease, only in combination with modulators such as the 
aminoglycosides, mitochondrial haplotypes and nuclear modifier genes (e.g., 
TFB1M, as already mentioned in Section 3.3). In the 16S rRNA gene (MT-RNR2) 
merely 3 mutations have been found: 2835C>T, 3093C>G, and 3196G>A.12 These 
mutations are thought to be associated with Rett syndrome, MELAS, and Alzheimer 
and Parkinson disease, respectively.229-231 Nevertheless, further investigations are 
necessary to determine their pathogenicity.
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5.2. nDNA mutations
Up till now, mutations in nine nuclear genes implicated in mitochondrial protein 
synthesis have been associated with mitochondrial disorders. The first report 
was a homozygous missense mutation in the tRNA modifying gene PUS1,14 
and shortly thereafter homozygous mutations were detected in the genes for 
elongation factor mtEFG115 and mitoribosomal protein MRPS16.18 Subsequently, 
four compound heterozygous mutations in GFM1 (coding for mtEFG1)22,25 
and homozygous mutations in TUFM (encoding mtEFTu),22 TSFM (coding for 
mtEFTs),21 MRPS22,19 PUS1 again,17 and in the arginine tRNA synthetase gene 
(RARS2)16 were found, bringing the total number of mutations on 12. Additionally, 
several compound heterozygous mutations have been reported in the gene for 
mitochondrial aspartyl-tRNA synthetase (DARS2).2023 Recently, 9 mutations were 
identified in the gene for another tRNA modifying gene, TRMU.24 All patients 
harboring these mutations show combined OXPHOS deficiencies, with (near) 
normal complex II activities, and a clear defect in mitochondrial translation (the 
latter was not tested for the MRPS22, RARS2 and DARS2 mutations). The one 
exception is DARS2: surprisingly, Blue-native PAGE as well as spectrophotometric 
measurements revealed normal OXPHOS enzyme activities.20 The clinical features 
differ substantially between all patients and even between patients that carry 
the same mutation, but generally the mutations result in severe and early-fatal 
diseases.
As already mentioned in Section 2.3, defects in the tRNA-modifying 
enzymes PUS1 and TRMU can result in mitochondrial disease. PUS1 converts 
uridine into pseudouridine at several cytoplasmic and mitochondrial tRNA 
positions and thereby improves translation efficiency in the cytosol as well as the 
mitochondrion.17 Thus it is not part of the translation machinery, but it is required 
for protein synthesis due to its function in post-transcriptional modification of 
tRNAs. Pseudouridylation is the most frequently found modification in tRNAs,232 
however, the exact function is not entirely clear. The marked variability in the 
severity of the MLASA syndrome, despite the presence of an identical PUS1 
mutation, could partly be explained by the dual localization of PUS1.17 A defect 
in PUS1 therefore impairs both cytosolic and mitochondrial translation, resulting 
in corresponding clinical symptoms that can vary due to individual differences 
in compensation mechanisms in both cell compartments. Bykhovskaya et al 
suggested that compensatory changes in transcript levels of ribosomal proteins 
can overcome the lack of pseudouridylation of tRNAs and that pleiotropic effects 
of PUS1 on non-tRNA substrates involved in transcription and iron metabolism 
are a major cause of the disease phenotype.233 Notably, complex II can be affected 
slightly in addition to the other OXPHOS complexes that all contain mtDNA- 
encoded subunits.17 This could be a primary effect of the decrease in cytosolic
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translation or it could be a secondary effect of the mitochondrial translation 
deficit, leading to disruption of the mtDNA-dependent complexes, which can 
subsequently cause destabilization of the entire OXPHOS system. TRMU (tRNA 
5-methylaminomethyl-2-thiouridylate methyltransferase) is responsible for the 
2-thio modification of the wobble-base of the mitochondrial tRNALys, tRNAGln 
and tRNAGlu. Defects in this enzyme result in reduced steady-state levels of these 
three tRNAs and consequently impaired mitochondrial protein synthesis.24,62 
The 2-thiouridylation is reported to be critical for effective codon-anticodon 
interaction and ribosome binding.234,235
Concerning the mitochondrial translation factors, defects have only been 
found in proteins involved in the elongation phase, in all elongation factors 
except for mtEFG2, which appears to function in termination instead elongation. 
In GFM1, mutations have been reported in nearly all protein domains, leading 
to severe hepato(encephalo)pathy.15,22,25 All mutations result in a marked global 
translation defect, with the strongest deficit in the three complex IV subunits and 
the two complex I subunits ND5 and ND6. Both subunits of complex V (ATP6 and 
ATP8) show normal or even increased synthesis rates, possibly caused by more 
efficient protein synthesis of bicistronic compared to monocistronic mRNAs, 
which would then also explain the near normal mitochondrial translation levels 
of ND4 and ND4L. This variable pattern in translation impairment was also found 
for a mutation in TSFM,21 which will be described below. Surprisingly, tissues are 
selectively affected by GFM1 mutations, in spite of its ubiquitous expression, 
with liver being most severely affected and heart hardly showing a defect.25 This 
tissue specificity appears to result from differences among tissues in the relative 
ratios of the elongation factors and in adaptive changes herein in response to 
dysfunction. For example, transcription of TUFM was upregulated in cardiac 
tissue in patients with a GFM1 mutation and overexpression of either TUFM or 
TSFM in control and patient fibroblasts impaired mitochondrial translation. 
Overexpression of GFM2, on the contrary, did not have a clear effect on protein 
synthesis in either control or patient cells.1525 Remarkably, mtEFTu or mtEFG2, 
but not mtEFTs or mtEFG1, can partially suppress the combined OXPHOS system 
defect caused by the 3243A>G mutation in tRNALeu(UUR).126 These observations 
evidence that efficient mitochondrial translation partly depends on appropriate 
ratios of the elongation factors. A homozygous mutation in TUFM was shown to 
be responsible for rapidly progressive encephalopathy.22 The mutation, located 
in the tRNA-binding region of mtEFTu, hampers the formation of the ternary 
complex with GTP and an aminoacylated tRNA, resulting in a severe decrease in 
mitochondrial protein synthesis.22,236 Notably, a homozygous mutation in TSFM 
led to encephalomyopathy in one patient and hypertrophic cardiomyopathy in 
another.21 This could be due to individual differences in relative abundance of
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the translation factors and compensatory mechanisms in the various tissues. 
Alternatively, as yet unknown genetic modifiers of the mitochondrial translation 
machinery could be involved. Steady-state levels of not only mtEFTs but also 
mtEFTu were reduced, and overexpression of either factor rescued the OXPHOS 
deficiency and translation defect. The most likely explanation for these findings 
is that the mutation, situated in a subdomain of mtEFTs that interacts with 
mtEFTu, destabilizes the mtEFTu-mtEFTs complex and promotes turnover of its 
components. Additional mtEFTu or mtEFTs would then stabilize the complex.
Of all 81 human MRPs, mutations have been found in merely two of them: 
MRPS16 and MRPS22.1819 Both defects resulted in a marked decrease in the 12S 
rRNA transcript level, probably caused by impaired assembly of the mitoribosomal 
small subunit, generating unincorporated and instable 12S rRNA. MRPS16 is 
evolutionary highly conserved, however, MRPS22 is only present in metazoa.107 
Recently, both proteins were shown to be important for assembly of the SSU.123 
In fibroblasts from patients with a MRPS16 or MRPS22 mutation, the level of 
MRPS11 was significantly reduced, whereas considerable amounts of MRPS2 were 
present. Furthermore, MRPS16 was barely detectable in the MRPS22-mutated 
patient. The presence of MRPS22 was not determined in these patients. On the 
other hand, near normal levels of MRPL13, MRPL15123 as well as 16S rRNA18,19 
were found. These observations indicate that both MRPS16 and MRPS22 are 
essential for assembly and stability of the SSU. A lack of these MRPs results in 
the failure to assemble part of the mitoribosome, containing at least MRPS11, 
MRPS16, MRPS22 and 12S rRNA, and subsequent degradation of its components. 
Both a macromolecular complex containing MRPS2 and the mitoribosomal large 
subunit can still be formed in the absence of a functional SSU, suggesting that the 
assembly of the mitoribosome is a process consisting of relatively independent 
subassembly steps.
Mutations in the mitochondrial arginyl- and aspartyl-tRNA synthetases (RARS2 
and DARS2) are associated with severe encephalopathy with pontocerebellar 
hypoplasia and LBSL (leukoencephalopathy with brain stem and spinal cord 
involvement and lactate elevation), respectively.16,20,23 In both genes, intronic 
mutations that affect splicing were detected. The absence of extracerebral 
symptoms might be explained by a potential difference in abundance of splicing 
factors between brain and the unaffected tissues, enabling synthesis of small 
amounts of wild-type transcript of the synthetases in most tissues. Alternatively, 
the vulnerability of the brain for aminoacyl-tRNA synthetase defects could be 
due to the high expression of mitochondrial tRNAs in this tissue.237 The tRNAArg 
transcript is scarcely present, but almost fully acylated, in patient fibroblasts 
harboring a RARS2 mutation. Presumably, the little available wild-type RARS2 
can aminoacylate a small portion of the tRNAArg molecules and the uncharged
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transcripts then become unstable. This will impair mitochondrial protein synthesis, 
which has only been confirmed in yeast.238 In contrast, DARS2 mutations do not 
seem to affect mitochondrial translation and likewise do not result in defects 
of the OXPHOS complexes, notwithstanding a clear reduction in aminoacylation 
activity.20 The reason for this is currently not understood.
Besides these nine gene products, numerous proteins are indirectly involved 
in mitochondrial translation, as should be evident from the current review, and 
defects in these proteins could undoubtedly also interfere with the translation 
process. For example, lack of the protease paraplegin (see Section 3.3 for 
information on its function) results in impaired mitochondrial translation in yeast 
and in a hereditary spastic paraplegia (HSP) mouse model.143 Nonetheless, HSP 
patients with mutations in paraplegin (HSP7) do not show consistent OXPHOS 
enzyme deficiencies;239-241 often only or mainly complex I is affected, while a 
combined defect would be expected. The selective involvement of certain neurons 
could in this case be rationalized by tissue-specific differences in the expression 
of m-AAA protease subunits and their assembly into proteolytic complexes, which 
vary in their subunit composition depending on subunit availability.242 This is 
analogous to the importance of elongation factor ratios for efficient mitochondrial 
translation and tissue-specific variability herein.
6 . Fu t u r e  p r o s p e c t s
We have provided an extensive overview of the proteins and processes (in)directly 
involved in mitochondrial translation and the biogenesis of the OXPHOS system. 
Even though our understanding of the mechanisms implicated in mitochondrial 
disease has increased rapidly over the last two decades, it is far from complete. Due 
to the multitude of proteins and intricacy of the processes needed for a properly 
functioning OXPHOS system, identifying the genetic defect that underlies an 
OXPHOS deficiency is not an easy task. The shortage of large or consanguineous 
families as well as the substantial clinical and genetic heterogeneity of mitochondrial 
disorders complicate the search by limiting the available strategies. For instance, 
techniques such as linkage analysis and homozygosity mapping that form powerful 
tools in combination with whole-genome experimental data sets136,243 often 
cannot be applied and mutation chips are currently only available for the mtDNA. 
Consequently, the molecular basis of many OXPHOS disorders remains unresolved. 
In the future, molecular genetic diagnosis of patients suspected to suffer from 
a mitochondrial disorder might no longer require extensive investigations that 
integrate information from clinical phenotype, family history, brain imaging and 
laboratory findings to direct the laborious tasks of screening known candidate genes 
and, when this is unsuccessful, searching for new genetic causes.43 Instead, recent 
progress in the development of next-generation DNA sequencing technologies,
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which are much cheaper and faster than the conventional approach of polymerase 
chain reaction followed by capillary sequencing, indicates that within the next few 
decades high-throughput sequencing could become a feasible option for mutation 
detection.244 245 These methods are anticipated to eventually enable sequencing of 
the entire human genome for under $1000 within a day, allowing their routine clinical 
use and accelerating the discovery of novel disease genes. Exome sequencing, that 
is the targeted sequencing of all protein-coding regions, offers an alternative to 
whole-genome sequencing by facilitating direct identification of the causative 
gene at a fraction of the costs.246,247 However, much remains to be achieved, for 
example proper bioinformatic tools to deal with the tremendous amounts of data, 
before such technologies can be readily applied to elucidate the genetic etiology 
of OXPHOS deficiencies and other disorders. Systems biology techniques will keep 
increasing our knowledge of the mechanisms underlying complex diseases and 
in combination with high-throughput sequencing these approaches will advance 
disease-gene discovery even more. Integrative analysis of functional data is useful 
especially for gaining insight into the scarcely understood field of modifier genes, 
which are thought to account for part of the clinical variability seen in mitochondrial 
diseases. Systematic mapping of genetic interactions revealed a class of modifier 
or "hub" genes that are proposed to enhance the phenotypic consequences of 
mutations in many different genes, the "specifier" genes that define the specific 
disorders, and thus serve as global modifier genes in multiple mechanistically 
unrelated disorders.248 Hopefully, these and other important findings will lead to 
the discovery of additional modifier genes implicated in mitochondrial disorders. 
Progress in mutation detection, both in specifier and modifier genes, is crucial 
for extending the possibilities for genetic counseling, prenatal diagnosis, and 
interventions to prevent transmission now and to cure these serious disorders in 
the future. Currently, no effective therapy is available; the various existing treatment 
strategies are mainly supportive.249250 Gene therapy might offer a solution since it 
allows for curative treatment without the need for a clear genotype-phenotype 
correlation, which is often lacking in mitochondrial disorders. Although the 
development is still in its infancy for both mtDNA and nDNA gene therapy and 
many challenges are to be overcome, promising results have been obtained in cell 
cultures and animal models, providing hope for a cure in the not-too-distant future. 
Thus rapid advances in technologies and consequently in our understanding of the 
pathogenesis of OXPHOS defects should lead to the ultimate goal of effectively 
preventing and curing these often devastating disorders.
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A b s t r a c t
Combined oxidative phosphorylation (OXPHOS) system deficiencies are a group 
of mitochondrial disorders that are associated with a range of clinical phenotypes 
and genetic defects. They occur in approximately 30% of all OXPHOS disorders 
and around 4% are combined complex I, III and IV deficiencies. In this study we 
present two mutations in the mitochondrial tRNATrp (MT-TW) and tRNAArg (MT-TR) 
genes, m.5556G>A and m.10450A>G, respectively, which were detected in two 
unrelated patients showing combined OXPHOS complex I, III and IV deficiencies 
and progressive multisystemic diseases. Both mitochondrial tRNA mutations 
were almost homoplasmic in fibroblasts and muscle tissue of the two patients 
and not present in controls. Patient fibroblasts showed a general mitochondrial 
translation defect. The mutations resulted in lowered steady-state levels and 
altered conformations of the tRNAs. Cybrid cell lines showed similar tRNA defects 
and impairment of OXPHOS complex assembly as patient fibroblasts. Our results 
show that these tRNATrp and tRNAArg mutations cause the combined OXPHOS 
deficiencies in the patients, adding to the still expanding group of pathogenic 
mitochondrial tRNA mutations.
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I n t r o d u c t i o n
Combined oxidative phosphorylation (OXPHOS) system deficiencies, in which 
two or more enzyme complexes show a decrease in activity, occur in around 
30% of all OXPHOS disorders diagnosed at our center, and approximately 4% 
consist of combined complex I, III and IV defects.1 Candidate genes for these 
deficiencies are, among others, all genes encoding proteins and RNAs involved 
in mitochondrial translation. Protein synthesis in the mitochondrion, which is 
responsible for the production of 13 polypeptides of the OXPHOS complexes 
I, III, IV and V, is executed by mitochondrial DNA (mtDNA)-encoded rRNAs and 
tRNAs and a multitude of nuclear-encoded factors. Although tRNA-encoding 
genes make up only 9% of the entire mitochondrial genome, over 40% of all point 
mutations reported in the mtDNA are located in tRNA genes.2 In contrast, rRNA 
sequences cover 15% of the mtDNA, but mutations in the two rRNAs account 
for only 4% of all mtDNA mutations. In addition, in recent years mutations in 
various nuclear-encoded proteins involved in the mitochondrial translation 
process have been found and this group of gene defects is expanding rapidly.3
This study describes two mutations, m.5556G>A in the tRNATrp and 
m.10450A>G in the tRNAArg gene, that lead to combined OXPHOS deficiencies 
and shows their pathogenicity.
M a t e r i a l s  a n d  m e t h o d s
Case reports
Patient T. This female child was born at term as the first child of healthy unrelated 
parents. She had feeding problems from birth and gastroesophageal reflux 
disease was suspected. From the age of 7 months, a regression of psychomotor 
functioning was noted and she became somnolent. In addition, she developed 
a severe constipation. There was failure to thrive; weight decreased from 0 to 
-2.5 SD, length from 0 to -1  SD and head circumference from +1 to -1  SD from 
the age of 1 month to the age of 10 months. Physical examination at the age 
of 10 months showed an irritable child with marked generalized hypotonia. 
She could not sit without support and showed no intentional hand function. 
Fundoscopy was normal. Gavage feeding was initiated. Laboratory studies 
revealed a metabolic acidosis. Plasma lactate was 12.3 mmol/l (N: <2.1 mmol/l) 
with an increased lactate/pyruvate ratio and CSF lactate was 12.5 mmol/l (N: <1.4 
mmol/l). Additional laboratory studies, including liver function tests, were normal. 
A muscle biopsy was performed at the age of 11 months. Immunohistochemistry 
and electron microscopy were normal. She became comatose and died at the age 
of 13 months because of respiratory insufficiency. Autopsy or additional studies 
were not performed.
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Patient A. This male patient was born at 37 weeks of gestation with a birth weight 
of 2.118 kg (< -2.5 SD), length 44.5 cm (< -2.5 SD) and head circumference 32.4 cm 
(-2 SD), as a first child of healthy, non-consanguineous parents. He was admitted 
to the neonatal unit for severe generalized hypotonia, respiratory insufficiency, 
feeding difficulty and anemia. He was further evaluated at the age of 4 months for 
severe psychomotor retardation, growth retardation, visual dysfunction, epilepsy 
(West syndrome) and chronic lactic acidemia. He received a gastric tube placement 
and started on nutritional intervention. A cranial MRI reported hypoplastic corpus 
callosum and abnormal signal intensity of the basal ganglia, including the globus 
pallidus and the nucleus caudatus. A follow-up cranial MRI showed progressive 
cerebral and cerebellar atrophy. EEG and VEP were severely abnormal. EEG showed 
generalized seizure activity; no burst suppression pattern was present. The VEP 
showed severe central visual perception loss. Metabolic studies showed markedly 
elevated lactate in both blood (3.6-7 mmol/l, N: <2.1 mmol/l) and CSF (3.8 mmol/l, 
N: <1.4 mmol/l), hyperalaninemia (860 Mmol/l, N: <460 Mmol/l) and increased 
urinary lactate and Krebs cycle intermediates. Additional laboratory studies were 
normal. At the age of 8 months, at the time of the surgical muscle biopsy, he had 
severe microcephaly; other growth parameters were normal. No internal organ 
dysfunction was noted. He had severe generalized hypotonia and hyporeflexia. 
The psychomotor development of the patient remained at the level of a 3-month- 
old baby. He had no visual contact with the surroundings and was suffering from 
intractable Blitz-Nick-Salaam (BNS)-type seizures. Using histological analysis, a 
homogenously decreased staining of COX activity was confirmed with a residual 
activity of 15-25%. No fiber-type disproportion, lipid storage or ragged red fibers 
were detected. The patient is currently 4.5 years old, has no acoustic or visual 
contact, is severely retarded and fully tube fed.
Cell culture
Skin fibroblasts were cultured in M199 medium (Gibco, Breda, The Netherlands) 
supplemented with 10% fetal calf serum (FCS) and antibiotics. Transmitochondrial 
cybrid cell lines were constructed as described elsewhere.4 The cybrids were grown 
in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 mg/ml glucose 
and supplemented with 10% FCS, 110 Mg/ml pyruvate, and antibiotics; for the 
mtDNA-less 143B206 cells this medium was additionally supplemented with 50 
Mg/ml uridine and 100 Mg/ml bromodeoxyuridine. The human osteosarcoma cell 
line 143B (TK-) was cultured in Eagle's minimum essential medium (EMEM) with 
Earle's BSS supplemented with 10% FCS and 15 Mg/ml bromodeoxyuridine.
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Enzym e m easurem ents
The activities of the OXPHOS enzyme complexes were measured in skin fibroblasts 
and muscle tissue of the patients as described previously.5,6
M olecular genetic analysis
DNA was isolated from cultured skin fibroblasts, muscle tissue or blood using 
salt extraction.7 The entire mtDNA of the patients was amplified and sequenced 
according to the protocol of Taylor et al8 with minor adaptations.
Percentage heteroplasmy was quantified using the Pyrosequencing 
technology (Biotage AB, Uppsala, Sweden). Pyrosequencing was performed on 
the PSQ96 MA platform according to the protocol of the manufacturer. Primer 
sequences are available upon request.
Analysis of m itochondrial protein synthesis
In vitro pulse labeling of mitochondrial translation was performed as described 
elsewhere,9 with a few adaptations. In short, cells were labeled for 60 min at 37 
°C in methionine-free DMEM with 10% dialyzed FCS, 200 MCi/ml [35S]methionine 
(Tran35S-Label, MP Biomedicals, Eindhoven, The Netherlands) and 100 Mg/ 
ml emetine, and subsequently chased for 10 min in regular DMEM with 10% 
FCS. Total cellular protein (100 Mg) was resuspended and incubated for 10 min 
in PBS containing 2% lauryl maltoside. Unsolubilized material was removed 
by centrifugation at 10 000 g for 10 min and loading buffer was added to the 
supernatant to a final concentration of 100 mM Tris-HCl (pH 6.8), 20% glycerol, 1% 
SDS, 0.02% Coomassie blue G-250 and 1% mercaptoethanol. Samples were run 
on 16% polyacrylamide gels,10 which were subsequently scanned on a FLA5100 
(Fujifilm Life Science, Düsseldorf, Germany) and analyzed using ImageQuant 
software (GE Healthcare, Diegem, Belgium). Equal protein loading was confirmed 
using Coomassie blue staining (data not shown).
Blue-native PAGE and com plex I in-gel activity assay
Blue-native PAGE was used for separation of the OXPHOS complexes on 5-15% 
polyacrylamide-gradient gels as described before.11 After electrophoresis of 40 Mg 
protein from fibroblast and cybrid cells, gels were further processed for in-gel activity 
assays and western blotting. Assembly of the OXPHOS complexes was analyzed 
using monoclonal antibodies against subunits of complexes I, III, V (Molecular 
Probes, Leiden, The Netherlands), II, and IV (MitoSciences, Eugene, OR, USA).
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Northern blot analysis
Total RNA samples (10 Mg) isolated from cultured fibroblast and cybrid cell lines 
using RNA-Bee (Tel-Test) were separated on a 15% denaturing UREA-PAGE 
gel and transferred to a Hybond-N membrane (Amersham Pharmacia Biotech, 
Roosendaal, The Netherlands) using electroblotting. For the conformational 
analysis, total RNA samples were separated for 24 h at 4 °C on a non-denaturing 
15% polyacrylamide gel. Denaturing was performed by placing the gel for 10 min 
in 0.2 M NaOH/ 0.5 M NaCl. Before electroblotting to a Hybond-N membrane 
(Amersham Pharmacia Biotech), neutralization was carried out by washing twice 
for 10 min in 5xTBE and twice for 10 min in 1xTBE. After hybridization with the 
tRNAArg probe, the membrane was washed and subsequently rehybridized with 
the tRNATrp probe.
For the detection of tRNATrp and tRNAArg, templates for hybridization probes 
were generated by PCR using oligonucleotides containing the T7 RNA polymerase 
promoter sequence in the reverse primer. Primer sequences are available upon 
request. For in vitro transcription, the gel-purified PCR template was incubated for 
2 h at 37 °C in 60 ml of buffer containing 40 mM Tris-HCl (pH 7.9), 6 mM MgCl2, 
2 mM spermidine, 10 mM NaCl, 10 mM dithiotreitol, 1 mM each of ATP, CTP and 
UTP, 0.1 mM GTP, 60mCi [a-32P]GTP and 45 U T7 RNA polymerase.
Imaging was performed using a PhosphorImager (Molecular Imager FX, Bio­
Rad, Veenendaal, The Netherlands); signal intensities for tRNATrp and tRNAArg were 
normalized to each other for each sample.
R e s u l t s
Enzym e m easurem ents
The biochemical assays of OXPHOS enzyme activities showed clear combined 
complex I, III and IV deficiencies in patients T and A (Table 1). The activities 
measured as percentage of the lowest control value ranged from 15 to 59% in
Table 1. OXPHOS enzyme activities in skeletal muscle and fibroblasts
Activities (mU/U citrate synthase) in 
Skeletal muscle Fibroblasts
Complex Patient T Patient A Control range Patient T Patient A Control range
I 26 31 70 -  251 39 39 100 -  310
II 387 455 335 -  749 774 544 520 -  845
III 1306 1870 2200 -  6610 571 1383 1320 -  2610
II+III 386 420 300 -  970 140 218 110 -  470
IV 322 157 810 -  3120 102 223 680 -  1190
Samples were supernatants obtained after 600g centrifugation of skeletal muscle or mitochondrial- 
enriched fractions from fibroblasts. The decreased activities as compared with controls are in bold.
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Table 2. Percentages of mutant mtDNA as determined using pyrosequencing
Subject Sample m.5556G>A m.10450A>G
Patient Fibroblasts 92 92
Skeletal muscle 93 93
Cybrid clone 1 90 91
Cybrid clone 2 93 90
Cybrid clone 3 96 88
Mother Blood 0 0
Fibroblasts ND 18
Abbreviation: ND, not determined.
patient T and from 19 to 44% in patient A, excluding complex III activity, which 
was not decreased considerably in patient A.
M olecular genetic analysis
Sequence analysis of the entire mitochondrial genome revealed 18 (patient T) and 
39 (patient A) known polymorphic variants compared with the revised Cambridge 
Reference Sequence,12 and two mutations: a G-to-A transition at position m.5556 
in the tRNATrp gene (MT-TW) in patient T and an A-to-G transition at position 
m.10450 in the tRNAArg gene (MT-TR) in patient A. The levels of the mutations 
were nearly homoplasmic in both patients, in muscle tissue as well as cultured 
fibroblasts (Table 2). In the blood of the mothers the mutations could not be 
detected, whereas in fibroblasts of the mother of patient A the m.10450A>G 
mutation was present with 18% heteroplasmy. The two mutations were not 
reported before and were found neither in 84 healthy control subjects and in 31 
patients with a combined OXPHOS complex I, III and IV deficiency (tested by PCR) 
nor in haplogroup-matched controls, 499 controls of haplogroup H for tRNATrp 
and 121 controls of haplogroup T for tRNAArg (database search).13 Position m.5556 
is located in the variable region of the tRNATrp structure and position m.10450 
is located in the T stem of tRNAArg (Figures 1a and b). The nucleotide mutated 
in tRNATrp is entirely conserved in mammals14 and also in several lower species 
(Figure 1c). The mutation in tRNAArg, in contrast, affects a base that is conserved 
in many mammalia,14 but not in lower species (Figure 1d).
Analysis of m itochondrial protein synthesis
As shown in Figure 2, both patients showed a marked reduction in radioactive 
labeling as compared with controls, indicating that the rate of mitochondrial 
protein synthesis is decreased. The total incorporation of [35S]methionine was 45% 
(patient T) and 57% (patient A) of that in controls; however, different polypeptides 
were affected to variable extents (Table 3). In patient T, the rate of mitochondrial
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Figure 1. Schematic representation of the tRNATrp (a) and tRNAArg (b) cloverleaf structures, showing 
the location of the mutations. Comparison of the sequences of the variable region of the tRNATrp 
gene (c) and the T-stem of the tRNAArg gene (d) across different species; the mutated bases are 
depicted in bold.
translation ranged from 22 to 126% and the three subunits of complex IV (COI- 
COIII) were most severely affected. In patient A, synthesis of COI showed by far 
the strongest decrease (12%) and the other polypeptides were affected only 
minimally with incorporation rates of 68% or higher. In both patients, the synthesis 
levels of the two ATP synthase subunits (ATP6 and ATP8; the latter migrated in a 
band together with ND4L) were comparable to or even higher than the levels in 
controls.
Blue-native PAGE and com plex I in-gel activity assay
To determine whether the combined OXPHOS deficiencies in the patients were 
indeed caused by a mtDNA defect, we analyzed the assembly of all OXPHOS 
complexes in fibroblasts and cybrid cell lines using blue-native PAGE analysis. 
Patient fibroblasts showed reduced levels of fully assembled complexes I, III 
(only in patient T), IV and V as well as decreased complex I activities (Figure 3), 
which is consistent with the deficiencies detected in the enzyme measurements 
(Table 1). This pattern was also found in the different cybrid clones, proving the 
mitochondrial origin of the OXPHOS defect. In addition to the fully assembled
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complex V, two subcomplexes were observed in most samples with raised levels 
in the patient samples. These subcomplexes are often increased in patients with 
a defect in the mtDNA, but sometimes they are entirely absent. This was the case 
for the experiment with fibroblasts from patient A and the control, which was 
probably caused during the preparation of the samples.
Northern blot analysis
To analyze the effect of both mutations on tRNA stability, steady-state levels 
of tRNATrp and tRNAArg were determined using northern blot hybridization in 
cultured fibroblasts and cybrid cell lines of the two patients. The amounts of 
mutant tRNA were markedly decreased (Figure 4): in patient T, the tRNATrp levels 
were reduced to 29% (fibroblasts) and 33% (cybrids), and in patient A the tRNAArg 
levels were reduced to 29% (fibroblasts) and 50% (cybrids) (after normalization to 
the tRNAArg or tRNATrp levels, respectively, and relative to average control values).
In addition, native gel electrophoresis provided insights into whether 
the mutations affect tRNA structure. Whereas on a denaturing gel the tRNA 
mutants migrated at the same rate as the wild type (see steady-state data, 
Figure 4), both tRNA mutations resulted in aberrant migration patterns under
Figure 2. In vitro labeling of mitochondrial translation products. Fibroblasts from the patients (PT 
and PA) and controls (C1 and C2) were labeled with [35S]methionine in the presence of emetine. The 
mitochondrial translation products are indicated on the left of the autoradiogram. COI-COIII, subunits 
of cytochrome c oxidase; cyt b, cytochrome b subunit; ND1-6, subunits of NADH CoQ oxidoreductase; 
ATP6-8, ATP synthase subunit 6 and 8.
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Table 3. Level of mitochondrial protein synthesis
Polypeptide Patient T Patient A
COI 28 12
Cytb/ND2 56 86
ND1 35 82
COIII/COII 22 68
ATP6 124 163
ND6/ND3 82 89
ND4L/ATP8 126 94
The values represent percentages of the average incorporation of [35S]methionine measured in two 
controls. Abbreviations: COI-COIII, subunits of cytochrome c oxidase; cyt b, cytochrome b subunit; 
ND1-6, subunits of NADH CoQ oxidoreductase; ATP6-8, ATP synthase subunits 6 and 8.
non-denaturing conditions (see conformation data, Figure 4), indicating that 
they primarily affect the secondary or tertiary structure of the tRNAs. The 
mutation in tRNATrp led to retardation of the electrophoretic mobility of the 
residual tRNATrp compared with controls. The analysis of tRNAArg revealed 
the presence of two different conformations with accelerated mobility.
As the cybrid clones showed similar steady-state levels and migration 
patterns as found in fibroblasts of the patients, these results are again consistent 
with the mitochondrial origin of the OXPHOS defects.
Figure 3. Blue-native PAGE and complex I in-gel activity assay. Fibroblasts and cybrid clones from 
patient T (PT) and A (PA) and controls (C1-3 and 143B) were analyzed. The blue-native PAGE gels were 
immunoblotted with antibodies directed against specific individual subunits to assess the amount of 
each of the five fully assembled OXPHOS complexes. Complex II was used as a loading control. IGA, 
in-gel activity.
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Figure 4. Steady-state levels and conformation of tRNATrp and tRNAArg. Fibroblasts and cybrid clones 
from patient T (PT) and A (PA) and controls (C1-3 and 143B) were analyzed using high-resolution 
northern blot under denaturing (steady-state) and native (conformation) conditions. Signal intensities 
for tRNATrp and tRNAArg were normalized to each other for each sample, as shown in the column 
charts (only relevant steady-state levels are depicted). The asterisks indicate the position of altered 
conformations of mutant tRNATrp and mutant tRNAArg.
D i s c u s s io n
In this study we clearly show that the m.5556G>A and m.10450A>G mutations are 
pathogenic and are the cause of the combined OXPHOS disorders found in the 
two patients. This conclusion is based on the following evidence: (1) the mutations 
are not present in healthy controls or in asymptomatic maternal relatives (or with 
a low mutant load), (2) the mutations affect evolutionary conserved bases (applies 
more to the tRNATrp mutation than the mutation in the tRNAArg gene), (3) patient 
fibroblasts have a general mitochondrial translation defect, (4) tRNA steady-state 
levels and conformation are affected by the mutations and (5) transmitochondrial 
cybrids show similar OXPHOS complex and tRNA defects as patient fibroblasts.
Although the mutation in the tRNATrp gene was not found in the blood 
of the patient's mother, we cannot conclude that it is a de novo mutation. 
Mutation load can vary greatly between tissues causing the mutation to be 
undetectable in, for instance, blood, as was the case for the tRNAArg mutation. 
In patient A the mutation was present at 92% heteroplasmy, whereas his mother 
had a mutant load of only 18% in fibroblasts, which is apparently below the 
threshold level for this mutation and therefore does not result in clinical disease.
Approximately 70% of pathogenic mutations occur in the stems of the
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tRNA cloverleaf structure.1516 Furthermore, the disruption of Watson-Crick base 
pairing is an important characteristic of pathogenic mutations located in the stem 
structures.15 The mutation in the tRNAArg gene affects base 50 in the T stem and 
disrupts Watson-Crick base pairing, which makes it a likely candidate for the 
disease-causing mutation. However, a wobble base pair can still be formed with 
the mutant base. The disturbance of Watson-Crick base pairing could affect the 
secondary structure of the tRNAArg, leading to misfolding and instability of the 
mutant tRNA. This was confirmed using northern blotting, which showed reduced 
tRNAArg steady-state levels and the existence of two aberrant conformations 
in the absence of the normal tRNA. In contrast, the site that is mutated in the 
tRNAArg gene is conserved merely in mammalia. Although most pathogenic tRNA 
mutations are found at highly conserved sites, there are exceptions, indicating 
that evolutionary conservation is not required for a mutation to be pathogenic.1617
The m.5556G>A mutation is located at position 46 in the variable region 
of tRNATrp, which is not a common site for pathogenic mutations.15 However, this 
base is highly conserved. In addition, a potential tertiary interaction between 
nucleotides 13-22-46 in tRNATrp has been described.14 This interaction is present in 
all mammalian tRNA families and is part of a set of three tertiary interactions that 
are thought to be minimally required for proper functioning of the mitochondrial 
tRNAs. Nucleotide 46 is N7-methylated in many tRNAs of different species.18 This 
post-transcriptional modification, together with hydrogen bonding to the bases 
G22 and C13, results in a positive charge, which could be necessary for the L-shaped 
three-dimensional tRNA structure and/or for protein recognition.19 In general, the 
role of modified bases for the maintenance of the tRNA tertiary structure is of 
higher importance in mitochondrial tRNAs than in their cytosolic counterparts.20 
Certain mitochondrial tRNAs will consequently be completely non-functional when 
lacking the post-transcriptional modification. Northern blot analysis revealed a 
clear decrease in the amount of mutant tRNATrp as well as an altered conformation, 
indicating that the mutation might indeed interfere with the tertiary interaction 
and thereby disturb the three-dimensional tRNA structure and tRNA stability.
Although the MITOMAP database lists the m.5556G>A transition as an 
unpublished polymorphism,21 our results clearly show that this nucleotide 
change is a pathogenic mutation in our patient. This underscores the importance 
of functional studies in defining the pathogenicity of tRNA mutations. Seven 
pathogenic mutations have been reported in the mitochondrial tRNATrp gene.2 
None of these mutations are located near the m.5556G>A mutation that we found. 
However, the m.5532G>A mutation22 affects base 22, which is supposedly involved 
in the tertiary interaction with base 46 (m.5556) mentioned above. Unfortunately, 
the effect of this point mutation on tRNA stability and conformation has not been 
analyzed. A common feature of most tRNATrp mutations is a profound complex
80
Mitochondrial tRNATrp and tRNAArg mutations
IV defect.22-28 In some cases complex IV is selectively decreased, in other cases 
complex I is affected to a similar extent and occasionally complex III is involved 
as well. Biochemical analysis revealed a combined complex I, III and IV deficiency 
in patient T, in which complex IV was most severely affected (on average, 28% 
of control levels) followed by complex I (38%) and last by complex III (51%). 
The results of the in vitro translation assay also supported this as the synthesis 
rates of COI and COIII/COII showed the strongest decrease as compared with 
control rates. The fact that complex IV is more susceptible to tRNATrp mutations 
could be explained by the higher percentage of tryptophan in the subunits COI 
and COIII as compared with other complex subunits, as has been proposed 
before.26,27 Nonetheless, a correlation between the relative amount of tryptophan 
in individual subunits and the reduction of their mitochondrial translation rates in 
our patient was not evident, which has also been observed by Sacconi et al for the 
m.5545C>T mutation.24 They found COI and COIII translation to be most severely 
disturbed, but in contrast to our results ATP6 showed a profoundly decreased 
synthesis as well. Increased synthesis of ATP6 and ATP8, as we observed for 
our tRNATrp and tRNAArg mutations, has been reported before29-32 and has been 
suggested to be caused by the fact that bicistronic mRNAs can be translated 
more efficiently than monocistronic mRNAs, thereby giving the translation 
of ATP6 and ATP8 an advantage.32 Many patients with a tRNATrp mutation, 
including our patient, show developmental delay, gastrointestinal symptoms 
and failure to thrive.22,24,25'28 In addition, visual defects, deafness, epilepsy and 
neurodegenerative disease are frequently observed in other patients.22-28,33
In the mitochondrial tRNAArg gene only two pathogenic mutations have 
been reported so far: m.10406G>A and m.10438A>G.2 In the patient with the 
m.10438A>G mutation, no clear OXPHOS deficiency was found, only a minor 
decrease in complex IV activity.34 In contrast, the m.10406G>A mutation caused a 
marked reduction in complex IV activity, and complex I and III were also affected.35 
This is consistent with our findings, except that complex III was hardly impaired 
in patient A. The clinical phenotypes of the three patients carrying tRNAArg 
mutations are variable; the only common features are muscle weakness and brain 
abnormalities. Furthermore, visual dysfunction and progressive psychomotor 
retardation were observed both in our patient and for the m.10438A>G mutation.34 
The clinical presentation of the m.10406G>A mutation is considerably different 
with Asperger syndrome and normal cognitive function.35 Our patient manifested 
the most severe symptoms in a progressive multisystem disorder. The variability 
in clinical phenotypes could be explained by the fact that all three mutations 
are located in different domains of the tRNA cloverleaf structure. A distinct 
correlation seems not to exist between clinical presentation and the specific 
tRNA that is mutated.16,36 For our m.10450A>G mutation, the disproportionate
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decrease in synthesis of some polypeptides (mainly COI synthesis was 
impaired) is not correlated with the arginine content of the polypeptides. The 
effects on translation have not been analyzed for the other tRNAArg mutations.
In conclusion, we show that the mutations in the mitochondrial tRNATrp and 
tRNAArg genes are pathogenic. The effect of the mutations on the tertiary (tRNATrp) 
or secondary (tRNAArg) structure will likely lead to misfolding and instability, 
resulting in increased degradation and possibly also in impaired aminoacylation. 
Consequently, the scarcity and malfunctioning of the tRNAs cause a combined 
OXPHOS deficiency through reduced rates of mitochondrial protein synthesis. This 
gives rise to a progressive multisystem disease in both patients, marked by failure 
to thrive, lactic acidosis, feeding difficulties, gastrointestinal problems, generalized 
muscle hypotonia, progressive psychomotor retardation and microcephaly.
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A b s t r a c t
The 13 polypeptides encoded in mitochondrial DNA (mtDNA) are synthesized 
in the mitochondrial matrix on a dedicated protein-translation apparatus that 
resembles that found in prokaryotes. Here we have investigated the genetic basis 
for a mitochondrial protein-synthesis defect associated with a combined oxidative 
phosphorylation enzyme deficiency in two patients, one of whom presented 
with encephalomyopathy and the other with hypertrophic cardiomyopathy. 
Sequencing of candidate genes revealed the same homozygous mutation 
(C997T) in both patients in TSFM, a gene coding for the mitochondrial translation 
elongation factor EFTs. EFTs functions as a guanine nucleotide exchange factor 
for EFTu, another translation elongation factor that brings aminoacylated transfer 
RNAs to the ribosomal A site as a ternary complex with guanosine triphosphate. 
The mutation predicts an Arg333Trp substitution at an evolutionarily conserved 
site in a subdomain of EFTs that interacts with EFTu. Molecular modeling showed 
that the substitution disrupts local subdomain structure and the dimerization 
interface. The steady-state levels of EFTs and EFTu in patient fibroblasts were 
reduced by 75% and 60% respectively, and the amounts of assembled complexes 
I, IV and V were reduced by 35-91% compared with the amounts in controls. 
These phenotypes and the translation defect were rescued by retroviral expression 
of either EFTs or EFTu. These data clearly establish mutant EFTs as the cause of 
disease in these patients. The fact that the same mutation is associated with 
distinct clinical phenotypes suggests the presence of genetic modifiers of the 
mitochondrial translation apparatus.
88
Mitochondrial elongation factor Ts mutation
I n t r o d u c t i o n
Defects in mitochondrial oxidative phosphorylation (OXPHOS) are estimated to 
occur in approximately ~1 in 5,000 live births.1 They can be classified biochemically 
as either isolated or combined deficiencies of any of the five OXPHOS complexes.2 
Genetic defects leading to combined deficiencies of complexes I, III, IV, and V can 
be caused by mutations in mtDNA or in the components of the mitochondrial 
translation apparatus encoded by nuclear genes.3
Synthesis of the 13 mitochondrial-encoded proteins occurs on a dedicated 
mitochondrial translation apparatus similar to that found in prokaryotes and 
requires, in addition to the tRNAs and ribosomal RNAs (rRNAs) encoded in 
mtDNA, the concerted action of several translation factors and a large number 
of mitochondrial ribosomal (mitoribosome) proteins, all of which are encoded 
by nuclear genes. Two mammalian initiation factors, IF2 and IF3; four elongation 
factors, EFTu, EFTs, EFG1, and EFG2 (reviewed by Spremulli et al);4 one release 
factor, RF1; and one ribosomal recycling factor, RRF,5 have been cloned and 
sequenced. Mitoribosomes are distinct from both prokaryotic and eukaryotic 
cytosolic ribosomes; they are 55S particles composed of a small (28S) and a 
large (39S) subunit and contain a much higher protein:RNA ratio than that of the 
bacterial 70S ribosome.6
Although the vast majority of components of the mitochondrial translation 
system are nuclear encoded, most mutations associated with mitochondrial 
translation defects have been reported in mtDNA-encoded tRNAs and rRNAs.7,8 
However, we recently reported mutations in the nuclear-encoded translation 
elongation factor EFG19,10 and in MRPS16, a protein of the small ribosomal 
subunit,11 in patients with autosomal recessive mitochondrial translation defects. 
Encouraged by these findings, we investigated a cohort of 16 patients with 
combined OXPHOS enzyme defects expressed in both muscle and fibroblasts 
in which mtDNA sequencing and complex II activity-measurement results were 
normal. We describe the first mutation in the mitochondrial elongation factor 
EFTs (encoded by TSFM [MIM 604723]) associated with a fatal mitochondrial 
encephalomyopathy in one pedigree and with fatal hypertrophic cardiomyopathy 
in another, and demonstrate the molecular basis for the defect.
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M a t e r i a l s  a n d  m e t h o d s
Case reports
Patient 1, a boy, was born at term as the second child of consanguineous Turkish 
parents by cesarean section performed on maternal indication. Birth weight 
(3,140 g), length (50 cm), and head circumference (36 cm) were age appropriate. 
Muscular hypotonia, sucking weakness, and a severe lactic acidosis (pH 6.8; base 
excess -26; lactic acid 42 mM [control <2.1 mM]) were the initial clinical signs and 
symptoms, followed by rhabdomyolysis with creatine kinase values up to 7,252 U/ 
liter (control <248 U/liter). The initial lactate:pyruvate (L:P) ratio was 92 (control 12­
15). During life, lactic acid dropped to values between 4 and 5.5 mM, with L:P ratios 
~25. Artificial ventilation was needed because of persistent dyspnea. On the 3rd 
day of life, generalized convulsions became obvious. The electroencephalogram 
showed a discontinuous pattern with bifrontal symmetrical sharper spikes. 
Repeated ultrasound imaging of the brain showed reduced gyri on day 4, plexus 
bleeding with enlarged ventricles on day 6, and abnormal signal intensity of the 
thalami on day 9. Echocardiographic examination on day 6 revealed a persistent 
ductus arteriosus Botalli, with left-to-right shunting, and a persistent foramen 
ovale. Septum thickness and contractility were age appropriate. On the basis of 
the suspicion of a mitochondrial disorder, a fibroblast culture was established 
and a skeletal muscle (m. vastus lateralis dextra) biopsy sample was obtained for 
measurements of the OXPHOS enzymes. Despite intensive treatment, the patient 
died of progressive encephalomyopathy and respiratory failure at age 7 wk.
Patient 2, a girl, was the third child of second cousins once removed whose 
parents are of Kurdish Jewish origin. Two older children were healthy. The mother 
reported a paucity of fetal movements throughout the pregnancy. Delivery was 
vaginal, and birth weight was 2,600 g. Initial examination results were normal, 
and the patient was breast-fed. At age 36 h, apathy, irregular breathing, and 
severe muscular hypotonia were noted. Laboratory investigation revealed severe 
metabolic acidosis (pH 6.93; HCO3 -4.6; base excess -26). Serum lactate level 
was increased (17.6 mM; control <2.4 mM), as were blood ketone levels (3-OH- 
butyrate 4,803 |jM; acetoacetate 257 |jM; control values <200 |jM and <100|jM, 
respectively) and serum ammonia levels (268 |jM; control <32 |jM). Blood count and 
liver enzyme levels were normal. Echocardiographic examination disclosed severe 
concentric hypertrophic cardiomyopathy with normal contractility. Apart from 
generalized muscle hypotonia, neurological examination, including fundoscopy 
and brain CT scan, were normal. Skin biopsy for fibroblast culture and muscle 
biopsy from the right quadriceps were performed at age 2 wk; histochemical 
analysis of the muscle revealed a generally decreased cytochrome c oxidase (COX) 
stain, whereas the succinate dehydrogenase stain was normal. The patient was
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given treatment with carnitine, sodium-dichloroacetate, thiamine, idebenone, and 
riboflavin, but the lactate level remained elevated, and cardiac function gradually 
deteriorated. Her death at age 7 wk was preceded by severe hyponatremia with 
a low urinary output of 2 d. An open-liver biopsy was performed 20 min after her 
death.
Southern-blot analysis of the muscle, liver, and fibroblast DNA revealed 
normal size and abundance of mtDNA. Northern-blot analysis showed that the 
steady-state levels of several mitochondrial transcripts (ND6, COXI, COXII, and 
12S rRNA) were normal. Sequencing of the 22 mitochondrial tRNA genes failed to 
identify a pathogenic mutation.
Human studies
Informed consent was obtained, and research studies were approved by the 
Helsinki committee of Hadassah-Hebrew University Medical Center, the Radboud 
University Medical Centre Nijmegen, and the Montreal Neurological Institute 
Institutional Review Boards.
Cell culture
Primary human skin fibroblasts were immortalized with a retrovirus expressing 
the E7 gene of type 16 human papilloma virus and a retroviral vector expressing 
the protein component (htert) of human telomerase.12 Patient and control 
skin fibroblasts were cultured in Dulbecco's modified Eagle medium (DMEM) 
supplemented with 10% fetal calf serum (FCS).
Enzym e m easurem ents
The activities of the OXPHOS enzyme complexes in skeletal muscle and fibroblasts 
were measured according to described protocols.13,14 COX and citrate synthase 
activities were measured in fibroblast cell extracts as described elsewhere.15
Sequence analysis
Total RNA was extracted from cultured skin fibroblast of the patient by use 
of RNAzol (Campro Scientific). The TSFM cDNA (GenBank accession number 
NM_005726) was amplified by superscript II reverse transcriptase/Toq DNA 
polymerase (Life Technologies) in four overlapping fragments (primer sequences 
available on request). After treatment with ExoI (Promega) and SAP (Promega), 
the PCR fragments were used as templates in sequencing reactions with the 
chemistry of BigDye1.1 (Applied Biosystems) according to manufacturer's protocol. 
The labeled fragments were separated on a 3130xl Genetic Analyzer (Applied 
Biosystems). Sequence data were evaluated with Sequencher 4.2 sequence-
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analysis software (Gene Codes) by comparison with the reference sequence of 
TSFM. Sequence analysis of the last part of exon 7 of the TSFM gene was performed 
on genomic DNA by use of the primers 5'-CTTGGGCAGCCATGTGG-3'(forward) 
and 5'-ACCCATGCATTCTCGGTCTG-3'(reverse).
Blue-native PAGE and im munoblotting
Blue-native PAGE was used for separation of the OXPHOS complexes on 6%-15%  
polyacrylamide-gradient gels.16 Mitoplasts, which were prepared from fibroblasts 
by treatment with 0.8 mg of digitonin per mg of protein, were solubilized with 1% 
lauryl maltoside, and 20 |jg of the solubilized protein was used for electrophoresis.17 
Assembly of the OXPHOS complexes was established by immunoblot analysis with 
the use of monoclonal antibodies against subunits of complexes II-V (Molecular 
Probes) and a polyclonal antibody against the ND1 subunit of Complex I (a kind 
gift of A. Lombes, Paris). For immunoblotting, fibroblasts were solubilized with 
1.5% lauryl maltoside in PBS, and 20 |jg of protein was separated by TRIS-Glycine 
SDS-PAGE gel. After transfer to a nitrocellulose membrane, individual proteins 
were detected using monoclonal antibodies against subunits of complexes I-V  
(Molecular Probes), porin (Sigma), MnSOD (Stressgen), and polyconal antibodies 
directed against ND1, EFTu (a kind gift of N. Takeuchi, Tokyo), EFTu/Ts (a kind gift 
of L. Spremulli, Chapel Hill, NC), and EFG1.10
Pulse labeling of m itochondrial translation products
In vitro labeling of mitochondrial translation was performed as described 
elsewhere.18 In brief, cells were labeled for 60 min at 37°C in methionine-free 
DMEM with 10% dialyzed fetal bovine serum, containing 200 ^Ci/ml of [35S] 
methionine and 100 |jg/ml of emetine, followed by a 10-min incubation in regular 
DMEM with 10% fetal bovine serum. Total cellular protein (50 |jg) was resuspended 
in loading buffer containing 93 mM Tris-HCl (pH 6.7), 7.5% glycerol, 1% SDS,
0.25 mg bromophenol blue per ml, and 3% mercaptoethanol, was sonicated for 
3-8 s, and was run on 12%-20% polyacrylamide-gradient gels. The gels were 
scanned on a Storm Phosphorimager (Molecular Dynamics) and analyzed with 
ImageQuant software. Under the conditions of the experiment, all signals were in 
the linear range.
cDN A constructs, virus production, and infection
Retroviral vectors containing the cDNA sequence of TUFM (GenBank accession 
number NM_003321) and TSFM were created with the Gateway cloning system 
(Invitrogen) as described elsewhere.10 The PCR constructs were cloned into 
a Gateway-modified retroviral-expression vector (pBABE-puro). Retroviral 
constructs were transiently transfected into Phoenix packaging cell line by use
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of the HBS/Ca3(PO4)2 method (Helper Dependent Protocol Web site). Patient 
and control fibroblasts were infected 48 h later by exposure to virus-containing 
medium in the presence of 4 |jg/ml of polybrene, as described elsewhere.12
Com putational modeling
The crystal structure of the bovine EFTu/EFTs complex has been described 
elsewhere.19 On the basis of this model, the structure of wild-type and mutant 
EFTs protein were determined with the YASARA-WHAT IF twin set software.20 The 
R333W mutation was predicted using the method of De Fillippis et al.21 Molecular 
figures were drawn with the POV-Ray module in YASARA. Further modeling 
details are available at the TS Modelling Web site.
R e s u l t s
Skeletal muscle and fibroblasts from patient 1 showed decreased enzyme 
activities of complexes I, III, and IV of the respiratory chain (table 1). The activities 
of complexes I, III, and IV in the skeletal muscle of patient 2 were similarly reduced
Figure 1. Pulse labeling of mitochondrial translation products in patient fibroblasts. Fibroblasts from 
the two patients (P1 and P2) and two controls (C1 and C2) were labeled with [35S]methionine in the 
presence of emetine, a cytosolic translation inhibitor, as outlined in the "Material and Methods" section. 
Fibroblasts from patient 1 were also analyzed after transduction with retroviral vectors overexpressing 
the mitochondrial translation factors EFTu or EFTs. The mitochondrial translation products are indicated 
on the left of the autoradiogram. COI-COIII = subunits of cytochrome c oxidase; cytb = cytochrome 
b subunit; ND1, ND2, ND3, ND4, ND4L, ND5, and ND6 = subunits of NADH CoQ oxidoreductase; 
ATP6 and ATP8 = subunits of ATP synthase. The numbers at the bottom of the gel indicate the total 
incorporation of [35S]methionine relative to the corresponding control.
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Table 1. OXPHOS enzyme activities in skeletal muscle and fibroblasts of patient 1
Activities (mU/U citrate synthase) in
Skeletal muscle Fibroblasts
Complex Patient Reference range Patient Reference range
I 0 70 -  250 53 100 -  310
III 753 2,200 -  6,610 1,250 1,320 -  2,610
II + III 228 300 -  970 163 110 -  470
IV 186 810 -  3,120 397 680 -  1,190
PDH 60 34 -  122 ND ND
Note.-Samples were 600 g of supernatant of skeletal muscle or mitochondrial enriched fraction from 
fibroblasts. ND = not determined; PDH = pyruvate dehydrogenase complex.
to 30%, 14%, and 14% of the control means, respectively, whereas complex II 
was unaffected (123% of the control mean). In fibroblast mitochondria from 
patient 2, complexes I, IV, II+III, and II activities were 44%, 25%, 77%, and 107% 
of the control mean, respectively. Pulse labeling of the mitochondrial translation 
products in fibroblasts from both patients revealed a generalized mitochondrial 
protein-synthesis defect; however, different polypeptides were variably affected 
(fig. 1 and table 2). The overall incorporation of [35S]methionine was 39%-49% 
of that in controls, and the rate of synthesis of most polypeptides was reduced 
to 30%-60% of control values. However, the synthesis of the two ATP synthase 
subunits (ATP6 and ATP8) actually increased relative to control levels in patient 1 
and was similar to control levels in patient 2 (table 2).
These data suggested that the genetic defect was due to a component of the 
mitochondrial translation apparatus, and the failure to identify any abnormalities 
in mtDNA (data not shown) suggested a nuclear gene defect. Two strategies 
were employed to identify the underlying genetic defect. In patient 1 (and 14 
additional patients with a similar combined OXPHOS deficiency), we sequenced 
the cDNAs for the known mitochondrial translation initiation, elongation, and 
termination factors. In patient 2, we used the Affymetrix Human Mapping 50K 
Array Xba240 to genotype 58,495 SNPs to identify regions of homozygosity. The 
latter analysis identified a long segment of consecutive homozygous SNPs on 
chromosome 2 spanning 22.1 Mb (213.1-235.2 Mb) and another segment on 
chromosome 12 spanning 30.79 Mb (26.48-57.27 Mb). With use of the MitoP2 
prediction program22 for mitochondrial localization (score >60), two proteins 
with known function in mitochondrial translation were identified within these 
regions -  the mitochondrial ribosomal protein S35 and mitochondrial translation 
elongation factor EFTs (encoded by TSFM).
Sequence analysis of TSFM revealed the same homozygous C997T mutation 
in exon 7 in both patients (fig. 2). A BLAST search showed that the C997T mutation
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was not present in any reported human EST, and the mutation was not found in 
the other 14 patients tested or in 135 controls. The mutation was heterozygous 
in the parents in both families and in the two healthy sibs of patient 2 (data not 
shown). A sib of patient 1 was homozygous wild-type (data not shown). Analysis 
of microsatellite markers on chromosome 12 demonstrated that the mutation 
did not arise on a common haplotype in the two patients (fig. 2D). Human TSFM 
appears to be alternatively spliced, since exon 5 was not present in any of the 
patient or control cDNAs analyzed. Exon 5 is present in a single EST sequence 
in the human database, derived from bone marrow of a patient with acute 
myelogenous leukaemia.
The mutation predicts an Arg333Trp substitution in the C-terminal domain of 
EFTs, and sequence alignment of this protein from several species shows that the 
mutated amino acid is highly conserved from human to bacteria (fig. 2B). This Arg 
residue makes favorable hydrophobic and electrostatic interactions within the 
helical part of subdomain C (fig. 3). Mutational analysis using the crystal structure 
of the bovine EFTu^EFTs complex shows that it is not possible to introduce a 
Trp at this position without serious clashes between the Trp side chain and the 
backbone atoms in the immediate surroundings. The close-up of the region of Ts 
that harbors the mutation shows three preferred rotamers of Trp, representing
Table 2. Synthesis of individual mitochondrial polypeptides in fibroblasts 
from patients P1 and P2 after pulse labeling with [35S]methionine
Incorporation o f [35S]methionine (% o f control)
Polypeptide P1 P2 P1 + EFTu P1 + EFT s
ND5 22 18 59 49
COI 34 32 59 61
ND4 42 33 65 52
ND2/cytb 61 51 56 43
ND1 56 55 58 46
COIII/COII 42 34 56 60
ATP6 134 64 69 31
ND6 59 21 60 72
ND3 103 68 112 91
ND4L 29 30 43 48
ATP8 244 113 94 22
Note.- The results are presented as a percentage of the average incorporation of [35S]methionine 
in two relevant controls. Mitochondrial translation was also analyzed in patient 1 after transduction 
with retroviral constructs overexpressing EFTu or EFTs. COI-COIII = subunits of cytochrome c oxidase; 
cytb = cytochrome b subunit; ND1, ND2, ND3, ND4, ND4L, ND5, and ND6 = subunits of NADH CoQ 
oxidoreductase.
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Figure 2. Sequence analysis of TSFM. A, DNA sequence chromatogram from a control and patient 1 
(homozygous C997T) and a heterozygous chorionic villus sample. B, Domain structure of EFTs (N-terminal 
in black, subdomain N in white, and subdomain C in gray) showing the predicted Arg333Trp substitution 
in subdomain C. C, Protein sequence alignment for Homo sapiens, Bos taurus, Caenorhabditis eiegans, 
and E. Coli. The alignment from human to bacteria shows that the mutated Arg333Trp is highly conserved 
among different species. D, Analysis of microsatellite markers spanning the TSFM locus on chromosome 
12. The markers are arbitrarily assigned to chromosomes in both patients.
three different energy minima (fig. 3, lower panel). The rotamer that is predicted 
to be the most favorable in the absence of a surrounding bumps into the helical 
domain immediately beneath it, and the other two rotamers that normally are 
energetically favorable bump into other local residues, as indicated in the legend 
of figure 3. The mutation is predicted to disrupt the interaction between the 
long helix and two strands in subdomain C, moving the domain that holds the 
long helix away from domain III of EFTu19 and preventing it from contributing to 
EFTu^EFTs binding (fig. 3).
To directly test whether the lack of a functional EFTs protein was the cause of 
the defective mitochondrial translation, we transduced patient fibroblasts with a 
retroviral vector expressing the wild-type TSFM cDNA. Since EFTs and EFTu form
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a dimer in human cells, we also tested whether overexpression of wild-type EFTu 
could suppress the translation defect. Overexpression of either of these constructs 
(two-to-threefold for EFTu and three-to-fourfold for EFTs; fig. 4) had a dominant 
negative effect on mitochondrial translation in control cells. In independent 
experiments with different control lines, global mitochondrial translation was 
61% ± 18% (five independent transductions in two control lines) of control in 
cells overexpressing EFTu and 74% ± 14% of control in cells overexpressing EFTs 
(four independent transductions in two control lines). In the results shown in 
figure 1, global mitochondrial translation is 68% and 75% of the control in cells 
overexpressing EFTu and EFTs, respectively. A relatively modest increase in global 
mitochondrial protein synthesis was observed in patient cells overexpressing EFTs
Figure 3. Computational modeling based on the crystal structure of the bovine EFTu^EFTs complex. 
The top panel shows the structure of the Tu^Ts dimer. Tu is on the left side of the model, and Ts on 
the right. The wild-type Arg 333 residue (depicted in orange) is superimposed on three Trp rotamers 
(depicted in yellow). The lower panel is a close-up of the region containing the mutation, which shows 
that the Arg residue fits well in front of the C-terminal side of the helix beneath it. The most favorable 
Trp rotamer bumps into this same helix. The second- and third-best local minima for the Trp rotamer 
bump into Glu 644 and Phe 637, respectively. The second rotamer also bumps into its own backbone.
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compared with the appropriate control; however, there was a significant increase 
in the rate of synthesis of several polypeptides of complex I and complex IV, and 
the rate of synthesis of ATP6 and ATP8 was significantly reduced relative to that 
observed in untransduced patient fibroblasts (table 2 and fig. 1). The results were 
generally similar in patient cells overexpressing EFTu. Thus, overexpression of 
either translation elongation factor could partially suppress the translation defect 
in the patient cells.
To investigate the mechanism of suppression of the translation defect by 
EFTu, we analyzed the steady-state levels of the translation elongation factors by 
immunoblot analysis. EFTs and EFTu in patient fibroblasts were reduced to 25% and 
40% of control levels, respectively (fig. 4). Overexpression of EFTu partially rescued 
EFTs levels, and EFTu levels were completely rescued by overexpression of EFTs. 
Overexpression of EFTs also slightly reduced EFTu levels in control cells. The levels 
of another mitochondrial translation elongation factor, EFG1, were unaltered in 
patient cells and were not changed in any of the cells overexpressing EFTs or EFTu.
Figure 4. Immunoblot analysis of fibroblasts from patient 1. Immunoblot analysis of the steady-state 
levels of three translation elongation factors (EFG1, EFTu, and EFTs) and eight OXPHOS system subunits 
(COI-49kDa, COI-39 kDa, COI-ND1, COII-70 kDa, COIII-Corel, COIV-COXI, COIV-COXIV, and COV-a) 
in control and patient fibroblasts before and after transduction with retroviral constructs expressing 
the mitochondrial translation elongation factors EFTu or EFTs. Porin and manganese superoxide 
dismutase (MnSOD) were used as loading controls.
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Figure 5. Blue-native PAGE analysis of the assembly of the OXPHOS complexes in patient fibroblasts. 
Fibroblasts from patient 1 and two controls (C1 and C2) were analyzed by blue-native PAGE before 
and after transduction with retroviral constructs expressing the mitochondrial translation elongation 
factors EFTu or EFTs. The gels were immunoblotted with antibodies directed against specific individual 
subunits to assess the amount of each of the fully assembled complexes.
To investigate whether the increased mitochondrial protein synthesis in 
patient cells overexpressing EFTu or EFTs resulted in increased OXPHOS function, 
we examined the assembly of the OXPHOS complexes by blue-native PAGE 
analysis (fig. 5). Patient fibroblasts showed reduced levels of fully assembled 
complexes I, IV, and V but normal levels of complex II and III, consistent with the 
deficiencies demonstrated by enzyme activity assays (table 1). The assembly of 
all three affected complexes was restored to control levels (in comparison with 
control fibroblasts overexpressing the same construct) by overexpression of either 
elongation factor (fig. 5). Functional complementation of the biochemical defect 
in patient cells overexpressing the elongation factors was also demonstrated by 
immunoblot analysis, which showed similar steady-state levels of both nuclear- 
and mitochondrial-encoded subunits of the OXPHOS complexes in patient cells 
and controls (fig. 4). Interestingly, overexpression of both factors led to slightly 
higher steady-state levels of some complex I subunits (39 kDa, 49 kDa, and ND1) in 
the patient cell line compared with controls and a markedly decreased expression 
of MnSOD, the mitochondrial superoxide dismutase.
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D i s c u s s i o n
This study firmly establishes mutations in the mitochondrial translation elongation 
factor EFTs as the cause of disease in two unrelated patients with mitochondrial 
dysfunction due to a combined deficiency of OXPHOS enzymes. Several pieces 
of evidence support this conclusion. First, pulse labeling of the mitochondrial 
translation products in patient fibroblasts identified a global translation defect 
in both patients, leading to a failure to assemble adequate amounts of three of 
the OXPHOS complexes containing subunits encoded in mtDNA. This phenotype 
could be rescued by retroviral expression of the wild-type cDNAs for either EFTs 
or EFTu. Second, a homozygous missense mutation, predicting an amino acid 
substitution at an evolutionarily conserved site, was identified in TSFM in both 
patients. Molecular modeling predicts that this mutation would disrupt the Tu^Ts 
dimerization interface. Finally, the steady-state levels of mutant EFTs and wild­
type EFTu were reduced in patient fibroblasts, and this phenotype was rescued by 
overexpression of either EFTu or EFTs.
Much of our knowledge of the mechanism of mitochondrial translation 
in mammals comes from studies of prokaryotic organisms, which share most 
of the same initiation, elongation, and termination factors.4 EFTs is a guanine 
nucleotide exchange factor that binds to the EFTu^guanosine diphosphate (GDP) 
complex, promoting the release of GDP and the formation of a stable EFTu^EFTs 
heterodimer. Guanosine triphosphate (GTP) then promotes dissociation of 
EFTs from this complex, regenerating EFTu^GTP, which can then bind another 
aminoacyl tRNA. This ternary complex associates with the ribosomal A site, and, 
when correct codon-anticodon recognition is established, GTP is hydrolyzed, 
releasing EFTu^GDP, and the cycle repeats itself. Interestingly, not all organisms 
require EFTs. For instance, the budding yeast Saccharomyces cerevisiae contains 
only EFTu, which can function both as a guanosine triphosphatase and its own 
guanine nucleotide exchange factor.23
Human TSFM maps to chromosome 12q13-q14, has an ORF of 1,040 bp, 
and comprises seven exons, although it appears that exon 5 is spliced out of the 
coding sequence in the human protein. EFTs from Escherichia coli is organized into 
four recognizable modules: N-terminus, core domain (consisting of subdomains 
N and C), coiled-coil domain, and C-terminal domain.24 The crystal structure of 
the bovine mitochondrial elongation EFTu^EFTs complex has been determined 
to a 0.22-nm resolution,19 and it appears to be broadly similar to that in E. coli, 
with a notable exception of the virtual absence of the coiled-coil and C-terminal 
domains in the mammalian protein.19 Human EFTu is 95% identical25 and human 
EFTs is 91% identical26 to the bovine sequence, and this permitted us to model 
the effects of the homozygous Arg333Trp mutation onto the bovine sequence
100
Mitochondrial elongation factor Ts mutation
without altering the backbone structure.
Molecular modeling predicts that the mutation will alter the local structure of 
subdomain C, abolishing most of the important interactions of this portion of EFTs 
with domain III of EFTu (fig. 3). This is likely to lead to the destabilization of the 
EFTu^EFTs complex and an increased turnover of its components, explaining the 
decreased steady-state levels of both factors we observed in the patient cells (fig. 
4). Expression of the wild-type version of either factor would stabilize the complex, 
thus increasing the total EFTu^EFTs pool. This can explain why overexpression of 
EFTu acts as a suppressor of the translation defect in patient cells. However, the 
observation that overexpression of either EFTu or EFTs in control cells acts as a 
dominant negative -  decreasing the rate of mitochondrial protein synthesis by 
~35%-40% and ~20%-25%, respectively10 (fig. 1) -  shows that the relative ratio 
of these elongation factors is a critical determinant of mitochondrial translation 
efficiency. Indeed, we observed that overexpression of EFTs slightly reduced the 
levels of EFTu in control fibroblasts, again suggesting that the relative expression of 
both factors is finely tuned. Consistent with this interpretation, co-overexpression 
of both EFTu and EFTs partially rescued the dominant negative effect of EFTu in 
control fibroblasts.10
It is not clear why the synthesis of the different mtDNA-encoded polypeptides 
is variably affected as a result of the TSFM mutation, but a similar phenomenon 
has been observed in fibroblasts from patients with mutations in the elongation 
factor EFG1.9,10 The most striking difference in this study, and in patients with EFG1 
mutations, is in the synthesis of the two complex V subunits (ATP6 and ATP8), 
for which the rate of synthesis is similar to the control or even increased in the 
presence of the mutant elongation factor. The most parsimonious interpretation 
of this observation is that the mRNA coding for these polypeptides, a bicistronic 
mRNA with overlapping reading frames, can be translated more efficiently than 
can mRNAs coding for the other polypeptides, most of which (except ND4/4L) 
are translated from monocistronic mRNAs. Whether this difference reflects an 
increased efficiency of translation of the ATP6 and ATP8 mRNA per se, or simply 
reduced competition from other transcripts for a limited number of ribosomes, 
remains uncertain, since the factors that regulate the efficiency of translation 
initiation and elongation in mitochondria are largely unknown.
The Arg333Trp TSFM mutation in patient 1 led to a fatal mitochondrial 
encephalomyopathy, with muscle weakness, hypotonia, rhabdomyolysis, 
and epilepsy as the most prominent clinical signs and symptoms. In striking 
contrast, the identical mutation in patient 2 was associated with a hypertrophic 
cardiomyopathy, but the results of neurological examination and CT scan 
were normal. Although tissue specificity in the clinical phenotype is common 
in mitochondrial disease, as far as we are aware, this is the first example of a
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nuclear-encoded mitochondrial accessory factor in which the identical mutation is 
associated with such a remarkable difference in clinical presentation. In addition, 
in the patients with EFG1 mutations, cardiac function was normal, and the only 
apparent OXPHOS defect in this tissue was a modest reduction in the assembly 
of complex IV.9,10 Moreover, none of the other study patients with combined 
OXPHOS enzyme deficiencies presented with early-onset cardiomyopathy as 
the major clinical symptom. This suggests the presence of genetic modifiers, but 
these await identification. Combined enzyme deficiencies of the OXPHOS system 
are a frequent cause of mitochondrial disorders. The traditional genetic diagnostic 
approach in affected patients often includes the study of mitochondrial tRNAs 
and, more recently, sequencing of the entire mitochondrial genome. This study 
suggests that it will be useful to include a genetic screen of nuclear-encoded 
translation elongation factors in the diagnostic program for these patients or to 
perform SNP genotyping in all patients originating from consanguineous families.
A c k n o w l e d g e m e n t s
We thank the support staff of the Nijmegen Centre for Mitochondrial Disorders 
for biochemical analysis of the patient skeletal muscle and fibroblast OXPHOS- 
system enzyme activities. J.S. and B.v.d.H. are currently supported by grants 
from the Radboud University Medical Centre Nijmegen, the Prinses Beatrix 
Fonds, and the European Union (EUMITOCOMBAT [LSHM-CT-2004-503116] and 
MitoCircle). This research was supported by the Canadian Institutes of Health 
Research (CIHR) (to E.A.S.), by the Israel Science Foundation (grant 1354-2005 
[to O.E. and A.Saada]), and the Israeli Ministry of Science and Technology (grant 
3-904 [to O.E.]). G.V. acknowledges BioSapiens, which is funded by the European 
Commission within its FP6 Programme, under the thematic area "Life sciences, 
genomics and biotechnology for health," contract LSHG-CT-2003-503265. E.A.S. 
is an international scholar of the Howard Hughes Medical Institute and a senior 
scientist of the CIHR.
102
Mitochondrial elongation factor Ts mutation
w e b  r e s o u r c e s
Accession numbers and URLs for data presented herein are as follows:
BLAST, http://www.ncbi.nlm.nih.gov/BLAST/
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for TSFM [accession number 
NM_005726] and TUFM [accession number NM_003321])
Helper Dependent Protocol, http://www.stanford.edu/group/nolan/protocols/ 
pro_helper_dep.html
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/ 
Omim/ (for TSFM)
POV-Ray, http://www.povray.org/
TS Modelling, http://swift.cmbi.ru.nl/gv/service/ts/
YASARA, http://www.yasara.org/
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Life is not always fair. 
Sometimes you can get a splinter 
even sliding down a rainbow. 
Terri Guillemets
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A b s t r a c t
The mitochondrial translation system is responsible for the synthesis of 13 
proteins required for oxidative phosphorylation (OXPHOS), the major energy- 
generating process of our cells. Mitochondrial translation is controlled by various 
nuclear encoded proteins. In 27 patients with combined OXPHOS deficiencies, 
in whom complex II (the only complex that is entirely encoded by the nuclear 
DNA) showed normal activities and mutations in the mitochondrial genome 
as well as polymerase gamma were excluded, we screened all mitochondrial 
translation factors for mutations. Here we report a mutation in mitochondrial 
elongation factor G1 (GFM1) in a patient affected by severe, rapidly progressive 
mitochondrial encephalopathy. This mutation is predicted to result in an 
Arg250Trp substitution in subdomain G' of the elongation factor G1 protein 
and is presumed to hamper ribosome-dependent GTP hydrolysis. Strikingly, the 
decrease in enzyme activities of complex I, III and IV detected in patient fibroblasts 
was not found in muscle tissue. The OXPHOS system defects and the impairment 
in mitochondrial translation in fibroblasts were rescued by overexpressing wild­
type GFM1, establishing the GFM1 defect as the cause of the fatal mitochondrial 
disease. Furthermore, this study evinces the importance of a thorough diagnostic 
biochemical analysis of both muscle tissue and fibroblasts in patients suspected 
to suffer from a mitochondrial disorder, as enzyme deficiencies can be selectively 
expressed.
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I n t r o d u c t i o n
Mitochondria harbor a translation system distinct from the one in the cell's 
cytoplasm. This system is essential for the functioning of the oxidative 
phosphorylation (OXPHOS) system, and thus for energy production, through the 
synthesis of 13 proteins of OXPHOS complexes I, III, IV and V. The remaining 
OXPHOS system subunits, as well as all other mitochondrial proteins, including 
those involved in mitochondrial translation, are encoded by nuclear DNA. Defects 
in the mitochondrial translation machinery, due to either mitochondrial (mt) or 
nuclear (n) DNA mutations, can lead to the dysfunction of multiple mtDNA-reliant 
OXPHOS complexes. Mitochondrial disorders caused by OXPHOS deficiencies are 
often devastating diseases that are estimated to occur in 1:5000 live births.1
Sequencing of all mitochondrial translation factors (MTIF2, MTIF3, TSFM, 
TUFM, GFM1, GFM2, MTRF1, MTRF1L and MRRF) in a cohort of 27 patients with 
combined OXPHOS enzyme deficits in fibroblasts and/or muscle tissue, in whom 
complex II showed normal activities and mutations in mtDNA and polymerase 
gamma were excluded, revealed a novel mutation in elongation factor G1 
(gene: GFM1, protein: EFG1) in one patient. In this report, we demonstrate 
that the combined OXPHOS deficiency and mitochondrial protein synthesis 
defect detected in patient fibroblasts are the result of the GFM1 mutation, 
ultimately leading to mitochondrial encephalopathy inducing rapid neurological 
deterioration, therapy-resistant epilepsy and death at 2 years of age.
M a t e r i a l s  a n d  m e t h o d s
Case report
The female patient was born at term as the second of a dizygotic twin after 
an uneventful gestation and birth. She was small for gestational age, with a 
birth weight of 2330 g at 40 weeks of gestation. Parents were consanguineous 
(second cousins). Two days after birth she was briefly admitted to the hospital 
because of feeding problems and reduced consciousness that were attributed 
to an infection. Cultures of urine and blood, however, remained negative. In 
the following months, she developed very slowly compared with her healthy 
twin-sister. In addition, she was severely hypotonic, made poor eye contact 
and continued to have significant feeding problems. Seizures were noted from 
the age of 8 weeks onwards. Examination at the age of 3 months showed a 
borderline microcephalic girl (head circumference was -2.5 SD) with wandering 
eye movements (suggesting delayed visual maturation) and without dysmorphic 
features. Axial hypotonia was accompanied by hypertonia of the extremities with 
brisk tendon reflexes. Liver function tests, including bilirubin levels, were normal, 
except for a repeatedly low alanine aminotransferase (ALAT range 3-15 U/l, N:
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10-50 U/l; ASAT range 24-68 U/l, N: 20-65 U/l). Blood ammonia was normal. 
Biochemical examination revealed elevated lactate levels in blood (4.9 mmol/l, 
N: <2.1mmol/l) and cerebrospinal fluid (CSF) (2.5 mmol/l, N: <2.1 mmol/l) as 
well as an increased plasma lactate:pyruvate ratio (22, N: 12-18). Amino acids in 
plasma and CSF were normal. Urine organic acids showed increased excretion of 
lactate (454 mmol/mol creatinine, N: < 156 mmol/mol creatinine), but no other 
abnormalities. Ophthalmological and cardiological investigations were normal. 
Neuroimaging revealed a small frontal cortex, a thin corpus callosum and delayed 
myelination. Multifocal epileptic discharges were found on electroencephalogram 
(EEG): a disturbed background pattern with multifocal spikes and waves, no clear 
hypsarrythmia; seizures consisting of 1-3 s of background suppressions with high 
frequency discharge, predominantly over occipital areas, resulting in nystagmus; 
and an occasional tonic component, resembling infantile spasm. A muscle biopsy 
was performed on suspicion of a mitochondrial disease. Histological examination 
of the skeletal muscle showed normal mitochondrial morphology without ragged- 
red fibers. On follow-up she deteriorated. She lost the ability to suck within the 
first year of life. Microaspirations persisted after introducing tube feeding and 
induced recurrent pneumonia. In addition, she developed hepatomegaly (4 cm 
below the right costal margin at the age of 8 months). The epilepsy progressed, 
the EEG evolving into a Lennox-Gastaut syndrome, and was resistant to various 
antiepileptic drugs (vigabatrin, nitrazepam and ACTH), whereas a ketogenic diet 
had only a modest favorable effect. She died at the age of 2 years of respiratory 
insufficiency secondary to pneumonia. The parents did not consent to perform a 
postmortem.
Cell culture
Human skin fibroblasts were cultured in M199 medium (Gibco, Breda, The 
Netherlands) supplemented with 10% fetal calf serum and antibiotics. For 
complementation experiments, primary skin fibroblasts were immortalized with 
a retroviral vector expressing the E7 gene of type 16 human papilloma virus and 
another retroviral vector expressing the protein component (htert) of human 
telomerase.2 Patient and control skin fibroblasts were cultured in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum.
Enzym e m easurem ents
The activities of the OXPHOS enzyme complexes were measured in skin fibroblasts 
and muscle tissue as described previously.34 The pyruvate oxidation and ATP 
production rates were determined in muscle tissue.5
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Sequence analysis
Total RNA was isolated from cultured skin fibroblasts using RNA-Bee (Tel- 
Test, Friendswood, TX, USA); complementary DNA (cDNA) was prepared 
using superscript II reverse transcriptase (Invitrogen, Breda, The Netherlands). 
Sequence analysis of the open reading frame of GFM1 (GenBank accession 
number NM_024996) was performed in four overlapping fragments (primer 
sequences are available on request). The presence of the mutation was confirmed 
on genomic DNA, isolated from patient fibroblasts and from blood from control 
subjects and from the patient's parents using salt extraction,6 with primers 
5'-CATTACTCTTATTTGCCATTTG-3' (forward) and 5'-GGGTCCTCAATAACTTTTC-3' 
(reverse). Both strands were used for direct sequencing on a 3130xl Genetic 
Analyzer, using the BigDye terminator v1.1 cycle sequencing kit according to 
the manufacturer's protocol (Applied Biosystems, Nieuwerkerk a/d IJssel, The 
Netherlands). Sequence data were analyzed with Sequencher 4.8 software (Gene 
Codes, Ann Arbor, MI, USA) by comparison with the reference sequence of GFM1.
Com putational modeling
The structures of the wild-type and mutant EFG1 proteins were based on the 
crystal structure of Thermus thermophilus EFG.7 Modeling, energy minimization 
and analysis were performed using the YASARA (YASARA Biosciences GmbH, 
Vienna, Austria) and WHAT IF Twinset software (WHAT IF Foundation, Nijmegen, 
The Netherlands).8 The human EFG1 and T. thermophilus EFG proteins share 45% 
sequence identity; the first 43 EFG1 residues could not be modeled. Molecular 
figures were drawn with the POV-Ray module in YASARA.
cDN A constructs and virus production and infection
A retroviral vector containing the cDNA sequence of GFM1 was created with the 
Gateway cloning system (Invitrogen, Carlsbad, CA, USA). The GFM1 cDNA was 
amplified from I.M.A.G.E. clone No. 5574223 (ATCC) using specific primers and 
this PCR construct was subsequently cloned into a Gateway-modified retroviral 
expression vector, pBABE. The fidelity of the cDNA clone was confirmed by 
automated DNA sequencing. The retroviral construct was transiently transfected 
into a Phoenix packaging cell line using the HBS/Ca3(PO4)2 method (http://www. 
stanford.edu/group/nolan/protocols/pro_helper_dep.html). Patient and control 
fibroblasts were infected 48 h later by exposure to virus-containing medium in 
the presence of 4 ^g/ml of polybrene, as described.2
Blue-native and SDS-PAGE analysis
Blue-native PAGE was used for separation of the OXPHOS complexes on 6-15%  
polyacrylamide gradient gels.9 Mitoplasts, which were prepared from fibroblasts by
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treatment with 0.8 mg of digitonin/mg of protein, were solubilized with 1% lauryl 
maltoside, and 20 |jg of the solubilized protein was used for electrophoresis.10 
Assembly of the OXPHOS complexes was investigated by immunoblot analysis 
using monoclonal antibodies against subunits of complexes II-V (Molecular 
Probes/Invitrogen, Carlsbad, CA, USA) and a polyclonal anti-ND1 antibody for 
complex I detection (a kind gift of A. Lombes, Paris).
One-dimensional 10% SDS-PAGE analysis was performed as described 
previously.11 A polyclonal antibody directed against EFG112 and a monoclonal 
antibody against the 70 kDa subunit of complex II (Molecular Probes/Invitrogen, 
Leiden, The Netherlands) were used for detection.
Pulse labeling of m itochondrial translation products
35S labeling of mitochondrial translation was performed as described elsewhere.13 
In short, cells were labeled for 60 min at 37 °C in methionine-free DMEM with 200 
|jCi/ml of a [35S]-methionine and -cysteine mixture (Perkin Elmer, Woodbridge, 
ON, Canada) and 100 |jg/ml emetine, and subsequently chased for 10 min in 
regular DMEM. Total cellular protein (50 |jg) was resuspended in loading buffer 
containing 93 mM Tris-HCl (pH 6.7), 7.5% glycerol, 1% SDS, 0.25 mg bromophenol 
blue per ml and 3% mercaptoethanol, sonicated for 3-8 s and run on 15-20% 
polyacrylamide gradient gels.
R e s u l t s
Patient fibroblasts showed decreased enzyme activities of OXPHOS complexes
I, III and IV, whereas complex II activity was normal (Table 1). Strikingly, skeletal 
muscle biochemistry revealed normal enzyme activities for OXPHOS complexes 
I and IV, whereas complex III was only moderately decreased compared with the 
lowest reference range value. The capacity of the mitochondrial energy generating
Table 1. OXPHOS enzyme activities in skeletal muscle and skin fibroblasts
Activities (mU/U citrate synthase) in 
Skeletal muscle Skin fibroblasts
Complex Patient Reference range Patient Reference range
I 79 70 -  250 34 100 -  310
II 97 67 -  177 595 520 -  845
III 2151 2200 -  6610 1038 1320 -  2610
II+III 319 300 -  970 122 110 -  470
IV 1103 810 -  3120 168 680 -  1190
Abbreviation: OXPHOS, oxidative phosphorylation.
Samples were 600 g of supernatant of skeletal muscle or mitochondrial enriched fraction from 
fibroblasts.
Decreased activities as compared with controls are in bold.
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Table 2. Pyruvate oxidation and ATP production rates in skeletal muscle
Substrate Patient Reference range
[1-14C]pyruvate + malate 1.53 a 3.61 -  7.48 a
[1-14C]pyruvate+carnitine 2.07 a 2.84 -  8.24 a
ATP + CrP from oxidation of pyruvate 13 b 42 -  81 b
Abbreviations: ATP, adenosine triphosphate; CrP, phosphocreatine. 
a nmol CO2/hr mU citrate synthase 
b nmol ATP/hr mU citrate synthase
system, however, was clearly reduced in muscle tissue, indicated by impairments 
in pyruvate oxidation and ATP production rates (Table 2).
After excluding mutations in mtDNA and polymerase gamma (POLG and 
POLG2), the nine known mitochondrial translation factors (MTIF2, MTIF3, TSFM, 
TUFM, GFM1, GFM2, MTRF1, MTRF1L and MRRF) were sequenced. This revealed 
a homozygous C to T transition at position 748 of the coding sequence of GFM1 
(Fig. 1A). The mutation was not present in any reported human EST or in 100 
control subjects and was found heterozygous in both parents (Figure 1a). This 
mutation is predicted to result in an Arg250Trp substitution in helix A of the G' 
subdomain, which is part of domain I of the EFG1 protein (Figure 1b). Sequence 
alignment of EFG1 orthologs in several species shows that this amino acid is 
highly conserved from humans to bacteria (Figure 1c). Immunoblot analysis 
revealed a severe reduction in the steady-state level of EFG1 in patient fibroblasts 
(Figure 1d). Figure 2 depicts how the Arg residue is positioned on the periphery 
of the protein and forms a hydrogen bond with Glu 153; this bond is lost when 
the Trp residue is introduced. Furthermore, a positive charge, which could be 
important for interactions between helix A and other proteins, is lost because of 
the mutation. In addition, the large and aromatic Trp side chain could interfere 
with these protein interactions.
To investigate whether the lack of functional EFG1 protein was responsible 
for the combined OXPHOS system defect, we transduced patient fibroblasts 
with a retroviral vector expressing the wild-type GFM1 cDNA. Patient fibroblasts 
displayed markedly reduced levels of fully assembled OXPHOS complexes (Figure 
3b), corresponding to the deficiencies detected using enzyme activity assays 
(Table 1), as well as a clear impairment in mitochondrial protein synthesis (Figure 
3a). These phenotypes were rescued by overexpressing wild-type GFM1 (Figures 
3a and b). The mitochondrial translation rate increased from 51 to 92% of control 
levels and the activity of complex IV was restored from 20 to 88% of the activity 
in control fibroblasts.
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Figure 1. Mutational analysis of GFM1. (a) DNA sequence chromatogram from the patient (homozygous 
c.748C>T) and both parents (heterozygous). (b) EFG1 protein structure with the functional domains 
showing the predicted Arg250Trp substitution in the G' subdomain of domain I. (c) Protein sequence 
alignment from humans to bacteria. The alignment shows that the mutated Arg250Trp is highly conserved 
among different species. (d) Immunoblot analysis in patient (P) and control (C) fibroblasts reveals the 
absence of the EFG1 protein. The 70 kDa subunit of complex II (CII) was used as a loading control.
Figure 2. Computational modeling based on the crystal structure of the T. thermophilus EFG protein. 
The left panel shows the structure of the entire human EFG1 protein and the right panel is a close-up 
of the outlined region containing the mutation. The wild-type Arg 250 residue is depicted in green 
and the mutant Trp is depicted in red (bound GDP is depicted in yellow). The right panel shows that 
the Trp residue fits in the structure; however, the hydrogen bond that Arg forms with Glu 153 is lost.
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Figure 3. Rescue of the mitochondrial translation defect and combined OXPHOS deficiency in patient 
fibroblasts by expression of GFM1. Control (C) and patient (P) fibroblasts were transduced with a 
retroviral vector expressing the wild-type GFM1 cDNA and analyzed by a mitochondrial translation 
assay (a) and BN-PAGE (b). The mitochondrial translation products are indicated on the left: seven 
subunits of complex I (ND), one subunit of complex III (cyt b), three subunits of complex IV (COX) and 
two subunits of complex V (ATP). Co I -  Co V = complex I to V.
D i s c u s s i o n
A hom ozygous mutation in subdom ain G' of translation elongation factor G1 
(Arg250Trp) led to a com bined OXPHOS deficiency and a clinical picture consistent 
with severe, rapidly progressive mitochondrial encephalopathy in our patient.
EFG1 is a GTPase that catalyzes the translocation step of mitochondrial protein 
synthesis, during which the deacylated tRNA moves from the ribosomal peptidyl 
(P) to the exit (E) site, the peptidyl-tRNA moves from the acceptor (A) to the P site 
and the m RNA is advanced by one codon, preparing for a new elongation cycle.14 
EFG1 consists of five domains; GTP-binding domain I (or G) contains a large 
insert, subdom ain G', which is indirectly required for translocation. The Arg250Trp 
mutation replaces a highly conserved arginine residue by tryptophan in helix A  of 
subdom ain G', which possibly disturbs the protein structure because of the loss of 
a stabilizing hydrogen bond and might ham per interaction of helix A  with other
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proteins. The G' domain of bacterial EF-G has been demonstrated to interact with 
ribosomal protein L7/L12 (L7 and L12 refer to the W-acetylated and unacetylated 
forms of the same protein).15,16 Multiple copies of L7/L12, together with protein 
L10, make up a peripheral stalk of the large ribosomal subunit; the end of the stalk 
contains the C-terminal domain (CTD) of L7/L12.17 The CTD of L7/L12 promotes 
recruitment of EF-G to the ribosome, greatly stimulates its GTP hydrolysis activity 
and controls the release of inorganic phosphate.1718 Research by Nechifor and 
Wilson indicated that helix A  of EF-G domain G' is directly involved in ribosome- 
activated GTP hydrolysis and thereby exerts indirect effects on translocation.19 
Mutating the conserved residue 224 or 228 in helix A  of Escherichia coli EF-G 
(corresponding to amino acids 255 and 259 in human EFG1), thus disrupting 
electrostatic interactions with L7/L12, resulted in severe defects in GTP hydrolysis 
in the presence of the ribosome (without effects on basal GTPase activity) and 
sm aller defects in ribosomal translocation. Hence, the Arg250Trp mutation in 
EFG1 reported in the current study is presumed to ham per ribosom e-dependent 
GTP hydrolysis, causing impairments in mitochondrial translation and oxidative 
phosphorylation and consequently fatal mitochondrial encephalopathy.
Previously, three other EFG1 defects have been described. The first patient 
harbored a hom ozygous mutation in the GTP-binding domain I (Asn174Ser),20 and 
subsequent reports revealed com pound heterozygous m issense and nonsense 
mutations affecting other dom ains of EFG1: Ser321Pro (on the boundary between 
dom ains I and II)+Leu607X (predicted to remove domain V)12 and Met496Arg (in 
domain III)+Arg47X (predicted to eliminate basically all domains).21 Mitochondrial 
translation was impaired in a similar m anner in all patients: a severe overall 
decrease in the rate of mitochondrial translation, with the expression of subunits 
ND5, ND6, COX I, II and III generally being the lowest. ND3 expression, on the 
contrary, was often increased compared with control levels. The previously 
reported patients all presented with OXPHOS enzym e deficiencies in m uscle and 
fibroblasts, in contrast to our patient, in whom decreased enzym e activities were 
detected merely in fibroblasts. Remarkably, the muscular sym ptom s were relatively 
mild in all cases. Lowered respiratory chain activities in fibroblasts with normal 
values in muscle tissue are an uncom m on finding in mitochondrial disorders, 
whereas the opposite is often observed. It should be noted that the capacity 
of the mitochondrial energy-generating system was affected substantially in 
m uscle tissue of our patient. The sensitivity of the assays used to determine this 
capacity, such as pyruvate oxidation, is much higher than that of the standard 
enzym e activity m easurem ents.22 However, the mechanism underlying the (near) 
normal enzym e activities in muscle is currently unclear. Adaptive processes (eg, 
com pensatory changes in the levels of other translation factors), which can differ 
quantitatively and qualitatively between tissues and patients, are likely involved.
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Two of the previous reports on EFG1 defects described a very severe 
phenotype characterized by intrauterine growth retardation, microcephaly, 
hypertonicity and profound liver dysfunction, resulting in liver failure and death 
within the first weeks or months.12,20 The clinical sym ptom atology in our patient 
is reminiscent of the som ewhat milder phenotype described by Valente et al,21 
which was characterized by feeding problems, axial hypotonia, increased limb 
m uscle tone and infantile-onset epilepsy. Notably, liver dysfunction was absent, 
as in our patient. W hereas ß-hydroxybutyrate in blood and urine were normal 
in our patient, Valente et al reported increased levels. The biochemical findings 
appear to correlate with disease severity: our patient showed lower blood lactate 
levels (4.9 versus 17 mmol/l) and lactate:pyruvate ratios (22 versus 38) compared 
with the first reported EFG1 patient,20 suggesting a more m odest disturbance of 
mitochondrial functioning.
The patient investigated here was part of a cohort of 27 patients with combined 
OXPHOS deficiencies. Sequence analysis of all mitochondrial translation factors 
additionally revealed a hom ozygous mutation in elongation factor Ts (TSFM) 
in one patient: Arg333Trp, which has been reported before in two unrelated 
patients.23 All three patients presented with extensive lactic acidosis and muscular 
hypotonia within 3 days after birth, displayed com bined complex I, III and IV 
deficiencies in fibroblasts as well as m uscle tissue, and died in the first few months 
of life. W hereas the mutation in TSFM was associated with either mitochondrial 
encephalom yopathy or hypertrophic cardiom yopathy in the previously published 
cases, our patient was affected by both. In addition, hepatom egaly was observed. 
The current study evinces the im portance of a thorough diagnostic biochemical 
analysis of m uscle tissue and fibroblasts in patients suspected to suffer from a 
mitochondrial disorder, as OXPHOS defects do not always manifest evidently in 
both tissues. Future research should elucidate the com pensatory and regulatory 
m echanism s, at the mitochondrial, cellular and tissue levels, responsible for the 
differences in phenotypic presentation of mitochondrial disorders due to GFM1 
and other mitochondrial translation factor mutations.
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The capacity to blunder slightly 
is the real marvel of DNA. Without 
this special attribute, we would still 
be anaerobic bacteria and there 
would be no music.
Lewis Thomas
Reconstructing the evolution of the 
mitochondrial ribosomal proteome
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A b s t r a c t
For production of proteins that are encoded by the mitochondrial genome, 
mitochondria rely on their own mitochondrial translation system, with the 
mitoribosom e as its central component. Using extensive hom ology searches, 
we have reconstructed the evolutionary history of the mitoribosomal proteome 
that is encoded by a diverse subset of eukaryotic genom es, revealing an 
ancestral ribosome of alpha-proteobacterial descent that more than doubled 
its protein content in most eukaryotic lineages. We observe large variations 
in the protein content of m itoribosom es between different eukaryotes, with 
m ammalian mitoribosom es sharing only 74 and 43%  of its proteins with yeast 
and Leishmania m itoribosomes, respectively. We detected many previously 
unidentified mitochondrial ribosomal proteins (MRPs) and found that several 
have increased in size compared to their bacterial ancestral counterparts by 
addition of functional domains. Several new MRPs have originated via duplication 
of existing MRPs as well as by recruitment from outside of the mitoribosomal 
proteome. Using sensitive profile-profile hom ology searches we found hitherto 
undetected hom ology between bacterial and eukaryotic ribosomal proteins, as 
well as between fungal and m ammalian ribosomal proteins, detecting two novel 
human MRPs. These newly detected MRPs constitute, along with evolutionary 
conserved MRPs, excellent new screening targets for human patients with 
unresolved mitochondrial oxidative phosphorylation disorders.
122
Evolution of mitochondrial ribosomal proteome
I n t r o d u c t i o n
Mitochondria are primary ATP-producing organelles which originated from an 
ancestral alpha-proteobacterial endosym biont.12 The oxidative phosphorylation  
(OXPHOS) pathway, consisting of the mitochondrial respiratory chain and the 
ATP synthase complex, is the final biochemical pathway in energy conversion.3 
However, mitochondria have been found to perform pivotal roles in m any other 
metabolic, regulatory and developm ental processes. During the evolution of the 
mitochondria, most genes of the ancestral endosym biont have been transferred 
from the mitochondrial to the nuclear genom e. The genes that reside on the 
mitochondrial DNA (mtDNA), e.g. 13 OXPHOS-related genes in human, are 
translated into their respective protein products by the mitochondrial translation 
machinery, which resem bles the prokaryotic translation system,4 comprising 
a mitochondrial ribosom e (mitoribosome) and several translation factors. In 
mammals, all proteins that constitute the mitochondrial translation m achinery 
are encoded by the nuclear genom e. Also the mitochondrial genom es of fungi 
generally encode only very few mitochondrial ribosomal proteins (MRPs). In 
contrast, the mitochondrial genom e of many protozoa and plants encode  
numerous MRPs. Most notably, the 'primitive' mitochondrial genom e of the 
freshwater protist Reclinomonas americana was found to contain as m any as 27 
MRP-encoding genes.5
M itoribosom es have undergone major remodeling during their evolution. 
For instance, it has been found that, despite the fact that their rRNA content is 
only half the content of bacterial ribosom es,6 m itoribosom es generally exceed the 
bacterial ribosom es both in molecular m ass as well as in physical dim ensions.6-8 
Mass spectrom etry studies of the bovine and yeast m itoribosomes, which 
have served as model systems during the past years, revealed that mammalian 
m itoribosom es comprise about 80 MRPs.9-13 In yeast, about 70 MRPs have been 
identified thus far, although protein-protein interaction data and mutational 
analysis suggest that this num ber might be substantially higher.14-16 Interestingly, 
a recent proteom ics survey of mitochondrial ribosom e-related complexes in the 
kinetoplast-mitochondria of Leishmania tarentolae revealed an additional protein 
complex which was found to be specifically associated with the small subunit 
(SSU), but not with the large subunit (LSU) of the m itoribosom e.17 The biological 
role of the additional SSU-associated complex, which mostly consists of proteins 
unique to kinetoplastida, remains unknown.
Apparently, m itoribosom es have expanded their protein content in the 
course of evolution by acquiring numerous extra 'supernumerary' MRPs. Currently 
information regarding the functions of these supernum erary MRPs is rather 
limited. In addition, loss of MRPs that are normally part of the 'bacterial core
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ribosome' is also observed.
Recently, several attempts have been made to identify the MRPs in other 
eukaryotes, such as Neurospora crassa,18 Arabidopsis thaliana19 and L. tarentolae,20 
however, a com prehensive study of the evolution of the mitoribosomal proteome 
remains to be established. Such a study bears relevance for the potential 
identification of genes that cause mitochondrial dysfunctions in human patients. 
Since mitochondria perform many fundamental functions, mitochondrial 
dysfunction results in a wide variety of multisystemic diseases, predominantly 
affecting tissues with high m etabolic energy rates.21 These disorders are mostly 
caused by the dysfunction of one or more enzym e complexes of the OXPHOS 
system and several mutations have been identified in m tDNA22 as well as in nuclear 
DNA23. Not only mutations in structural OXPHOS genes, but also mutations in 
genes involved in the mitochondrial transcription or translation, or in the assembly 
of OXPHOS complexes can result in OXPHOS disease. Although the vast majority 
of com ponents of the mitochondrial translation system are nuclear encoded, thus 
far most mutations associated with mitochondrial translation defects have been 
reported in m tDNA-encoded tRNAs and rRNAs.22,24 Recently, mutations in four 
different nuclear gene products involved in mitochondrial protein synthesis have 
been reported in patients with mitochondrial disease: elongation factors EFG1,25 
EFTs26 and EFTu,27 and small ribosomal subunit protein MRPS16.28 Additional 
information regarding which MRPs could be implicated in disease could be 
obtained by studying the evolutionary conservation of the MRPs.
The aim of the present study is 2-fold, from an evolutionary and a disease 
point of view: (i) gain insight into the evolution of the mitoribosom e and its 
protein content in various eukaryotic species; (ii) prioritize MRPs as candidates for 
their involvement in mitochondrial disease. We have performed a comprehensive  
comparative genom ics analysis of the MRPs in 18 eukaryotic species from which 
both the complete nuclear and the organellar genom e sequences were available. 
Representatives are included from different phylogenetic groups: six metazoa 
(Homo sapiens, Mus musculus, Tetraodon nigroviridis, Drosophila melanogaster, 
Anopheles gambiae and Caenorhabditis elegans), two fungi (Saccharomyces 
cerevisiae and N. crassa), one microsporidian (Encephalitozoon cuniculi), 
one m ycetozoan (Dictystelium discoideum), one plant (A. thaliana), one alga 
(Chlamydomonas reinhardtii), one apicomplexa (Plasmodium falciparum), one 
ciliophora (Tetrahymena thermophila), two kinetoplastida (Trypanosoma brucei 
and Leishmania major), one diplom onad (Giardia lamblia) and the mitochondrial 
genom e of the freshwater protist Reclinomonas americana. In addition, we 
included a balanced, phylogenetically diverse subset of com pletely sequenced  
prokaryotic genom es in our survey.
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Our analysis retrieved multiple previously unidentified MRPs in several 
species, two of which constitute potential novel human MRPs. Furthermore, 
the current study established orthology relationships between seven MRPs 
reported to be fungi-specific and ribosomal proteins from other eukaryotes. The 
establishm ent of these hom ology relationships enabled us to trace the origins 
of som e of the supernum erary MRPs and to predict their m olecular functions. 
In addition, we have investigated all MRPs on the presence of additional, newly 
acquired protein dom ains that might point at mitochondria-specific adaptations 
of the mitoribosome, and we have reconstructed the evolutionary history of the 
mitoribosomal proteome in terms of gains and losses of the MRPs along the 
different eukaryotic lineages. The newly detected mitochondrial ribosomal genes 
constitute, in addition to the set of evolutionary conserved MRPs, excellent new  
screening targets for human patients with unresolved mitochondrial oxidative 
phosphorylation disorders.
M a t e r i a l s  a n d  m e t h o d s
U se o f geno m ic data
G enom e data (both proteom es and genom es) of the eukaryotes described in 
this study were obtained from the Integr8 database (http://www.ebi.ac.uk/ 
integr8/, Release 41) at EBI,29 except for the genom es of Tetrahymena thermophila 
(version 2 obtained from TIGR, ftp://ftp.tigr.org/pub/data/Eukaryotic_Projects/t_ 
thermophila/), Trypanosoma brucei (version 4 obtained from Sanger, ftp:// 
ftp.sanger.ac.uk/pub/databases/T.brucei_sequences/), N. crassa (version 7.0 
obtained from Broad institute at MIT, http://www.broad.mit.edu/annotation/ 
genom e/neurospora/Downloads.htm l) and Chlamydomonas reinhardtii (version 
3.0 obtained from JGI, ftp://ftp.jgi-psf.org/pub/JGI_data/Chlamy/v3.0/). For most 
eukaryotic species, the organelle genom es were included in the gene set per 
species, otherwise those were downloaded separately from GOBASE30 (http:// 
megasun.bch.um ontreal.ca/ogm p/projects/other/mt_list.html).
In addition to the eukaryotic genom es mentioned above, we have also included 
a balanced, phylogenetically diverse subset of com pletely sequenced prokaryotic 
genom es. We have explicitly chosen not to include the complete set of completely 
sequenced prokaryotic genom es available, since the large num ber of prokaryotic 
proteins might cause an im balance in the PSI-BLAST analysis described below. 
Sequence data (proteomes and genom es) of the selected prokaryotic genom es 
were all downloaded from the Integr8 database at EBI, and included: Escherichia 
coli, Pseudomonas aeruginosa, Vibrio cholerae (gamma-proteobacteria), Bacillus 
subtilis, Clostridium acetobutylicum (firmicutes), Borrellia burgdorferi (spirochetes), 
Agrobacterium tumefaciens WashU, Brucella suis, Rickettsia prowazeckii,
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Caulobacter crescentus, Rhizobium meliloti, Rhodopseudomonas palustris (alpha- 
proteobacteria), Nostoc sp. PCC 7920, Synechocystis sp. PCC 6803, Prochlorococcus 
marinus SS120 (cyanobacteria), Deinococcus radiodurans (Deinococcus-Therm us 
group), Aquifex aeoliticus (aquificae), Sulfolobus solfataricus (crenarchaea), 
Pyrococcus furiosus (euryarchaea).
D etection  o f M R Ps in eu k aryo tic  geno m es
For each of the experimentally verified proteins of the Leishmania,1120 fungal14-16 
and m amm alian6 mitochondrial ribosomal proteins we have performed iterative 
PSI-BLAST searches31 against a locally assem bled protein database comprised of 
the proteom es of the organism s indicated above. For each of these searches, 
an E-value inclusion threshold of 0.005 was applied, and the proteins that were 
retrieved after five iterations were aligned using M USCLE.32
For those cases where a candidate MRP, from a species from which the 
query MRP was still missing, appeared in the PSI-BLAST hit list, but with an 
E-value between 0.005 and 10, a reciprocal search was performed. If this search 
successfully retrieved a bona fide MRP within five iterations (E-value inclusion 
threshold of 0.005), it was added to the initial set of hom ologous proteins, and 
a new alignment was created. W henever a given MRP was still not found in the 
predicted proteome of a eukaryotic organism, a hidden Markov model (HMM) of 
the respective protein was created from the above-m entioned alignments using 
the HMMER program.33 Subsequently, the HMM was used to screen the genom ic 
sequences at the DNA level. The latter screen served as a final control for missing 
MRPs that represent unpredicted genes in the genom e annotation process. To 
delineate orthologous groups, neighbor-joining trees were derived from these  
alignments using Kimura distances.34 A  bootstrap analysis using 1000 sam ples was 
conducted for each phylogenetic tree. The selection of the orthologous group for 
each MRP was subsequently done by manually examining all trees. Assignment 
of orthologous relationships among the eukaryotic sequences was based on the 
species-phylogeny for eukaryotes3536 and the presence of these sequences within 
a m onophyletic branch of the tree that contained known MRPs. Homologies 
between different families of MRPs, if not already found during the PSI-BLAST 
searches described above, were detected using the hhsearch algorithm ,37 by 
comparing HMM profiles constructed from aligned MRPs with each other, using 
an E-value cut-off of 1e-4.
P h y lo g enetic  an alyses
Maximum-likelihood (ML) trees were created using PHYML (version 2.2.4)38 based 
on alignments of the above-m entioned orthologous groups. Prior to the analyses, 
global and pairwise gaps were removed from the alignments. The appropriate
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model of protein evolution was selected using M ODELSELECTOR.39 Bootstrap 
support values were derived from 100 replicates.
D etection  o f n ew ly  evo lved  M R P do m ain s
All MRPs hom ologous to bacterial core RPs that were identified in the current 
research were examined for additional, potentially newly evolved domains. Using 
HM M ER,33 each MRP was analyzed with an HMM profile that was built from an 
alignment of its ancestral bacterial counterpart. These parts of the MRPs that were 
not covered by the respective HMM profile (minimum length 30 amino acids), 
were searched against the PFAM40 and CDD41 databases using HM M ER33 and 
RPS-BLAST41 respectively. Hits below an E-value threshold of 0.01 were regarded 
significant.
R e s u l t s
D etection  o f M RPs in eu k aryo tic  geno m es
We have employed a systematic analysis of nuclear and mitochondrial genom es in 
order to identify the mitoribosomal proteome content encoded in a wide variety of 
eukaryotic species. To avoid confusion regarding different nomenclatures that are 
used for ribosomal proteins, we have adopted the nomenclature for human MRPs, 
approved by the Human Genom e Nom enclature Com m ittee (http://www.gene. 
ucl.ac.uk/nomenclature/). All proteins are designated MRPSxx or MRPLxx, where S 
and L stand for small and large subunit, respectively, and xx is the num ber of the 
corresponding bacterial ribosomal protein. The MRPs lacking bacterial orthologs 
(supernum erary proteins) are assigned higher numbers, starting at MRPS22 and 
MRPL37 for the small and large subunit, respectively. In yeast, unfortunately, the 
nomenclature is as variable as the m ethods employed for their characterization. 
Therefore, in order to prevent further confusion about proteins with the same 
name in human and yeast that are not part of the sam e orthologous group, we 
have indicated all human MRPs in capital letters throughout the manuscript 
(e.g. MRPS28), whereas for the yeast proteins we only capitalized the first letter 
(e.g. Mrps28, which corresponds to MRPS15 in human, also see Table 1 and 
Supplem entary Data).
Starting from a curated list of MRPs that have been identified in various 
studies, we first searched for hom ologs using several search algorithms (see 
Materials and Methods). Subsequently, the list of hom ologs was subjected to 
a phylogenetic analysis in order to define orthologous groups of MRPs. Not 
only does our analysis distinguish MRPs from their cytosolic counterparts, it also 
enabled for differentiation between 'true' MRPs and hom ologous ribosomal 
proteins of other organelles, such as the chloroplast (in plants) or apicoplast (in 
the apicomplexa P falciparum). We realize that this approach has its limitations,
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Table 1. Phylogenetic distribution of SSU mitochondrial ribosomal proteins and their 
bacterial counterparts
(continued)
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Rsm26
Mrp10 *
Rsm28
Mrp8
Mhr1
Lm F03.0220
Lm F03.0630
Lm F15.0080
Lm F15.0410
Lm F15.0780
Lm F15.1400
Lm F16.1230
Lm F22.0830
Lm F22.0990
Lm F22.1220
Lm F24.0830
Lm F25.2160
Lm F26.2270
Lm F27.0180
Lm F27.0630
Lm F27.1895
Lm F28.2180
Lm F29.0430
Lm F30.0650
Lm F30.0740
Lm F30.3220
Lm F30.3530
Lm F32.0650
Lm F33.0010
Lm F33.2510
Lm F35.2230
Lm F35.3490
Lm F35.3940
Lm F36.4120
The first and second column contain, if1 applicable, the MRP identifiers according to the human 
and yeast nomenclature, respectively. MRPs and bacterial RPsthat were identified on the predicted 
proteome are indicated in yellow, MRPs that were not found in thie predicted proteome, but for which 
the unpredicted gene couldbe identified on the genomic DNA are indicated in b b er MRPs that have 
been experimental^ verified as bemg associatedwith the mitoribosome by means of large-scale 
proteomics mteraction srudies or small-scale functional s tu d e  are indicated in green (exeept for the 
human MRPs, for wlhich mostly the bovine counterparts were experimentally verified). MRPs that are 
encoded by the mitochondrial genome are indicated in red. A bracket (#) denotes a peculiar case of 
a split MRPS3 gene in D. discoideum, which is encoded by iTs mitochondrial genome. The 5' and 3' 
ends are fused to genes of1 unknown funrtion (ORF4c5 and ORF1740, respectively)/9-80 It is unknown 
f  the split MRPS3 genes results in a functional protein. An asterisk (*) denotes cases where a given 
MRP was not identified most probably as a result of incompleteness of the genome sequence, i.e. the 
MRP was not found in the predicted proteome, nor was it found by analyzing the genomic DNA, but 
could be identified in a closely related species. For example, MRPS28 and MRP10 were not detected 
in T. nigroviridis, but could be found in Danio rerio. See Supplementary Data for protein identifiers. 
Species abbreviations: Hsa: Homo sapiens; Mmu: Mus musculus; Tni: Tetraodon nigroviridis; Dme:
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Drosophila melanogaster; Aga: Anopheles gambiae; Cel: Caenorhabditis elegans; Sce: Saccharamyces 
cerevisiae; Ncr: Neurospora crassa; Ecu: Encephalitozoon cuniculi; Ddi: Dictyostelium discoideum; Ath: 
Arabidopsis thaliana; Cre: Chlamydomonas reinhardtii; Pfa: Plasmodium falciparum; Tth: Tetrahymena 
thermophila; Ram (mt): Reclinomonas americana (mitochondrial genome); Tbr: Trypanosoma brucei; 
Lma: Leishmania major; Gla: Giardia lamblia; Eco: Escherichia coli; Bsu: Brucella suis; Rpr: Rickettsia 
prowazekii.
as it does not account for potential retargeting events that have been shown to 
occur, such as in A. thaliana, where a chloroplast-type S13 protein encoded by 
a diverged duplicated nuclear gene has been demonstrated to be targeted to 
the m itochondrion.42 In order to account for such cases, we included such an 
experimentally verified protein in our list, whenever our analysis did not suggest 
a candidate MRP.
Altogether, our survey resulted in the identification of highly variable 
numbers of MRPs across the genom es of the investigated eukaryotic species, 
several of which had not been identified as MRPs previously (see Table 1, Table 
2 and Supplem entary Data). The total num ber of identified MRPs ranged from 
81 in most m etazoan species, to 80 in yeast, to 63 in plants, down to a mere 39 
MRPs in the apicom plexan P. falciparum. We recognize the fact that the latter 
numbers are probably an underestimate of the actual numbers of MRPs in these 
species, as there are no experimental studies to identify potential lineage specific 
supernum erary MRPs. Moreover, since protein sequences of these species have 
been found to evolve relatively fast,43 it is at least feasible that we failed to 
identify som e MRPs that have evolved beyond the detection limits of our search 
algorithms.
Apart from mapping MRPs that are encoded by eukaryotic genomes, we 
were able to find hitherto undetected homology between experimentally verified 
supernumerary MRPs and bacterial ribosomal proteins that were presumed to 
have been lost from the primitive eukaryotic mitoribosome. Using sensitive profile­
profile searches for detection of distant homology between protein families, we 
connected the MRPS24 orthologous group to the bacterial RPS3 ribosomal protein 
family (E-value 2.2e-5) and similarly, we connected the MRPL47 orthologous group 
to the bacterial RPL29 ribosomal protein family (E-value 8.6e-7) (see Figure 1). The 
complem entary phylogenetic distribution patterns of the respective genes are 
in support of this suggestion. For example, MRPL47 is present in all eukaryotes 
analyzed (except for E. cuniculi and G. lamblia), but not in bacteria. The opposite 
phylogenetic pattern is observed for bacterial ribosomal protein RPL29, for which 
no homolog was identified in any eukaryotic genome. Apparently, these MRPs have 
diverged almost beyond homology detection limits during the course of evolution 
(see Figure 1), possibly as an adaptation to specific mitoribosomal functionality. 
Given the detected homology between the above-mentioned MRPs and bacterial
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ribosomal proteins, we have placed the MRPs in the orthologous group of their 
respective bacterial counterparts (see Tables 1 and 2).
We also encountered som e cases where we could not detect an expected 
MRP ortholog in som e species, which might be caused by incom pleteness of 
the respective genom es. For example, despite the fact that we could identify 
orthologs of MRPL50, MRPS28 and Mrp10 in all metazoa analyzed in this survey, 
as well as in the Danio rerio genom e (data not shown), we were unable to detect 
these MRPs in the genom e of T. nigroviridis. Likewise, MRPL56 was found in 
all metazoa, including A. gambiae, but not in D. melanogaster (see Table 2). In 
addition, in som e instances our analysis proposed different proteins than have 
been reported in earlier reports. The discrepancies between our study and that of 
others are outlined in the Supplem entary Data.
Not unexpectedly, MRPs were not detected in the genom es of the 
microsporidian E. cuniculi and the diplom onad G. lamblia. These organism s do 
not contain full-fledged mitochondria, but instead they contain m itosom es (E. 
cuniculi) or mitochondrial remnants (G. lamblia), which typically lack organellar 
DNA. Consequently, these organism s have no need for mitochondrial translation 
m achineries, explaining the observed loss of MRP-encoding genes.
Id en tifica tio n  of novel (hum an) M RPs
Our analysis expanded orthologous groups that were previously reported to 
contain fungi-specific MRPs to include other eukaryotic proteins, resulting in the 
identification of two potentially novel human MRPs, namely the human orthologs 
of yeast SSU proteins Rsm22 and Mrp10, extending the total num ber of human 
MRPs to 81. The detection of human orthologs of yeast MRP proteins Rsm22 and 
Mrp10 is of particular interest, as defects within these genes might be linked to 
mitochondrial dysfunctions in human. Interestingly, extensive biochemical data is 
available for the yeast gene products, enabling to speculate about their respective 
m olecular functions.
Yeast Rsm22 is hom ologous to an rRNA m ethyltransferase and has been 
shown to be part of the SSU of the yeast mitochondrial ribosome.44 The association 
of Rsm22 with the SSU has also been confirmed in a large-scale affinity-capture 
m ass spectrom etry study.45 We have detected an ortholog of Rsm22 in most 
eukaryotes, as well as in som e prokaryotes. Interestingly, the STRING database46 
shows that the gene encoding the Rsm22 ortholog in som e prokaryotes is 
clustered on the genom e with genes that encode ribosomal proteins (not shown), 
suggesting that the Rsm22 orthologs in these species are also associated with 
the ribosome. In Schizosaccharomyces pombe, the genes encoding Rsm22 and 
Cox11 are fused. Cox11 is an assem bly factor of the OXPHOS enzym e complex 
cytochrome c oxidase and in S. cerevisiae, Cox11 has been shown to associate
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Table 2. Phylogenetic distribution of LSU mitochondrial ribosomal proteins and their 
bacterial counterparts
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co ntinued
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For explanation of used MRP protein names, color coding and species abbreviations, see comments 
below Table 1. Subunits that are indicated to be experimentally characterized for L. major were in 
fact identified to be part of the mitoribosome of the closely related species L tarentolae.17 A bracket 
(#) denotes a speciai case ot rhe A. thaliana MRPL2, of which the N-terminal half is encoded by 
the mitochondrial genome and the C-terminal half is nuclear encoded. See 77upplementary Data for 
protein identifiers. An asterisk (*) denotes cases where a given MRP was not identified as a result of 
incompleteness of tine genome sequence, i.e. the MRP was not found in the predicted pfoteome, nor 
was if found by analyzing the genomic DNA, but covld be identified in a closely related species. For 
example, MRPL56 was not detected in D. melanogaster, but was found in the genomes of D. willistoni 
and in A. gambiae. Originally, MRPS32 was identified as a protein in the small subunit9 and MRPL42 
as a protein in the large subunit (MRPL31 in reference89). However, the protein sequences of these 
proteins were found to be identical. Later, MRPS32 was omitted since its identification was probably 
caused by contamination in the preparation of small subunits, and thus was in fact MRPL42 (Thomas 
O'Brien, personal communication).
with the mitoribosom e and is postulated to function in co-translational insertion 
of copper ions into C o x l, a subunit of cytochrome c oxidase.47 Finally, Rsm22- 
deficient yeast strains exhibit a growth defect on non-fermentable (respiratory) 
carbon sources, indicative of mitochondrial respiratory dysfunction.44 All these 
lines of evidence suggest that Rsm22 is a protein of the mitoribosomal small 
subunit that is essential for proper mitochondrial function. As Rsm22 is a predicted 
rRNA methyltransferase, it might be involved in methylation of mitochondrial 
rRNA, and as such play a role in the regulation of protein translation efficiency.
Yeast M rplO was shown to be a com ponent of the SSU of mitoribosom es as 
well and disruption of the gene resulted in a mitochondrial translation defect and 
a tendency to accum ulate deletions in mtDNA.48 Jin et al observed low sequence  
similarity to yeast Mrpl37, a constituent oPthe LSU.49 Howevee, we identified yeast 
Mrfrl37 as an ortholog of human MRPL54 ared did not detect any significant 
sequence hom ology between M rplO and Mrpl37. Nevertheless, we did find 
M rplO orthologs in m any eukaryotes, all of which were found to contain a CHCH  
domain (Coiled coil 1-Helix 1-Coiled coil 2-Helix 2, PFAM domain 06747). Within 
each helix of this CHCH domain, two invariant cysteine residues are present in
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6 Figure 1. Distant homology between mitochondrial and bacterial ribosomal protein families detected in this study. Multiple sequence alignments of MRPL47 and RPL29 proteins (A) and of MRPS24 and RPS3 
proteins (B). Amino acid residues are shaded according to the following physicochemical properties: 
t: tiny (blue font on yellow shading); m: amphoteric (red font on green shading); h: hydrophobic 
(white font on black shading); o: positive (red font on blue shading); p: polar (black font on green 
shading); s: small (green font on yellow shading); a: aliphatic (red font on gray shading); r  aromatic 
(blue font on gray shading); c: charged (white font on blue shading). Sequences are annotated by the 
organism name and Swiss-Prot protein identifier and the boundaries of the segment that is used in 
the alignment are indicated. A 90% consensus sequence is depicted below the alignments using the 
same classification, with invariant residues being indicated in capitals.
a C -X 9- C  motif. Besides in Mrp10, CHCH domains have also been detected in 
Cox19 and in the respiratory complex I (NADH-ubiquinone oxidoreductase) 19 
kDa subunit (NDUFA8).50 In yeast, Cox19 is present in the cytoplasm as well as in 
the inter m em brane space of the mitochondria, where it is suggested to play a 
posttranslational role in the assem bly of cytochrome c oxidase through copper 
transport to mitochondria. It has been proposed that the conserved cysteine 
residues of the CHCH motif in Cox19 m ediate as ligands for the copper ions.51,52 
Most likely, yeast Mrp10 and their orthologs in other eukaryotes, including human, 
constitute an essential com ponent of the mitochondrial translation machinery 
and we anticipate that the CHCH domains that are present in this orthologous 
group, as well as in complex I subunit NDUFA8, are involved in trafficking of metal 
ions.
We also detected a potential third novel human MRP, P p el, however this 
case is less clear-cut than these described above. P p e l is a protein, which has 
been shown to be part of the SSU of the yeast mitoribosom e.53 We detected P p el 
orthologs in all eukaryotes analyzed, except for P falciparum and T. thermophila
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(and the m tDNA lacking eukaryotes). However, the localization of P p e l in the 
m itochondrion is questionable, as the report by Kitakawa et al is the only indication 
for this.53 Moreover, the yeast and human P p e l have previously been reported 
to function as protein phosphatase methylesterases of Protein phosphatase  
2A,5455 which are mainly localized in the nucleus and cytoplasm .56 Additionally, 
yeast P p e l mutant strains do not exhibit any growth defects,55 while mutations 
affecting synthesis or function of respiratory chain com ponents generally result 
in growth impairment on a non-fermentable carbon source. Thus currently there 
is, besides the reported association with SSU of the m itoribosome in yeast, no 
clear indication that P p e l is implicated in mitochondrial translation. Therefore, 
additional research is needed to corroborate the cellular localization and function 
of yeast P p e l and its orthologs in other eukaryotes.
T h e  evo lutio n  o f th e  m ito cho n d ria l ribo som al p ro teom e a long  e u karyo tic  
lineages
The protein composition of mitoribosom es is variable, not only in terms of the 
num ber of MRPs, but also in terms of the specific MRPs contained (see Tables 
l  and 2). By mapping the distribution of the orthologous groups of MRPs onto 
a reconstructed tree of the eukaryotes35 while always considering the most 
parsimonious scenario, we obtained an overview of the history of gains and 
losses of MRPs during the divergence of eukaryotes (see Figure 2). Mitoribosomes 
originated from the bacterial ribosom e present in the alpha-proteobacterial 
ancestor of mitochondria, consisting of a microbial core of 54 ribosomal proteins 
in total. Already in the earliest stage of eukaryotic evolution, prior to the major 
divergence of the fungal, plant and m etazoan lineages, several supernum erary  
proteins were recruited to the m itoribosome, while only one bacterial core protein 
was lost at this stage (RPS20, see Figure 2), resulting in a primitive eukaryotic 
mitoribosom e of 68 MRPs. Subsequent to the gain of this primary set of l5  
proteins, the m itoribosome diversified along the various eukaryotic lineages 
and a num ber of lineage-specific gain and loss events can be observed. Another 
gain of MRPs occurred at the level of the metazoa, prior to the bifurcation of 
nem atodes and eum etazoa. At this stage, l4  proteins were recruited to the 
metazoan m itoribosome, whereas seven bacterial core proteins were lost. Major 
protein gains at these two time points have also been observed in the evolutionary 
history of complex I.57 Additionally, l l  fungi-specific MRPs were recruited after 
the animal-fungi radiation. In the lineage towards the kinetoplastida, a major 
surge of 29 proteins is observed. These proteins have been shown to comprise a 
protein complex that is associated with the SSU of kinetoplastid-m itoribosom es.:L7 
The role of this additional protein complex and its association with the SSU is still 
unclear. Apart from this major gain in the kinetoplastida, we observe loss of several
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Figure 2. Reconstruction of the evolutionary history of the mitochondrial proteome across the different 
eukaryotic lineages. (A) Incoming and outgoing arrows indicate the gain and losses of the MRPs that 
are indicated in the box. Genes encoding proteins of the bacterial core are shown in bold. The scenario 
of gene gain and loss was adjusted according to the MRP content encoded by the mitochondrial 
genomes of rice and R. americana5 (dashed line, position in tree inferred from reference89). Dotted 
lines indicate lineages with highly reduced mitochondria in which all MRP-encoding genes have 
been lost. Species for which the mitoribosomal proteome has been experimentally investigated are 
highlighted in a gray shaded box. Numbers following the species names denote the total number 
of MRPs identified in that species. Note that several MRPs have been lost independently in different 
lineages. For example, MRPSl is lost independently in C. reinhardtii, A. thaliana (MRPSl is encoded on 
the mitochondrial genomes of Oryza sativa and R. americana) and in the kinetoplastida and alveolata 
lineages. (b) Evolutionary trajectory towards the human mitochondrial ribosomal proteome. Main 
gene gain events can be observed at major branching points of the tree, such as in the ancestral 
eukaryote and at the origin of the metazoa, after which the mitoribosomal proteome is maintained at 
a constant level. AVE: alveolates, viridiplantae and excavates branch.
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proteins in the AVE (alveolates, viridiplantae and excavates) lineage, predominantly 
consisting of bacterial core proteins, but also including supernum erary MRPs in 
som e lineages. Possibly, som e of these proteins remained undetected due to 
sequence divergence. The fact that the AVE lineages are dominated by loss events 
of MRPs is likely due to the lack of experimental data of mitoribosomal content 
in these species.
Compared to the 54 ribosomal proteins present in the alpha-proteobacterial 
ancestor, 8 l  MRPs in human represent a substantial gain in complexity (see Figure 
2B). However, the observed increase in complexity following the endosymbiotic 
event is not uncom mon, as it has also been reported for electron transport chain 
com plexes.57 It has been proposed that the recruited supernum erary proteins 
are mainly involved in the assem bly and stabilization of the complexes.5758 
The mammalian supernum erary MRPs are shown to be mostly localized to the 
peripheral regions of the m itoribosom e.59-61 Since all proteins synthesized by 
metazoan mitoribosom es are inserted into the inner mitochondrial membrane, 
at least som e of the m etazoa-specific supernum erary MRPs are presumed to be 
associated with positioning the mitoribosom e during co-translational insertion of 
nascent polypeptides into the m embrane. Interestingly, a protein that has been 
proposed to be essential for co-translational insertion in yeast, M b a l (MRPL45, 
see 'Origins from outside of the mitoribosomal proteome -  MRP recruitment'), 
was already part of the primitive eukaryotic m itoribosome and has been recruited 
from the alpha-proteobacterial ancestor. Similar to the evolution of complex I, 
we observe the recruitment of proteins of bacterial origin to the mitoribosome 
(MRPL45 and Rsm22), however, this num ber is considerably lower (only two, 
compared to six in complex I), especially considering that in the evolution of the 
mitoribosom e more proteins were added compared to complex I (37 and 32 in 
the human m itoribosome and complex I, respectively).
tra c in g  th e  o rig in s o f su p e rn u m erary  M RPs
As outlined above, the protein content of the m itoribosome has significantly 
increased in most species during the evolution of the mitochondria. Our analysis 
indicates that in several stages of the mitoribosomal evolution various extra 
proteins, the supernum erary MRPs, have been added to the mitoribosomal 
proteome. Som e of these supernum erary MRPs were found to be present in all 
eukaryotes that were investigated, but not in bacteria, such as MRPS29 (see Table 
1). Clearly, these MRPs have been recruited in an early stage of the evolution of 
the eukaryotes, before the formation of major eukaryotic kingdoms. In contrast, 
other MRPs have originated relatively recently, such as MRPL37, which is specific 
for the metazoa. However, it is not only interesting to know 'when' certain MRPs 
were added to the m itoribosome, it is also enticing to trace their origins. We found
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table 3. Paralogous relationships involving MRPs
MRP Mitochondrial [cytosolic] 
ribosome homolog
Other
SSU
S10 L48, [S20]
S18 S18A, S18B, S18C
S26 Several coiled coil containing proteins, 
including subunit 10 theta of the eukaryotic 
translation initiation factor 3
S27 TPR/PPR repeat proteins/salt-inducible 
proteins (Arabidopsis)
S29 DAP3
S30 L37 PDCD9
Mrpl Rsm26 (yeast) Superoxide dismutase
Petl23 Several coiled coil containing proteins
Mrpl0 COX19, NDUFA8
Rsm28 Kinases
LmjF30.3530 Rhodanese, inactive domain
LmjF25.2l60 Ubiquitin
LmjF32.0650 AKAP7
LSU
L2 [L8] NUZM (fungi-specific OXPHOS complex I 
subunit)
L38 Phosphatidylethanolamine-binding protein 1 
(PEBP-1) and Flowering Locus T
L39 Threonyl- and alanyl-tRNA synthetase
L43 S25 Respiratory Complex I subunit B8
L44 Mrpll5, Mrpl3 (yeast) Ribonuclease III and other ribonuclease_3 
domain containing proteins
L45 Tim44
L46 mRNA decapping enzyme 2 (DCP2) and 
Nudix hydrolase (NUDT)
L56 Beta-lactamase
Mrpl20 Mesenchymal stem cell protein
Names of MRPs are indicated in the first column and supernumerary MRPs and proteins from outside 
the ribosome are indicated in the second and third column, respectively. In addition, if a homologous 
cytosolic ribosomal protein is present, it is indicated between square brackets in the second column.
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that several of the supernum erary MRPs are hom ologous to other proteins, some 
of which are also part of the m itoribosome (see Table 3). The latter finding implies 
that gene duplication events have played a substantial role in the expansion of 
the mitoribosomal proteom e (see Table 3). Below we will discuss som e of the 
most protruding cases.
Figure 3. Maximum-likelihood tree of the MRPS18 orthologous group. The metazoa contain three 
copies of this family (MRPS18A, MRPS18B and MRPS18C) as a result of two consecutive duplication 
events at the root of the metazoan radiation. Proteins are indicated by a species name and a protein 
identifier. Bootstrap values for partitions that are supported with values above 50% (out of 100
replicates) are displayed. _________
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O rig in s fro m  w ith in  th e  m ito rib o som al p ro teom e -  M R P dup lication
Som e supernum erary MRPs are hom ologous to MRPs that are part of the bacterial 
core of the mitoribosome. These proteins have seem ingly been duplicated from 
within the mitoribosomal proteome. One of the most straightforward examples 
is the em ergence of three variants of MRPS18 in the m etazoan lineage resulting 
from gene duplication events (see Figure 3). In contrast with earlier reports,9 
we identified three MRPS18 variants in C. elegans and we found that all three 
m etazoan variants emerged from the sam e ancestral m etazoan sequence, which 
is unlikely to be derived from chloroplast S18, as was reported by Cavdar Koc 
and co-workers9 (see Figure 3). All three C. elegans MRPS18 variants seem to 
be essential in embryonal developm ent, as targeted disruption of these genes 
result in an em bryonic lethal phenotype.62 Independent from the observed  
MRPS18 duplications in metazoa, it is interesting to note that most sequenced  
actinobacterial genom es encode two variants of the S18 gene, probably the result 
of a gene duplication event in these species. Currently, experimental evidence  
regarding the functions of the different MRPS18 versions in metazoa is lacking, 
but it is believed that each mitoribosom e contains only one copy of MRPS18, 
giving rise to a heterogeneous population of m itoribosom es.9
Another example can be found in the duplication of MRPS10 in the lineage of 
the metazoa, which gave rise to MRPL48 (see Table 3 and Figure 4). This duplication 
event constitutes one of the cases where the duplicate gene product has becom e  
part of the other mitoribosomal subunit, in this case from the SSU (MRPS10) to 
the LSU (MRPL48). Likewise, a duplication event at the base of the metazoan  
radiation seem s to have given rise to the supernum erary MRPs MRPS30 and 
MRPL37, both of which are only present in metazoa (See Figure 5). Interestingly, 
M RPS30 is also known as programm ed cell death protein 9 (PDCD9 or p52).63,64 
Another supernum erary protein, MRPS29, is also implicated in apoptosis, as it 
has been shown to be identical to death-associated protein 3 (DAP3).63,65 Given 
the dual roles of these MRPs, the processes of mitochondrial translation and 
apoptosis are apparently closely coupled.66
O rig in s fro m  o u tsid e  of th e  m ito rib o som al p ro teom e -  M R P recru itm en t
We found that som e supernum erary MRPs have probably been recruited to 
the mitoribosome, as they display significant hom ology to other mitochondrial 
proteins, som e of which are also implicated to play a role in mitochondrial 
translation (see Table 3). Of course, it cannot always be resolved if an MRP has 
been part of the mitoribosom e prior to the duplication event. For som e instances, 
we can use the phylogenetic distribution patterns of the copies in order to point 
out which was first. One of such examples, where a pre-existing protein has been 
recruited to the m ammalian mitoribosome, is the acquisition of MRPL39, which is
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Figure 4. Maximum-likelihood tree showing the origin of supernumerary MRPL48 as a result of a 
duplication event at the base of the metazoan radiation within the MRPS10 orthologous group. 
All depicted proteins were connected using PSI-BLAST (see Materials and Methods for details). For 
instance, a search started with human MRPS10 retrieved both the human MRPL48 (Q96GC5) and the 
cytosolic SSU ribosomal protein RPS20 (RS20_HUMAN) in the second iteration with E-values of le-9 
and 0.001, respectively. Proteins are indicated by a species name and a protein identifier. Bootstrap 
values for partitions that are supported with values above 50% (out of 100 replicates) are displayed.
hom ologous to the W-terminal domain of threonyl-tRNA synthetases and which 
has a universal phylogenetic distribution. This hom ology has been noticed before 
and it is suggested that MRPL39 can bind tRNA in a similar m anner as the E. coli 
threonyl-tRNA synthetase.67 Conceivably, the W-terminal tRNA-binding domain of 
a mitochondrial threonyl-tRNA synthetase was recruited to the mitoribosom e in 
order to com pensate for the loss of bacterial ribosomal proteins that are involved 
in tRNA binding, such as RPS13 and RPL5 (see Tables 1 and 2).
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The most striking example of MRP recruitment is that of MRPL45 (See 
Figure 6). First we found that MRPL45 and yeast protein Mba1 belong to the 
sam e orthologous group, which in addition com prises proteins from all metazoa, 
the plant A. thaliana, the alga C. reinhardtii as well as from the mycetozoan D. 
discoideum. Mba1 is a mitochondrial protein associated with the matrix face of 
the inner m embrane, which associates with the highly conserved inner mem brane 
protein Oxa1. Mba1 and Oxa1 orchestrate the insertion of both mitochondrial- 
and nuclear-encoded proteins from the mitochondrial matrix into the inner 
m em brane.68,69 Moreover, we detected hom ology between MRPL45 (including 
Mba1) and Tim44 (see Figure 6), a peripheral mitochondrial inner membrane 
protein that is an essential com ponent of the import motor PAM of the TIM23 
complex, which is implicated in the translocation of proteins from the inter 
m em brane space to the mitochondrial matrix (for reviews see references7071). 
The apparent sequence homology, as well as functional hom ology (i.e. protein 
translocation), suggests that MRPL45 and Tim44 share a com m on alpha- 
proteobacterial origin. Many alpha-proteobacteria contain two distinct types of 
Tim44/MRPL45-like genes (see Figure 6).
Figure 5. Maximum-likelihood tree showing that metazoan-specific supernumerary MRPs MRPS30 
and MRPL37 originated as a result of a duplication event at the base of the metazoan radiation. 
The depicted proteins were connected using PSI-BLAST (see Materials and Methods for details). For 
instance, a search started with human MRPS30 retrieves human MRPL37 within the first iteration with 
an E-value of 0.001. All proteins are indicated by a species name and a protein identifier. Bootstrap 
values for partitions that are supported with values above 50% (out of 100 replicates) are displayed.
142
Evolution of mitochondrial ribosomal proteome
Figure 6. Maximum-likelihood tree indicating common ancestry of supernumerary mitoribosomal 
protein MRPL45 and Tim44, an essential component of the TIM23/PAM complex, which mediates the 
translocation of nuclear-encoded proteins across the mitochondrial inner membrane. The tree contains 
alpha-proteobacterial sequences from which mitochondrial MRPL45 and Tim44 have evolved. Note 
that there are two paralogous Tim44-like families within the alpha-proteobacteria, resulting from a 
duplication within that lineage. The depicted proteins were connected using PSI-BLAST as outlined in 
the Materials and Methods. For instance, a search started with human MRPL45 retrieves the Rhizobium 
meliloti Type I Tim44-like protein (Q92TE6) in the second iteration with an E-value of 1e-7. The yeast 
Mba1 and human Tim44 proteins were both retrieved in the third iteration (with E-values of 2e-13 
and 2e-10, respectively). Proteins are indicated by a species name and a protein identifier. Bootstrap 
values for partitions that are supported with values above 50% (out of 100 replicates) are displayed.
A close examination of MRPL45 and Tim44 proteins reveals that the /V-terminal 
region of Tim44 is absent in MRPL45 (not shown). This region is supposed to 
be located in the mitochondrial matrix where it interacts with mitochondrial 
Hsp70 chaperone, which is also a com ponent of the PAM complex.72 Apart from 
its association with Oxa1, MRPL45 has been shown to be a constituent of the 
mitoribosomal LSU in multiple studies.10,73 Moreover, it has been shown that in
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yeast, transcription of MBA1 is tightly co-regulated with that of genes encoding 
MRPs,74 implying a functional link between the respective gene products. The 
anticipated association of the m itoribosome and m em brane-bound constituents 
of the mitochondrial protein insertion m achinery would explain the fact that 
up to 50% of the bovine m itoribosom es are found to associate with the inner 
m em brane fraction of mitochondria.75 Taking all this in consideration, we 
postulate that MRPL45 functions as a bridging factor between the mitoribosome 
and Oxa1, and as such constitutes an essential com ponent for successful co- 
translational insertion of proteins into the inner m em brane of mitochondria in 
eukaryotes. Interestingly, the MRPL45 orthologous group, which also includes the 
bacterial Tim44-like proteins, shows a similar phylogenetic distribution pattern 
as the orthologous group of Cox11, an assem bly factor of cytochrome oxidase, 
which is involved in the co-translational insertion of copper ions into the nascent 
Cox1 protein.47 The observed pattern of co-presence and absence of these genes 
across a phylogenetically diverse set of species indicates that their gene products 
might be involved in the sam e process.76 As Cox11 has been shown to associate  
transiently with the m itoribosome as well, it is feasible that MRPL45 and Cox11 
act together in order to functionally insert Cox1 into the inner mitochondrial 
m em brane.47
Other examples of MRPs that have been recruited to the m itoribosome are the 
supernum erary proteins MRPL43 and MRPS25 (see Table 3), which are hom ologous 
to each other as well as to the B8 subunit (NI8M) of respiratory complex I (NADH- 
ubiquinone oxidoreductase) of the OXPHOS system.57,77 Presumably, MRPL43 and 
the B8 subunit of complex I originated from a single gene that was present in 
the primitive eukaryote, as they are present in a phylogenetically wide range of 
organisms. Most likely, another duplication of MRPL43 then gave rise to MRPS25, 
which is only found in metazoa and fungi. More examples of MRP recruitment 
include yeast MRPs Mrp1 and Rsm26, which are both part of the iron/manganese  
superoxide dism utase family,44 and MRPL44, which is hom ologous to a wide range 
of double-stranded RNA-binding proteins (see Table 3).
D etection  o f o rth o lo g s of M R Ps p rev io u sly  repo rted  to  be fu n g i-sp ecific
Several com prehensive experimental studies on the yeast mitochondrial translation 
m achinery have significantly extended its mitoribosomal proteom e.14-16 However, 
for a large num ber of MRPs that have been characterized in yeast thus far, no 
significant or conclusive sequence similarity has been reported to ribosomal 
proteins from other sources. In the current study, we were able to link seven 
of these seem ingly fungi-specific MRPs to known ribosomal proteins in other 
species, as will be outlined below.
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Apart from the hom ology between yeast Mba1 and MRPL45, which has 
already been discussed above, we identified Mrp49 as the ortholog of MRPS25. 
It is, however, surprising that the orthologs of MRPS25 found in S. cerevisiae as 
well as in N. crassa are reported to be located in the large instead of the small 
subunit of the m itoribosom e,1878 in contrast with the location of bovine MRPS25.59 
It is possible that the subunit localization of the MRPS25 orthologs is different 
between metazoa and fungi; however, further experimental evidence is needed in 
order to clarify this.
We also connected Rsm27, a yeast protein of the small subunit,44 to the 
MRPS33 protein family. In addition, we detected MRPS33 orthologs in all metazoa 
as well as D. discoideum and A. thaliana. Moreover, we found that yeast MRPs 
Mrpl28,53 Mrpl44,79 Mrpl5053 and Mrpl4053 are in fact the orthologs of MRPL40, 
MRPL53, MRPL9 and MRPL24, respectively. Both MRPL24 and Mrpl40 were found 
to contain a KOW motif (PFAM domain pfam00467), which is present in a variety 
of ribosomal proteins as well as in the bacterial transcription elongation factor 
NusG.80 The hom ology between Mrpl50 and bacterial RPL9 has been noted 
before,14 but it was dismissed as being insignificant, since the sequence similarity 
was not conserved throughout the full length of Mrpl50. In our analysis, however, 
we did detect significant hom ology between Mrpl50 and the MRPL9 family 
(including bacterial RPL9). Our finding is supported by the fact that Mrpl50 and 
MRPL9 representatives reside within the sam e protein superfam ily (SSF55658, 'L9 
N-domain-like').81
Finally, we were able to confirm the distant hom ology between Var1 and 
Rps5, two m tDNA-encoded hom ologs of bacterial RPS3 in fungi, as was previously 
reported by Lang and colleagues.82 Var1 and Rps5, which are the only mtDNA- 
encoded MRPs in yeast and N. crassa, respectively, have both been identified as 
essential com ponents of the SSU of the m itoribosome, showing similar phenotypes 
in mutant strains.82 Despite the fact that RPS3 has been shown to play an essential 
role in bacterial ribosom e assembly, and that Var1 and Rps5 are both essential for 
assem bly of the mitochondrial SSU in fungi, we were unable to detect candidate 
mitochondrial RPS3 hom ologs in metazoa. In the latter organisms, this essential 
role in ribosome assem bly could be performed by MRPS24, which displays 
distant hom ology to RPS3 (see Figure 1). Moreover, we could detect mtDNA- 
encoded RPS3 hom ologs in T. thermophila and D. discoideum,8283 the latter of 
which constitutes a peculiar case where the RPS3 encoding gene is split and 
both the 5' and 3' parts are fused to an ORF of unknown function (ORF425 and 
ORF1740, respectively). In any case, the fact that genes encoding RPS3 homologs 
are present on several mitochondrial genom es implies an alpha-proteobacterial 
origin of this protein.
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Figure 7. Domain architectures of MRPs to which additional functional domains have been added. 
Protein identifiers are depicted as in Table 1 or 2 and species distribution is indicated. Proteins are 
drawn approximately according to scale. Domain abbreviations: (1) Pkinase (pfam00069): Protein 
kinase catalytic domain. (2) DUF298 (pfam03556): Domain of unknown function, containing a basic 
helix-loop-helix leucine zipper motif. (3) Collagen (pfam01391): Collagen triple helix repeat. (4) VAR1 
(pfam05316): This domain is specific for some fungal mitochondrial ribosomal S3 proteins and is 
often present in two copies (also see text). (5) AAA (pfam00004): ATPase family associated with 
various cellular activities. Proteins containing AAA domains often perform chaperone-like functions 
that assist in the assembly, operation, or disassembly of protein complexes. (6) RRM (pfam00076): 
RNA-binding domain, found in a variety of RNA-binding proteins (also see text). (7) Cu (pfam02298): 
Copper-binding domain found in various proteins (also see text). (8) In plants, the N-terminus (S3_N, 
pfam00417) and C-terminus (S3_C, pfam00189) of MRPS3 are separated as a result of an insertion of a 
protein domain of unknown function (pfam B domain PB012879). (9) COG5373: Predicted membrane 
protein present in prokaryotes. (10) CBS (pfam00571) and PB1 (pfam00564) domains: CBS domains 
are small intracellular modules, which have a regulatory role in making proteins sensitive to adenosyl 
carrying ligands. PB1 is present in many eukaryotic cytoplasmic signaling proteins. (11) COG0021: 
Transketolase (1-deoxyxylulose-5-phosphate synthase).
A d ap tive  evo lutio n  o f co re  M R P s
Compared to bacterial ribosomes, mammalian m itoribosom es contain scarcely 
half as much rRNA and over twice as much protein, due to the presence of 
enlarged bacterial core proteins and supernum erary proteins.6 Previously, it has 
been hypothesized that these proteins might com pensate for the loss of rRNA 
segm ents in the m itoribosom e.684 Recently however, it was shown that many
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supernum erary MRPs occupy new quaternary positions in both the large and 
small subunits of the mitoribosom e,61 inconsistent with this hypothesis. We 
compared the sequences of all core MRPs with their bacterial counterparts in 
order to explore the possibility that core MRPs contain additional dom ains that 
perform extra, mitochondria-specific functions. Indeed, we observe that MRPs are 
significantly larger (on average almost twice as large) than their bacterial ancestral 
sequences (see Supplem entary Data, Figure S8). In som e cases, we could identify 
functional domains within these newly evolved regions, which we expect to be 
linked to ribosom e assem bly or function (see Figure 7). For instance, we identified 
a RNA recognition motif (RRM_1, pfam00076) and a copper-binding domain  
(Cu_bind_like, pfam02298) in the N-terminal regions of A. thaliana MRPS19 and 
MRPL22, respectively (see Figure 7). The RRM motif that is present in MRPS1985 
is found in a wide variety of RNA-binding proteins, which are implicated in a 
wide variety of cellular processes. Here, the motif is most likely involved in 
increasing the binding affinity to and/or stabilization of the tertiary structure of 
rRNA. The role of the copper-binding domain in MRPL22 is less clear. It might be 
involved in the co-translational insertion of copper ions into proteins that require 
copper for activity, in a similar way as has been observed for the cytochrome c 
oxidase assem bly factor in yeast, Cox1147 (also see above). The functions of other 
functional domains that are fused to MRPs are still obscure, such as a bacterial- 
type m em brane protein (COG5373) to MRPL27 in N. crassa (see Figure 7).
D i s c u s s i o n
In the present study we have m apped the evolution of the mitochondrial 
ribosomal proteome using a comparative genom ics approach that combined the 
most recent experimental data and computational techniques. The results of our 
study hint at a complex evolutionary scenario in which an ancestral ribosome of 
alpha-proteobacterial descent doubled its am ount of protein in most eukaryotic 
lineages by elongation of its proteins and by recruiting new proteins of diverse 
origins. We observe that the mitoribosom e has a complex history in terms of 
MRP gene gain and loss events during evolution. A  major protein gain of the 
mitoribosom e in eukaryotic evolution occurred prior to the divergence of the 
main eukaryotic domains, resulting in a primitive eukaryotic mitoribosom e of 68 
MRPs. Subsequently, the mitoribosom e diversified along the different eukaryotic 
lineages with a continuous recruitment of new proteins, including a large gain 
after the bifurcation of the animal-fungi clade in each lineage. Another notable 
surge has taken place in the kinetoplastida lineage, where 29 new proteins were 
found to form a new, distinct protein complex with unknown function, which 
associates with the SSU of the Leishmania m itoribosom es.17
Chapter
6
147
Chapter 6
Chapter
6
In addition to the gain of MRPs, we also observe that numerous MRPs 
have been lost during the course of evolution, som e of which have occurred 
independently in different lineages, as guided from ribosomal protein content 
that is encoded by the 'ancestral' mitochondrial genom e of R. americana.5 The 
extensive loss of genes encoding core MRPs in som e lineages contrasts with the 
evolutionary scenario that is observed for another mitochondrial protein complex 
with an alpha-proteobacterial ancestry, respiratory complex I (NADH:Ubiquinone 
oxidoreductase). During the evolution of this protein complex, which has 
approximately tripled its size in most eukaryotes, hardly any gene loss was 
observed, except for these lineages in which the com plete respiratory complex 
was lost.57 Moreover, the bacterial core of complex I has been restricted from 
gene loss events in all eukaryotic genom es analyzed thus far, which contrasts 
with the scenario of the m itoribosome. W hat is the underlying reason for the 
observed differences in the evolutionary trajectories? Evidently, som e of the 
core ribosomal proteins are not as essential as the core subunits of complex I for 
proper functioning of the protein complex, and are therefore expendable. This 
is the case for RPS20 and RPL25, which are absent from most mitoribosomes, 
for example. RPS20-deficient E. coli strains were found to be viable, but showed 
an increased misreading ability of nonsense codons;86 RPL25-defective and wild­
type E. coli ribosom es were found to translate at the sam e rate in vitro, albeit 
that the mutant type was less efficient.87 In contrast, som e MRPs that are missing 
in most eukaryotic species, such as MRPS1 and MRPL5, are indispensable for 
translation in E. coli and result in lethal phenotypes when mutated.8788 Moreover, 
MRPL5-deficient yeast strains display a respiratory-deficient phenotype, probably 
caused by a defect in the mitochondrial translation m achinery.15 Apparently, the 
evolution of the mitoribosomal proteome involved several drastic events that 
altered the absolute necessity of som e ribosomal proteins.
In addition, the present study was performed in order to prioritize MRPs for 
their potential involvement in mitochondrial respiratory diseases. Based on the 
fact that essential genes appear more evolutionary conserved than non-essential 
genes, the bacterial core ribosomal proteins and translation factors that are 
conserved in most eukaryotes constitute excellent screening targets for human 
mitochondrial disorders. Mutations in non-essential MRPs could be risk factors 
for these diseases. Thus far, mutations in patients with mitochondrial respiratory 
disorders have been reported for the gene encoding small ribosomal subunit 
protein MRPS16.28 But what about the supernum erary MRPs? In general, they are 
phylogenetically less conserved than the bacterial core proteins; however, their 
recruitment bears functional relevance, as is indicated by knock-out studies in 
yeast and C. elegans. As such, the two novel human MRPs, orthologs of yeast 
Rsm22 and Mrp10, are good candidates for unresolved mitochondrial disorders,
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since they show a wide phylogenetic distribution, have not been investigated 
before and yeast mutants show clear respiratory deficient phenotypes. 
Translation-related mitochondrial disorders are not solely caused by mutations 
in mitoribosomal genes, but also by mutations in genes encoding factors that 
functionally interact with the mitoribosome, such as mitochondrial translation  
elongation factors EFG125 and EFTs.26 In addition to the newly discovered human 
MRPs, these interactors constitute excellent screening targets for human patients 
with unresolved mitochondrial OXPHOS system disorders.
Altogether, our study reveals that the mitoribosomal proteom e has, after 
initially having been acquired via the alpha-proteobacterial endosymbiont, been 
subjected to a complex evolution that involved numerous gain and loss events, 
resulting in a large variety in mitoribosomal protein content between different 
eukaryotic lineages. Potentially, the increased am ount of proteins that seem to 
be associated with all modern eukaryotic mitoribosom es might reflect specific 
adaptations to m itochondria-specific functions, or, it might even reflect the 
increased complexity of eukaryotes them selves. Finally, we expect that additional 
experimental studies of mitoribosomal proteomes, such as the one that was 
recently performed on Leishmania m itoribosomes, will reveal an even more 
dramatic picture of the evolutionary trajectory of this protein complex. It will be a 
major challenge to gain more insight in the functional roles of the newly acquired 
MRPs.
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S u p p l e m e n t a r y  d a t a
Supplem entary text
Discrepancies between our study and other reports
This section describes the differences between the current analysis and some comparative 
analyses performed by others.1-4 In some cases we failed to detect MRPs where these 
were proposed, and in other cases our proposed candidate did not correspond to the 
candidate proposed. In either such case, we have performed bidirectional homology 
searches and a phylogenetic analysis in order to verify the proposed identity.
Koc et al. reported orthologs for MRPS36 and MRPL52 for C. elegans (CAA90335 
and CAA21620, respectively).2,3 We, however, performed extensive homology searches 
but failed to connect the proposed C. elegans candidate proteins to the respective 
MRPs. We therefore conclude that the genes encoding MRPS36 and MRPL52 are 
missing in C. elegans.
In addition, we were unable to detect significant sequence homology between N. 
crassa protein NCU05552 and yeast Mrpl13, which contrasts with results from Gan et al,5 
who detected sequence homology between these proteins. However, given the limited 
sequence similarity (less than 15% over the full length of the proteins) and given the 
fact that we were unable to connect these proteins in bidirectional homology searches, 
it is conceivable that NCU05552 and Mrpl13 are unrelated and thus constitute different 
components of the LSU. Further experiments are needed to corroborate this however.
Additionally, several differences were observed between the results of the 
current study and a study performed by Bonen and Calixte, who compiled data for 
the bacterial-origin MRPs from A. thaliana and Oryza sativa.1 In our study, we failed 
to detect mitochondrial candidates for ribosomal proteins S1, S20, L10, L31 and L35, 
suggesting that these genes have been lost. Bonen and Calixte also report these MRPs 
to be missing, but they propose that proteins from a non-alpha-proteobacterial origin 
might have substituted for these MRPs, as has been experimentally verified for MRPS8 
(divergent copy of cytosolic-origin S8)6 and MRPS13 (divergent copy of chloroplast- 
origin S13).6,7 Alternatively, they propose that nuclear-encoded chloroplast-type 
homologs might be dually targeted to the chloroplast as well as to the mitochondrion.1 
We confirmed a chloroplast origin for the proposed S1, S20, L10, L21, L31, L34 and L35 
candidates (not shown). However, they have not been included in our dataset since 
evidence of mitochondrial targeting of these proteins is still lacking. Bonen and Calixte 
also proposed a protein of chloroplast origin for mitochondrial S21 in plants, but we 
detected a more likely candidate of bacterial origin (See Table 1 and Supplementary 
Table 4). Moreover, we were able to detect proteins with significant sequence similarity 
to bacterial RPL25 encoded by the nuclear genomes of A. thaliana, O. sativa, as well as 
D. discoideum, indicating that the genes encoding these proteins have not been lost in 
the early stage of plant evolution as is suggested by Bonen and Calixte.1
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Supplem entary data
MS-Excel files containing supplementary information of the orthologous groups of 
MRPs used in this study can be downloaded from the NAR website.
For small subunit: 'Supplementary Table 4 (SSU).xls'
For large subunit: 'Supplementary Table 5 (LSU).xls'
ssu
S7 S8 S9 S10 S11 S12 S13 S14 S15 S16 S17 S18 S19 S21
Ribosomal protein
LSU
g  400 
350 
300 
I  250 
! 200 
<
150 i  
100
I RP 
i MRP
I
L1 L2 L3 L4 L5 L6 L9 L10 L11 L12 L13 L14 L15 L16 L17 L18 L19 L20 L21 L22 L23 L24 L25 L27 L24 L27 L28 L30 L31 L32 L33 L34 L35 L36
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Supplementary Figure S8. Mitochondrial ribosomal proteins of the small (A) and large subunit (B) 
have increased in size compared to their bacterial counterparts. The average lengths of MRPs are 
indicated with purple bars and their bacterial counterparts (RP) with orange bars. The lengths of the 
respective ribosomal proteins as depicted on the Y-axis was calculated by averaging the length of 
all the proteins that were present in the same orthologous group as defined by the COG database 
(RPs) or as defined in this study (MRPs). Only those ribosomal proteins are depicted that have a 
mitochondrial counterpart.
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I am not discouraged, because 
every wrong attempt discarded 
is another step forward. 
Thomas Edison
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A b s t r a c t
The oxidative phosphorylation (OXPHOS) system, comprising five enzyme 
complexes, is located in the inner mem brane of mitochondria and is the final 
biochemical pathway in oxidative ATP production. Defects in this energy- 
generating system can cause a wide range of clinical symptoms; these diseases 
are often progressive and multisystemic. Num erous genes have been implicated 
in OXPHOS deficiencies and m any mutations have been described. However, in a 
substantial num ber of patients with decreased enzym e activities of two or more 
OXPHOS complexes, no mutations in the mitochondrial DNA or in nuclear genes 
known to be involved in these disorders have been found. In this study, four 
nuclear candidate genes -  NIPSNAP1, GBAS, CHCHD1 and METT11D1 -  were 
screened for mutations in 22 patients with a com bined enzym atic deficiency of 
primarily the OXPHOS complexes I, III and IV to determ ine w hether a mutation 
in one of these genes could explain the mitochondrial disorder. For each variant 
not yet reported as a polymorphism, 100 control sam ples were screened for the 
presence of the variant. This way we identified 14 new polymorphism s and 2 
presumably non-pathogenic mutations. No mutations were found that could 
explain the mitochondrial disorder in the patients investigated in this study. 
Therefore, the genetic defect in these patients must be located in other nuclear 
genes involved in m tDNA maintenance, transcription or translation, in import, 
processing or degradation of nuclear encoded mitochondrial proteins, or in 
assem bly of the OXPHOS system.
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I n t r o d u c t i o n
In this study, four nuclear candidate genes for com bined deficiencies of the 
oxidative phosphorylation (OXPHOS) system were screened for mutations in a 
group of 22 patients: nipsnap homolog 1 (C. elegans) (NIPSNAP1), glioblastoma 
amplified sequence (GBAS), coiled-coil-helix-coiled-coil-helix domain containing 
1 (CHCHD1), and methyltransferase 11 domain containing 1 (METT11D1).
The oxidative phosphorylation system is located in the inner membrane 
of mitochondria and is the primary source of ATP in all aerobic organism s.1 In 
case of a defect in the energy-generating system, we speak of a mitochondrial 
disorder. Mitochondrial disorders are a group of genetically and clinically 
heterogeneous diseases that are often progressive and multisystemic. They are 
among the most comm on inherited human diseases with an estimated incidence 
of 1:5000 living births.2 Currently, therapy is mainly focused on symptom relief 
and only in up to 25% of the cases diagnosed at our centre can the underlying 
genetic defect of the mitochondrial disorder be found. Accordingly, in many 
families prenatal diagnosis is not possible, although in selected cases prenatal 
diagnosis on the basis of biochemical m easurem ents can be considered.3 The 
human OXPHOS system is com posed of the four enzym e com plexes (complexes 
I-IV) that make up the mitochondrial respiratory chain, and the ATP synthase 
complex (complex V), which uses the energy generated by electron transport 
along the respiratory chain to produce ATP. All the complexes contain nuclear (n) 
as well as mitochondrial (mt) DNA-encoded protein subunits with the exception 
of complex II, which is entirely encoded by the nuclear genom e. Consequently, 
a reduced enzym e activity of one or more of the complexes can be caused by 
m tDNA or nDNA mutations. Approximately 30% of the OXPHOS deficiencies in 
fresh m uscle biopsies investigated at our centre consist of combined enzymatic 
deficiencies.4 Num erous mutations have been described in m tDNA as well as in 
nDNA.5 However, in a substantial num ber of patients with combined OXPHOS 
system deficiencies, despite extensive investigations, no mutations in the mtDNA  
or in nuclear genes known to be involved in these disorders have been found. 
Thus, research into new candidate genes is warranted.
The four nuclear candidate genes investigated in this study were selected on the 
basis of their potential role in the pathogenesis of combined OXPHOS deficiencies. 
The function of NIPSNAP1 and GBAS (also known as NIPSNAP2) is am biguous. 
Both genes belong to an evolutionary well-conserved family consisting of four 
human NIPSNAP genes, divided into two subfamilies: (a) NIPSNAP1 and GBAS, 
and (b) NIPSNAP3A and NIPSNAP3B (also known as NIPSNAP3 and NIPSNAP4, 
respectively).6 NIPSNAP1 has a strong sequence similarity to the central portion 
of a hypothetical Caenorhabditis elegans protein, which is located between a
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4-nitrophenylphosphatase (NIP) domain and non-neuronal SNAP25-like protein.7 
Chromosom al region 7p12, which contains GBAS, is amplified in approximately 
40%  of glioblastom as.8 The transcripts of both genes are expressed ubiquitously 
at variable levels, with NIPSNAP1 mRNA being most abundant in liver, brain and 
kidney7,9 and GBAS mRNA in brain, skeletal m uscle and heart.7,8 These tissues have 
high energy dem ands and have been shown to be often affected in mitochondrial 
diseases. All NIPSNAP proteins have been reported to play a role in vesicular 
transport, mainly on the basis of hom ology data and the location of the C. elegans 
NIPSNAP gene in an operon with the SNAP25-like gene;6,7,10,11 the SNAP25-like 
protein is implicated in synaptic vesicle docking and fusion. However, functional 
studies have not confirmed this hypothesis yet, at least not for NIPSNAP1 and 
GBAS. More recently, NIPSNAP1 was shown to be located in the mitochondrion, 
in the inner m em brane.12,13 Additionally, NIPSNAP1 was found to be associated  
with mtDNA, possibly functioning as a mitochondrial nucleoid protein in mtDNA  
m aintenance and segregation.14 Since m tDNA defects can cause mitochondrial 
disorders, NIPSNAP1 and its close homolog GBAS are candidate genes for these  
diseases and for combined OXPHOS deficiencies in particular. For instance, 
defects in the m tDNA m aintenance protein POLG (polymerase gamma), the 
only m tDNA polymerase and also a constituent of mitochondrial nucleoids, are 
associated with a variety of mitochondrial disorders.15,16 The other two candidate  
genes, CHCHD1 and METT11D1, were shown to be orthologues of yeast genes 
coding for mitochondrial ribosomal small subunit proteins MRP10 and RSM22, 
respectively.17 Two human mitochondrial ribosomal proteins (MRPs) of the small 
subunit, MRPS16 and MRPS22, have already been shown to be implicated in 
com bined OXPHOS diseases.18,19 The two newly identified human MRPs are good 
screening targets for unresolved com bined OXPHOS disorders because they 
show a wide phylogenetic distribution, they have not been investigated before, 
and yeast mutants show clear respiratory-deficient phenotypes.
We performed sequence analysis on the DNA level for the four candidate 
genes in a group of 22 patients with a com bined enzym atic deficiency of primarily 
the OXPHOS com plexes I, III and IV in muscle and/or fibroblasts to determine  
whether a mutation in one of these genes could explain the mitochondrial 
disorder. This revealed 14 new polymorphism s and 2 probably non-pathogenic  
mutations. Consequently, the genetic defect in this group of patients must be 
located in other nuclear genes involved in processes such as m tDNA maintenance, 
transcription or translation.
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M a t e r i a l s  a n d  m e t h o d s
Sub jects
The patient group consisted of 22 patients diagnosed at our centre with a 
com bined OXPHOS deficiency of primarily the complexes I, III and IV; the enzyme 
activities were measured in skeletal muscle tissue and/or cultured skin fibroblasts 
(see Table 1). In all patients, m tDNA mutations were excluded by sequencing the 
entire mitochondrial genom e. Additionally, POLG and all known mitochondrial 
translation factors (MTIF2, MTIF3, TSFM, TUFM, GFM1, GFM2, MTRF1, MTRF1L 
and MRRF) and multiple MRPs (MRPS12, MRPS14, MRPS16, MRPL11, MRPL12 
and MRPL45) were systematically screened; no convincing pathogenic sequence  
variants were found. The control material for our standard control group was 
derived from 100 healthy persons who had been referred to our centre for 
reasons not related to mitochondrial dysfunction. The two ethnically matched 
control groups each consisted of 100 inhabitants of The Netherlands who either 
had a Dutch or a Turkish background.
Cell cu ltu re  and b io ch em ical m easurem en ts
Human skin fibroblasts were cultured in M199 medium (Gibco, Breda, The 
Netherlands) supplem ented with 10% fetal calf serum and antibiotics. The 
activities of the OXPHOS enzym e com plexes were measured in skin fibroblasts 
and muscle tissue as described previously.20,21
S eq u ence  analysis
DNA was isolated from cultured skin fibroblasts (patients) or blood (controls) 
using salt extraction.22 The entire coding sequences including the intron-exon 
boundaries were screened for mutations. The sequence of the oligonucleotide  
primers and the PCR conditions used for amplification can be obtained upon 
request. Both strands were used for direct sequencing on a 3130xl Genetic 
Analyzer, using the BigDye terminator v1.1 cycle sequencing kit according to 
the manufacturer's protocol (Applied Biosystems, Nieuwerkerk a/d IJssel, The 
Netherlands). Sequence data were analysed with Sequencher 4.8 software (Gene 
Codes, Ann Arbor, MI, USA) by comparison with the reference sequences. Genbank 
accession numbers: AC005529.7 (NIPSNAP1), AC092579.3 (GBAS), AC022400.9 
(CHCHD1), AF321003.1 (METT11D1).
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R e s u l t s
Direct sequencing of the four genes NIPSNAP1, GBAS, CHCHD1 and METT11D1 
in 22 patients with a combined OXPHOS deficiency revealed m any known 
polymorphism s (data not shown) but no pathogenic mutations. However, 14 new  
polymorphism s and 2 mutations, presum ably non-pathogenic, were identified by 
screening 100 controls for the genetic variants found in the patients (see Table 2). 
The numbering of the variants is based on the following coding DNA reference 
sequences: NM _003634.1 (NIPSNAP1), NM _001483.1 (GBAS), NM_203298.1 
(CHCHD1), and NM _001029991.1 (METT11D1). We classified a sequence variation 
as a new polymorphism when detected in at least 1 % and as a mutation when  
found in less than 1 % of the control population. Four variants were found in 
less than 1% of our standard control group and therefore we also screened 100 
ethnically matched controls for these variations. Both GBAS c .93-51T>C and 
METT11D1 c.517G>T (p.Ala173Ser) were present in a Turkish control group with an 
allele frequency of 0.02 and were consequently regarded as new polymorphisms. 
The two other variants were considered to be non-pathogenic mutations. In 
NIPSNAP1, a heterozygous mutation was identified in patient 21, a transversion  
of a G to a C located in the 3' UTR (untranslated region), 170 nucleotides after 
the stop codon (c.*170G>C). This mutation was also found to be heterozygous in 
one Turkish control. In METT11D1, patient 20 harboured a heterozygous G-to-A  
transition located 21 nucleotides before exon 6 (c.529-21G>A). The mutation 
was not detected in a Dutch control population. Investigation on the cDNA level 
revealed no effect on splicing.
We also screened 100 controls for the presence of the following 11 known 
polymorphism s found in the four genes we investigated: rs34114704, rs9625833, 
rs1058646, rs35864418, rs7098766, rs11538172, rs35402434, rs34207344, 
rs2771348, rs35308618, and rs2771350. None of these polymorphism s was found 
in our patient or control group.
Additionally, we detected two discrepancies between Genbank reference 
sequences and patient sequences. The NIPSNAP1 reference sequence  
(NM_003634.1) contains CG on position c.468_469, whereas all patients and 
the Ensembl reference sequence (ENST00000216121) have GC on this position. 
The GBAS reference sequence (NM_001483.1) contains a G on position c.*1082; 
however, all patients and the Ensembl reference sequence (ENST00000322090) 
show a T at this location. BLAST searches revealed that both sequence variations 
deposited in Genbank are present in only one of the available human expressed 
sequence tags.
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Table 1. OXPHOS enzyme activities of all patients
Patient Tissue CI CII CIII SCC CIV
1 Muscle 19 175 22 110 22
Fibroblast 53 95 66 210 20
2 Muscle 63 73 69 123 69
Fibroblast 144 121 ND 159 127
3 Muscle 0 ND ND 159 44
Fibroblast 17 151 94 192 30
4 Muscle 80 118 68 91 96
Fibroblast 110 129 78 118 65
5 Muscle 21 ND 27 50 25
Fibroblast 182 ND 153 144 125
6 Muscle 80 163 71 105 143
Fibroblast 75 ND 85 133 66
7 Fibroblast 43 123 76 113 14
8 Muscle 38 ND ND 249 54
Fibroblast 35 ND 87-136a 173 30
9 Muscle 80 67 51 64 95
Fibroblast 117 ND 127 111 136
10 Fibroblast 64 87 71 51 39
11 Muscle 54 91 78 ND 51
Fibroblast 27 93 65 ND 23
12 Muscle 31 222 25 77 22
Fibroblast 164 ND 142 100 121
13 Muscle 0 184 18 120 13
Fibroblast 166 153 126 189 137
14 Fibroblast 47 102 59 147 41
15 Muscle 60 224 69 96 23
Fibroblast 144 ND 66 110 64
16 Muscle 24 160 55 152 61
Fibroblast 169 ND 146 175 124
17 Muscle 6 ND 73 94 19
Fibroblast 231 ND 183 144 107
18 Muscle 17 109 56 113 54
Fibroblast 120 246 241 329 146
19 Muscle 116 158 78 101 157
Fibroblast 53 193 65 177 53
20 Muscle 26 178 109 142 78
Fibroblast 31 254 52 85 13
21 Muscle 4 ND 82 97 21
Fibroblast 119 ND 155 200 104
22 Muscle 9 130 35 102 26
Fibroblast 144 ND 144 194 148
CI—IV, complexes I-IV; SCC, succinate cytochrome c oxidoreductase; ND, not determined 
a Complex III activity was decreased in one fibroblast sample and normal in another sample.
All enzyme activities are expressed as percentage of the lowest control reference value. Lowered 
activities are shown in bold type.
In total 10 patients had lowered enzyme activities in muscle tissue, but normal values in fibroblasts. In 
10 other patients decreased enzyme activities were measured in muscle tissue as well as fibroblasts (in 
multiple cases not all three of the complexes I, III and IV were affected or measured in both tissues). 
For 3 patients muscle tissue was not available and therefore the enzyme activities were only measured 
in fibroblasts.
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table 2. New sequence variants found in our patient group
Gene Sequence variant Submitter SNP ID Allele frequency
Patients Controls
NIPSNAP1 c. -157C>T ss99308674 0.05 0.04
c. -123G>T ss99308675 0.02 0.03
c. -105G>A ss99308676 0.02 0.02
c.790+11C>G ss99308677 0.02 0.05
c.*170G>C - 0.02 0/0.005b
GBAS c.93-51T>C ss107796293 0.02 0.005/0.02b
c.444 + 17A>G ss99308678 0.11 0.23
c.444 + 197G>A ss99308679 0.11 0.23
c.585 + 130_585 + 131insATATATGTAT ss99308680 0.80 0.75
c.585 + 152_585 + 153delAC ss99308681 0.05 0.02
c.586-41delT a - 0.50 0.50
CHCHD1 c.-6-40delT ss99308682 0.05 0.03
METT11D1 c.76-37_76-36insGT ss99308683 0.02 0.02
c.364 + 55G>A ss99308684 0.02 0.03
c.517G>T ss107796294 0.02 0/0.02b
c.529-21G>A - 0.02 0/0b
c.997-32T>C ss99308685 0.02 0.02
a This is probably not a SNP but a sequence artefact due to a T-stretch of 10 nucleotides. 
b These sequence variants were screened in our standard control group and in ethnically matched 
control groups (Dutch for METT11D1 c.529-21G>A, Turkish for the 3 other variants); the first number 
refers to the allele frequency in the standard control group and the second number to the frequency 
in the ethnically matched group.
D i s c u s s i o n
In this study we screened four nuclear genes, NIPSNAP1, GBAS, CHCHD1 and 
METT11D1, which were selected based on their potential role in the pathogenesis 
of com bined OXPHOS deficiencies, for the presence of mutations in a group of 
22 patients with primarily an OXPHOS complex I, III and IV deficiency. Sequence  
analysis revealed no mutations that could explain the mitochondrial disorder of 
the patients. However, many sequence variations were detected, including 14 
new polymorphism s and 2 mutations. Both mutations are considered to be non- 
pathogenic on the basis of the location in the sequence (in non-coding regions), 
the presence in a control subject (applies only to the NIPSNAP1 mutation), the 
absence of an effect on splicing (only tested for the METT11D1 mutation), and 
the fact that the mutations were both heterozygous. The mutation in the 3' UTR 
of NIPSNAP1 could have an effect on the stability of the m RNA or the efficiency 
of binding of the mRNA to the ribosomes; this has not been investigated.
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Nevertheless, we do not expect this single nucleotide change to be the cause of 
the mitochondrial disorder.
Additionally, 11 sequence variations reported in the NCBI SNP database were 
not observed in either our patient group or the control group. For most of these 
variations, population frequency data were lacking or data showed the absence  
of the sequence variant (rs9625833, rs2771348, and rs2771350), and two SNPs 
(rs34207344 and rs35308618) were found with an allele frequency of only 0.013. 
Since the variations are probably all rare polymorphisms, it is not surprising that 
these SNPs were not detected in our study.
Furthermore, we found two discrepancies between the NIPSNAP1 and GBAS 
Genbank reference sequences and the patient sequences. Because the Genbank 
variations were only present in one of the available expressed sequence tags, we 
suspect that these variations are rare polymorphisms, mutations, or errors in the 
Genbank sequences.
A  possible explanation for the absence of disease-causing mutations in our 
patient group in the four candidate genes we screened is that the roles hypothesized 
for the proteins in mtDNA maintenance (NIPSNAP1 and GBAS) and mitochondrial 
translation (CHCHD1 and METT11D1) could be incorrect. Functional studies with 
human CHCHD1 and METT11D1 have not been performed so far. NIPSNAP1 has 
been shown to be associated with mtDNA14 but its potential role as nucleoid protein 
has not been investigated further; moreover, the function of GBAS is less certain, 
since it was not found in association with mtDNA. Additionally, NIPSNAP1 was 
recently reported to function as a negative modulator of the selective Ca2+ channel 
TRPV6 located in the kidney.9 Although the mechanism of this inhibition is not clear, 
vesicular trafficking processes appear not to be involved, even though other studies 
have reported the role of multiple NIPSNAP proteins in vesicular transport.6,7,10,11 
Thus the function of the NIPSNAP proteins remains elusive and further research is 
warranted to clarify this.
Moreover, there are of course many more candidate genes for combined 
OXPHOS complex I, III, and IV deficiencies: not only all genes involved in mtDNA  
maintenance, transcription and translation, in import, processing and degradation  
of nuclear-encoded mitochondrial proteins, but also genes involved in assem bly of 
the OXPHOS system, including assem bly of the complexes them selves and of the 
supercom plexes (containing, for instance, complex I, III and IV). All these processes 
are extremely complex and tightly regulated, which makes the identification of the 
remaining genes causing combined OXPHOS disorders a real challenge. Linkage 
analysis and hom ozygosity mapping are powerful tools for the identification of 
candidate genes and localization of the genetic defects, as has been shown for 
com bined OXPHOS defects as well.23-26 Because we only have sam ples from single 
patients, we could not put these techniques to use. A  method that has been shown
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to be useful on single patients is m icrocell-m edicated chrom osom e transfer;27 
however, this is a very tim e-consum ing technique. Hopefully, it will be possible to 
apply w hole-genom e sequencing to our patient cohort in the near future. Much 
data will be generated with this technique; therefore, bioinformatic tools will have 
to be developed and optimized to make whole genom e sequencing a feasible 
and relatively fast method -  compared with screening candidate genes one by 
one -  to find the genetic defects in patients with unresolved combined OXPHOS 
deficiencies.
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From the bitterness of disease 
man learns the sweetness of health. 
Catalan proverb
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A b s t r a c t
The oxidative phosphorylation (OXPHOS) system is under control of both the 
mitochondrial and the nuclear genomes; 13 subunits are synthesized by the 
mitochondrial translation machinery. We report a patient with Cornelia de Lange- 
like dysmorphic features, brain abnormalities and hypertrophic cardiomyopathy, 
and studied the genetic defect responsible for the combined OXPHOS complex 
I, III and IV deficiency observed in fibroblasts. The combination of deficiencies 
suggested a primary defect associated with the synthesis of mitochondrially 
encoded OXPHOS subunits. Analysis of mitochondrial protein synthesis revealed 
a marked impairment in mitochondrial translation. Homozygosity mapping 
and sequence analysis of candidate genes revealed a homozygous mutation in 
MRPS22, a gene encoding a mitochondrial ribosomal small subunit protein. The 
mutation predicts a Leu215Pro substitution at an evolutionary conserved site. 
Mutations in genes implicated in Cornelia de Lange syndrome or copy number 
variations were not found. Transfection of patient fibroblasts, in which MRPS22 
was undetectable, with the wild-type MRPS22 cDNA restored the amount and 
activity of OXPHOS complex IV as well as the 12S rRNA transcript level to normal 
values. These findings demonstrate the pathogenicity of the MRPS22 mutation 
and stress the significance of mutations in nuclear genes, including genes that 
have no counterparts in lower species like bacteria and yeast, for mitochondrial 
translation defects.
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I n t r o d u c t i o n
Mitochondrial disorders are generally caused by dysfunction of the oxidative 
phosphorylation (OXPHOS) system. The OXPHOS system, comprising five enzyme 
complexes located in the mitochondrial inner membrane, is responsible for the 
production of most of the cell's ATP. Synthesis of this energy-generating system 
is controlled by both the mitochondrial and the nuclear genomes (mtDNA and 
nDNA). The mtDNA codes for 13 subunits of the OXPHOS complexes I, III, IV and V 
as well as the tRNAs and rRNAs required for the translation of these transcripts. All 
other mitochondrial proteins, including over 70 OXPHOS subunits and all proteins 
of the mitochondrial translation machinery, are encoded by nuclear genes. The 
majority of mutations associated with combined OXPHOS deficiencies because 
of impaired mitochondrial translation are located in mtDNA genes;1 however, the 
list of nDNA mutations is steadily growing with defects reported in mitochondrial 
translation factors,2-5 mitochondrial ribosomal proteins,6,7 mitochondrial tRNA 
synthetases8-10 and tRNA-modifying enzymes.11-13
We investigated a group of 33 patients with combined OXPHOS deficiencies 
(and normal complex II activities) by mutational analysis of the entire mtDNA, 
polymerase gamma and nuclear genes implicated in mitochondrial translation. 
In this study, we report a mutation in mitochondrial ribosomal protein MRPS22 
detected in one patient and establish its pathogenicity.
M a t e r i a l s  a n d  m e t h o d s
Case report
The male patient was the first child of healthy, first-grade consanguineous Pakistani 
parents. Fetal ultrasound disclosed microcephaly with dilatation of the third 
ventricle and a left ventricular hypertrophic cardiomyopathy (HCM). The patient 
was born by spontaneous vaginal delivery at 35 weeks of gestation with a birth 
weight of 2610 grams (P50), length 44 cm (P10) and head circumference 29 cm 
(<P3). Physical examination showed Cornelia de Lange-like dysmorphic features 
(synophrys, low implanted posteriorly rotated ears, retrognathia, redundant skin 
over the neck, hypospadias, non-pitting edema of the limbs, back and eyelids, 
but no distal limb anomalies). Generalized muscle hypotonia and paucity of 
spontaneous movements were seen. Echocardiography showed biventricular and 
septal HCM with good function and pulmonary hypertension. MRI revealed corpus 
callosum hypoplasia and dilatation of the third ventricle, a subdural hematoma in 
the right fronto-parietal region, leukencephalopathy and delayed myelinisation. 
Chronic, severe metabolic acidosis with increased plasma lactate (max: 9 mmol/l, 
N: <2.1 mmol/l), elevation of alanine in plasma (684 |jmol/l, N: <400 |jmol/l) 
and elevated urinary excretion of Krebs-cycle intermediates were noted. In the
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following months, dysphagia and failure to thrive necessitated gastrostomy. The 
biventricular HCM remained stable over the years with a shortening fraction 
of 39%. ECG revealed Wolf-Parkinson-White syndrome. At the age of 2 years, 
he developed tonic seizures and EEG displayed a low background activity with 
multifocal sharp-slow waves. Seizures and EEG abnormalities disappeared 
spontaneously. Ophthalmological examination and hearing tests were repeatedly 
normal. Growth remained poor; growth parameters at the age of 4 years are as 
follows: weight 8.5 kg (<<<P3), length 80 cm (<<<P3), head circumference 40 cm 
(<<<P3). The facial features got less pronounced over the years. The boy hardly 
developed; now, at the age of 5.5 years, he shows a severe truncal hypotonia and 
tetraspasticity (left>right) with sparse but dystonic movements. He is unable to sit 
freely and communicate, but he reacts to light and sounds.
Cell culture
Human skin fibroblasts were cultured in M199 medium (Gibco, Breda, The 
Netherlands) supplemented with 10% fetal calf serum (FCS) and antibiotics.
For complementation experiments, human skin fibroblasts were grown in 
DMEM (Dulbecco's modified Eagle's medium, Kibbutz Beit Haemek, Israel) with 
4.5 g/l of glucose, in the presence of 10% FCS, 50 |jg/ml uridine and 110 |jg/ml 
pyruvate. Selection of transfected cells was done in glucose-free RPMI (Roswell 
Park Memorial Institute) supplemented with 50 |j M galactose and 10% dialyzed 
FCS.14 Viability was assessed by trypan-blue exclusion.
Enzym e m easurem ents
The activities of the OXPHOS enzyme complexes were measured in cultured skin 
fibroblasts as described previously; citrate synthase (CS) served as a control.15,16
Pulse labeling of m itochondrial translation products
In vitro labeling of mitochondrial translation was performed as described elsewhere,17 
with a few minor adaptations. In short, cells were labeled for 60 min at 37 °C in 
methionine-free DMEM with 10% dialyzed FCS, 200 ^Ci/ml [35S]methionine (Tran35S- 
Label, MP Biomedicals, Eindhoven, The Netherlands) and 100 |jg/ml emetine, and 
subsequently chased for 10 min in regular DMEM with 10% FCS. Total cellular protein 
(100 ^g) was resuspended and incubated for 10 min in PBS containing 2% lauryl 
maltoside. Unsolubilized material was removed by centrifugation at 10 000 g for 10 
min and loading buffer was added to the supernatant to a final concentration of 
100 mM Tris-HCl (pH 6.8), 20% glycerol, 1% SDS, 0.02% Coomassie Blue G-250 and 
1% mercaptoethanol. Samples were run on 16% polyacrylamide gels,18 which were 
subsequently scanned on a FLA5100 (Fujifilm Life Science, Düsseldorf, Germany). 
Equal protein loading was confirmed by Coomassie blue staining.
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Hom ozygosity mapping
Patient DNA was isolated from cultured skin fibroblasts by salt extraction.19 
Whole-genome homozygosity mapping was performed using the GeneChip 
Human Mapping 10K Array Xba 142 version 2.0 (Affymetrix, High Wycombe, UK) 
in accordance with the manufacturer's guidelines.20 This array contains 10 204 
single neutral polymorphisms (SNPs) with a mean intermarker distance of 258 kb, 
equivalent to 0.36 cM, and an average SNP heterozygosity of 0.38.
Sequence analysis
Genomic DNA (gDNA) was extracted from cultured skin fibroblasts (patient) 
or blood (parents and controls) by standard procedures.19 Total RNA was 
isolated from patient fibroblasts using RNA-Bee (Tel-Test, Friendswood, TX, 
USA); complementary DNA (cDNA) was prepared using superscript II reverse 
transcriptase (Invitrogen, Breda, The Netherlands). Sequence analysis of MRPS22 
(GenBank accession number NM_020191.2) was carried out on cDNA in two 
overlapping fragments; the parts of the first and last exon not covered, including 
the intron-exon boundaries, were amplified on gDNA. The presence of the 
mutation in exon 4 was confirmed on gDNA and subsequently screened for in 
both parents and 109 Pakistani controls. Sequence analysis of the entire open 
reading frame including the intron-exon junctions of NIPBL, SMC1A and SMC3 
(GenBank accession numbers NM_015384.4, NM_005445.3 and NM_006306.2, 
respectively) was performed on gDNA. Primer sequences and PCR conditions used 
for amplification can be obtained upon request. Both strands were used for direct 
sequencing on a 3130xl Genetic Analyzer, using the BigDye terminator v1.1 cycle 
sequencing kit according to the manufacturer's protocol (Applied Biosystems, 
Nieuwerkerk a/d IJssel, The Netherlands). Sequence data were analyzed with 
Sequencher 4.8 software (Gene Codes, Ann Arbor, MI, USA) by comparison with 
the reference sequences.
A ffym etrix NspI SNP array hybridization and analysis
Copy number variation (CNV) screening by means of microarray analyses 
was carried out on the Affymetrix GeneChip 250k (NspI) SNP array platform 
(Affymetrix, Inc., Santa Clara, CA, USA), which contains 25-mer oligonucleotides 
representing a total of 262 264 SNPs. Hybridizations were performed according 
to the manufacturer's protocols. Copy numbers were determined using the 2.0 
version of the CNAG (Copy Number Analyzer for Affymetrix GeneChip mapping) 
software package,21 by comparing SNP probe intensities from patient DNA with 
those of a sex-matched pooled reference DNA sample (DNA from 10 healthy 
male individuals). The average resolution of this array platform, described by 
McMullan et al,22 is 150-200 kb.
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Blue-native and SDS-PAGE analysis and in-gel activity assay
Blue-native (BN) PAGE was used for separation of the OXPHOS complexes on 
5-15% polyacrylamide-gradient gels as described before.23 After electrophoresis 
of 40 ^g mitochondrial protein from fibroblasts, gels were further processed for 
complex I in-gel activity assay and western blotting. Assembly of the OXPHOS 
complexes was investigated using monoclonal antibodies against subunits 
of complexes I, III, V (Molecular Probes, Leiden, The Netherlands), II and IV 
(MitoSciences, Eugene, OR, USA).
One-dimensional 10% SDS-PAGE analysis was performed as described 
previously.24 For detection of MRPS22, a polyclonal antibody raised against a GST- 
MRPS22 (full length) fusion protein (ProteinTech Group, Chicago, IL, USA) was 
used.
Transfection with w ild-type MRPS22 cDNA
Wild-type MRPS22 cDNA was cloned into the pLenti6/V5-D-TOPO 6969-bp 
expression vector by directional TOPO cloning (primers and PCR conditions are 
available upon request). The recombinant vector was propagated in One Shot 
Stbl3 Escherichia coli and introduced into 293FT cells after co-transfection 
with pLP1, pLP2 and pLP/VSVG plasmids using lipofectamine according to the 
manufacturer's instructions (ViraPower, Invitrogen, Carlsbad, CA, USA). Control 
and patient cells were infected with the lentiviral construct carrying the wild-type 
MRPS22, and clones of stably transfected cells were established by blasticin (4 |jg/ 
ml) selection and by selection on glucose-free medium.7,25 Patient cells were also 
transiently transfected with the lentiviral vector carrying an expression control 
plasmid, pLenti6/V5-GW/lacZ (Invitrogen).
Determ ination of com plex IV  levels
Protein was determined by Bicinchoninic Acid (BCA) protein assay kit (Sigma- 
Aldrich, Rehovot, Israel). Amount of complex IV was estimated using the MitoProfile 
Biogenesis Dipstick assay kit (MitoSciences) according to the manufacturer's 
instructions. Results were obtained after digital imaging with TINA 2.0 software.
Determ ination of m itochondrial 12S rRNA and 16S rRNA levels
Total mRNA isolated using TRI reagent (Sigma-Aldrich) was reverse transcribed 
with ImProm-II reverse transcriptase (Promega, Madison, WI, USA). The cDNA 
was amplified in a PCR reaction to detect the expression of specific nucleic acid 
sequences using SYBR Green (Applied Biosystems, Roche, NJ, USA). ß-Actin 
served as an endogenous control and mitochondrial 12S rRNA or 16S rRNA as 
the target cDNAs (primers are available on request). The levels of all cDNAs were 
equalized and real-time PCR reactions were performed using each primer set
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separately. The relative expression of the target transcript was calculated with the 
comparative Ct method (Applied Biosystems User Manual) and analyzed by two­
tailed Student's t-test.
R e s u l t s
Enzyme activities of OXPHOS complexes I, III and IV in patient fibroblasts were 
reduced to 45, 59 and 36% of the lowest control value, respectively; complex II 
was not affected (Table 1). BN-PAGE analysis confirmed this combined OXPHOS 
deficiency: complex I and IV were hardly detectable and complex III showed a 
slight decrease in the amount of fully assembled complex, whereas the level of 
complex II was normal (Figure 1). Additionally, complex I activity was again clearly 
lowered.
Table 1. OXPHOS enzyme activities in fibroblasts
Activities (mU/U citrate synthase)ab
Complex Patient Reference range
I 45 100 -  310
II 606 520 -  845
III 782 1320 -  2610
II+III 186 110 -  470
IV 242 680 -  1190
a Measured in mitochondrial-enriched fractions from fibroblasts.
b The activity of citrate synthase was 208 mU/mg protein (reference range 144-257 mU/mg protein). 
Decreased activities as compared with controls are shown in bold numbers.
C1 P C2
Figure 1. BN-PAGE analysis in patient fibroblasts. Antibodies directed against specific individual 
subunits were used to assess the amount of each of the fully assembled complexes in the patient (P) 
and controls (C1 and C2). Complex II was used as a loading control. CI-CIV=complex I-IV; IGA=in-gel 
activity.
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Figure 2. In vitro labeling of mitochondrial translation products. The patient (P) translation rates of 
the different subunits are expressed as percentages of the average [35S]methionine incorporation in 
two controls (C1 and C2). The level of translation of ND5 was obtained from an identical assay, in 
which this product was clearly visible. COI-COIII=subunits of cytochrome c oxidase (complex IV); cyt 
b=cytochrome b subunit (of complex III); ND1-6=subunits of NADH CoQ oxidoreductase (complex I); 
ATP6-8=ATP synthase (complex V) subunits 6 and 8.
Figure 3. MRPS22 mutation, conservation of the mutated residue, protein structure prediction and 
protein level in patient cells. (a) DNA sequence analysis of the patient (homozygous c.644T>C) and 
both parents (heterozygous). (b) Protein sequence alignment from human to worm, which shows that 
the mutated leucine residue is highly conserved among different species. (c) Prediction of the MRPS22 
protein structure, displaying part of the protein with the Leu215Pro substitution located in the middle 
of a helix. (d) Immunoblot analysis in patient (P) and control (C1 and C2) fibroblasts reveals the (near) 
absence of the MRPS22 protein. Complex II was used as a loading control.
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Pulse labeling of mitochondrial protein synthesis products revealed a marked 
and generalized mitochondrial translation defect (Figure 2): total incorporation 
of [35S]methionine was 26% of that in controls. The decrease in mitochondrial 
translation varied between different subunits, with the translation rates of ND5, 
ND6 and COIII/COII (10-15%) being most severely and of ATP8 and ND4L/ATP6 
(60-70%) being the least affected.
C C+MRPS22 P P+MRPS22(1) P+MRPS22(2) P+lacZ
b  160
C C+MRPS22 P P+MRPS22(1) P+MRPS22(2) P+lacZ
Figure 4. Restoration of mitochondrial rRNA levels by MRPS22 transfection. Patient (P) and control (C) 
fibroblasts were transfected with a viral vector carrying the wild-type MRPS22 cDNA. Stably transfected 
clones (C + MRPS22, P+MRPS22(1) and P+MRPS22(2)) were isolated by antibiotic selection. Patient 
cells were also transfected with a control vector (lacZ). 12S rRNA and 16S rRNA levels were quantified 
relative to ß-actin and presented relative to control values as mean percentages ± SD (a, b) or as the 
relative ratios of 12S rRNA:16S rRNA ± SD (c) of triplicate determinations. *Significantly different from 
the control (P<0.05).
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Table 2. Restoration of complex IV activity and amount by MRPS22 transfection
Activities (mU/U citrate synthase)0 Amountb
Sample Complex IV Complex II Complex IV
Control 2230 190 2.49
Control + MRPS22 1780 190 3.35
Patient 890 230 1.26
Patient+MRPS22(1)c 2440 190 2.88
Patient+MRPS22(2)c 2630 250 2.99
Patient+lacZ 650 240 0.40
a Measured in fibroblast homogenates. 
b Expressed relative to frataxin. 
c Stably transfected Patient+MRPS22 clones 1 and 2.
After excluding mutations in the mtDNA, polymerase gamma (POLG and 
POLG2) and all nine known mitochondrial translation factors (MTIF2, MTIF3, 
TSFM, TUFM, GFM1, GFM2, MTRF1, MTRF1L and MRRF) by direct sequencing, 
we used homozygosity mapping to guide further investigations. Multiple 
homozygous regions were found, containing mitochondrial ribosomal proteins, 
among others. On the basis of the mitochondrial translation deficit in patient 
fibroblasts and previously reported mutations, we selected MRPS16 (located in 
the largest homozygous region, spanning 110.9 Mb on chromosome 10) and 
MRPS22 (located in a region of 16.1 Mb between SNPs rs977683 and rs1112189 
on chromosome 3) as plausible candidate genes. Sequence analysis revealed a 
homozygous T to C transition at position 644 of the coding sequence of MRPS22, 
which is predicted to result in the substitution of the highly conserved leucine 
for proline at position 215 (Figure 3a and b). The mutation was heterozygous in 
both parents and absent in 109 ethnically matched controls. As MRPS22 has no 
ortholog in bacteria and no crystal structure exists for modeling, we used the 
PSIPRED server to predict the secondary structure of the MRPS22 protein.26 The 
mutation seems to be located in the middle of a helix (Figure 3c) and presumably 
disturbs it because of the lack of stabilizing hydrogen bond formation by proline 
and the possible introduction of a kink. The homology-based tools PolyPhen 
(Polymorphism Phenotyping, http://genetics.bwh.harvard.edu/pph/index.html)27 
and SIFT (Sorting Intolerant From Tolerant, http://sift.jcvi.org/)28 were applied to 
indicate the functional impact of the missense mutation. Both PolyPhen and SIFT 
predicted the mutation to be deleterious (with a PSIC score difference of 2.243 
and a score of 0.00, respectively). Western blotting revealed the (near) absence of 
MRPS22 in patient fibroblasts (Figure 3d).
To investigate whether the MRPS22 deficit causes the OXPHOS system 
deficiency, we introduced wild-type MRPS22 cDNA into patient cells. The complex
IV enzyme activity increased from 40% to 109-118% and its protein level went from
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51% to 116-120% of the control values (Table 2). Quantification of mitochondrial 
rRNA levels showed a restoration of 12S and 16S rRNA content from 36 and 
77% to 71-109% and 70-120% of control levels (Figure 4a and b), respectively, 
resulting in normal 12S rRNA/16S rRNA ratios (Figure 4c). Complex IV activity and 
amount, as well as rRNA content, were decreased after transfection of patient 
fibroblasts with a control vector.
Subsequently, genes known to be implicated in Cornelia de Lange syndrome 
were screened for mutations to shed light on the genetic origin of the Cornelia 
de Lange-like dysmorphic features. No mutations were found in the genes NIPBL, 
SMC1A and SMC3. In addition, analysis of patient DNA on the 250K NspI SNP 
array revealed a normal male profile, thus excluding any potentially clinically 
relevant copy number variants.
D i s c u s s io n
This study confirms the importance of mitochondrial ribosomal protein MRPS22 
for mitochondrial translation and consequently for the formation and functioning 
of the OXPHOS system. We described the second mutation in MRPS22 and 
determined its pathogenic role in the patient's mitochondrial disorder.
The combined OXPHOS complex I, III and IV deficiency, impairment of 
mitochondrial translation and absence of mutations in the mtDNA in our patient 
suggested that the genetic defect was located in a nuclear gene encoding a 
constituent of the mitochondrial translation machinery. Sequence analysis of 
all mitochondrial translation factors followed by homozygosity mapping led to 
the identification of a homozygous missense mutation in MRPS22, predicted 
to substitute a highly conserved leucine for proline (Leu215Pro). In patient 
fibroblasts, the MRPS22 protein was undetectable and expressing the wild-type 
MRPS22 cDNA rescued the disease phenotype, evinced by the restoration of 
OXPHOS complex IV amount and activity, as well as 12S rRNA transcript level, 
establishing the MRPS22 defect as the cause of the disease.
Human MRPS22 is a 360-amino-acid protein that has been found in a limited 
number of species, having no ortholog in fungi or prokaryotes.29 The exact location 
of MRPS22 in the three dimensional structure of the ribosome and its exact 
function are currently unknown. Recently, a MRPS22 defect was shown to strongly 
hamper assembly of the small ribosomal subunit, whereas assembly of the large 
subunit and part of the small subunit were only mildly affected.30 This is consistent 
with both our and previous findings that mutations in mitochondrial ribosomal 
small subunit proteins cause a marked decrease in the abundance of the 12S 
rRNA transcript and nearly no reduction in the level of 16S rRNA,67 since rRNAs 
are readily degraded unless they are incorporated into a ribosomal subunit.31 
Thus, although MRPS22 is evolutionary not well conserved, it is indispensable
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for the assembly of the human mitochondrial ribosome and consequently, 
as we have shown, for effective mitochondrial protein synthesis. Previously, a 
missense mutation in MRPS22 (Arg170His)7 and a non-sense mutation in MRPS16 
(Arg111X),6 which is highly conserved and essential for ribosome assembly,293032 
were reported to be lethal. The clinical phenotypes of patients with MRPS16 or 
MRPS22 mutations bear resemblances. All three mutations are associated with 
muscle hypotonia, lactic acidemia and edema of the limbs. Furthermore, both 
MRPS22 defects led to hypertrophic cardiomyopathy. The patient harboring 
the MRPS22 Arg170His mutation additionally presented with tubulopathy and 
no brain abnormalities were noted, in contrast to the patient reported in this 
study. It remains unclear whether the brain abnormalities observed in our patient 
are primarily due to the genetic defect or developed secondary to intrauterine 
ischemia; presumably both contributed. The dysmorphic features and brain 
abnormalities of our patient are similar to those seen in the MRPS16 patient, 
however, the latter did not develop hypertrophic cardiomyopathy. On the basis 
of the identification of a MRPS22 mutation and the absence of mutations or 
copy number variations responsible for the Cornelia de Lang-like symptoms 
in our patient, we advise to perform echocardiography, metabolic screening 
(plasma lactate, plasma amino acid analysis and urinary organic acid analysis) 
and cerebral MRI in patients with dysmorphic features suggestive of Cornelia de 
Lange syndrome. Notably, in our patient these features were quite prominent at 
birth but diminished over the years.
The patient reported in this study was part of a cohort of 33 patients with 
combined OXPHOS deficiencies. In seven other patients from this cohort, the 
causative genetic defect was found. Mutations were identified in the mitochondrial 
tRNALys, tRNAArg and tRNATrp genes (four patients),33 POLG (one patient) and 
translation factors TSFM and GFM1 (two patients), including three mutations 
that had not been published before. Our findings emphasize that nuclear gene 
mutations contribute substantially to mitochondrial translation deficits. Vastly 
exceeding 100 proteins, among which 81 mitochondrial ribosomal proteins,29 are 
(in)directly involved in the mitochondrial translation process, whereas in merely 
nine of these proteins mutations have been found up till now. Therefore, many 
more such defects are expected to be discovered. Progress in high-throughput 
sequencing technologies will hopefully make the difficult task of selecting the 
right candidate genes obsolete. In the meantime, supernumerary proteins such 
as MRPS22, lacking homologs in bacteria and other lower species, should not be 
disregarded during investigations of mitochondrial disorders as they evidently 
perform important roles.
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Most of our so-called reasoning 
consists in finding arguments for 
going on believing as we already do. 
James Harvey Robinson
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C o m b i n e d  o x p h o s  d e f ic i e n c i e s  -  h o w  t o  u n r a v e l  t h e i r  g e n e t i c
ORIGIN?
This thesis tackles the difficult task of unraveling the molecular genetic defects 
underlying combined oxidative phosphorylation (OXPHOS) complex I, III and IV 
deficiencies. Combined OXPHOS deficiencies are a subset of diseases generally 
known as mitochondrial disorders, which are frequent and often debilitating 
diseases that can lead to death early in life. Considering that mitochondrial 
function depends on thousands of genes, encoded by the mitochondrial (mt) 
as well as the nuclear (n) genome, and the intricate relationships between all 
proteins involved, it is hardly surprising that in many cases the genetic cause 
of the mitochondrial disorder remains unknown. Besides the genetic complexity 
and heterogeneity among patients, the general lack of a genotype-phenotype 
correlation also complicates the molecular diagnosis. Especially when multiple 
complexes of the OXPHOS system are affected, locating the pathogenic mutation 
is a daunting task. We aimed to identify new nuclear gene defects that cause 
combined OXPHOS complex I, III and IV deficiencies, with the focus on deficiencies 
originating from mitochondrial translation defects, to improve diagnostic 
possibilities, our understanding of underlying disease mechanisms, and hopefully 
curative therapy in the future.
For this purpose, we assembled a cohort of 33 patients (31 children and two adults) 
with decreased enzyme activities of complex I, III and IV -  and normal complex
II activities -  in fibroblasts and/or muscle tissue. After mtDNA mutations were 
excluded, 29 patients remained for mutational analysis of nuclear genes. Genes 
known to be implicated in combined OXPHOS deficits as well as new candidate 
genes were screened, leading to a total of 30 genes. This revealed pathogenic 
mutations in 'known' nuclear genes (POLG, TSFM, GFM1 and MRPS22) in four 
patients, including two not previously reported mutations. No clearly deleterious 
genetic defects were found in the remaining 25 patients. The results of these 
studies will be discussed in more detail and reflected upon in this chapter.
G e n e t i c  d e f e c t s  u n d e r l y i n g  c o m b in e d  o x p h o s  c o m p l e x  I, III AND  
i v  d e f ic i e n c ie s
At present, mutations resulting in mitochondrial disease have been identified 
in over 100 different mitochondrial and nuclear genes.1 The number of genes 
implicated in combined OXPHOS deficiencies is much lower but is growing 
rapidly. The mitochondrial tRNA genes and POLG contain a large proportion 
of the mutations currently known to cause combined OXPHOS deficits, but 
in 2004 the first mutation in one of the mitochondrial translation factors was
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identified,2 defining a new class of gene defects underlying these disorders. In 
addition to the mitochondrial rRNA and tRNA genes, there are now 21 nuclear 
genes -  required for nucleotide synthesis or transport, mtDNA replication, or 
mitochondrial translation -  reported to be responsible for combined complex
I, III and IV defects.3 Many more disease genes are expected and needed to be 
found to explain the numerous as yet unsolved cases of combined deficiencies.
M utational analysis of m itochondrial DNA
First of all, we screened the entire mitochondrial genome for mutations in our 
cohort of 33 patients with combined complex I, III and IV deficiencies. This 
revealed pathogenic tRNA mutations in four patients. It is possible, however, that 
heteroplasmic mtDNA mutations were missed because the affected tissue was 
not investigated. Approximately a quarter of all patients had normal OXPHOS 
enzyme activities in fibroblasts, and thus the mtDNA mutation load is expected 
to be low and perhaps undetectable in this tissue. Nevertheless, for all patients 
mutational analysis was performed in DNA isolated from cultured fibroblasts since 
the amount of muscle tissue available was often insufficient for DNA extraction.
Two patients harbored a mutation in tRNALys (MT-TK), m.8363G>A, which has 
previously been associated with a variety of clinical manifestations.4 Mitochondrial 
protein synthesis was slightly decreased in fibroblasts of both patients. 
Furthermore, an extra band appeared below the ND4 polypeptide, which has also 
been reported for the common m.8344A>G tRNALys mutation and which has been 
identified as a truncated COXI polypeptide arisen from premature termination of 
translation.5 In two other patients, novel tRNATrp (MT-TW) and tRNAArg (MT-TR) 
mutations were detected. Chapter 3 demonstrates that these mutations affect 
the conformation and steady-state levels of the tRNAs, causing mitochondrial 
translation impairment and consequently combined OXPHOS deficiencies. After 
publication of this paper, three new mutations in tRNATrp have been reported.6,7
These findings emphasize the rapid progress that is still being made in 
the identification of mitochondrial tRNA mutations and that such mutations 
are important contributors to mitochondrial disease. What should be noted, 
however, is that a considerable proportion of the reported tRNA mutations are 
not supported by sufficient evidence to be regarded as pathogenic.8,9 On the 
other hand, the tRNATrp mutation that we clearly demonstrated to be deleterious 
in our patient was previously listed as a polymorphism. Scoring systems8,9 could 
be used to determine whether additional studies, such as analysis of the effect on 
tRNA stability and structure, are required to properly classify a nucleotide change 
in a mitochondrial tRNA gene.
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M utational analysis of nuclear DNA
Polymerase gamma
Subsequently, we performed sequence analysis of POLG and POLG2, the genes 
coding for the catalytic and accessory subunits of the mtDNA polymerase, 
respectively. With over 150 deleterious mutations, POLG is a major locus for a 
wide range of mitochondrial disorders.10 POLG mutations are associated with a 
variety of OXPHOS enzyme deficits as well as with an entirely normal OXPHOS 
system; generally, multiple enzymes (sometimes including complex II) are affected 
in muscle tissue, whereas in fibroblasts often normal enzyme activities are 
seen.11,12 The most prevalent POLG mutation, Ala467Thr,10 was found compound 
heterozygous with Gly848Ser in one of our patients, who showed symptoms 
of Alpers syndrome. In patients with Alpers syndrome, Ala467Thr is the most 
frequent mutation and Gly848Ser is very common as well.13 This patient showed 
profound combined OXPHOS complex I, III and IV deficiencies in muscle tissue, in 
contrast with previous reports on such cases.12,14
Three other patients from our cohort also harbored formerly described 
mutations in POLG, Asn468Asp (1 patient) and Gly517Val (2 patients), but these 
mutations were heterozygous without a second mutation being detected. 
The Asn468Asp variant has been presented as a recessive mutation, yet the 
pathogenicity of the mutation is unclear: patients were found to be compound 
heterozygous and healthy family members were found to be carriers, suggesting 
that the other heterozygous mutation resulted in dominant disease.15,16 In cases 
where Asn468Asp is the only POLG mutation, as in our patient, it is possible 
that the disease-causing mutation is actually located in another gene.17 Thus, 
Asn468Asp may just be a neutral polymorphism or a disease-modifying mutation. 
Nonetheless, one report showed dominant cosegregation of Asn468Asp.18 A 
similar situation applies to the Gly517Val mutation, which was originally published 
as a dominant mutation19 but is now viewed as an unclassified sequence variant 
with unknown clinical relevance.1720 Therefore, the Asn468Asp and Gly517Val 
mutations were considered not to be responsible for the mitochondrial disorder 
in these three patients. To exclude deletion of one or more POLG exons on one 
allele, which could be missed by standard sequencing methods and could lead 
to disease on its own or in combination with a (recessive) mutation on the other 
allele, multiplex ligation-dependent probe amplification (MLPA) should still be 
performed for all patients. This is a multiplex PCR technique that can be used to 
detect the relative copy number of all exons within a gene.21
Furthermore, one possibly pathogenic and not previously reported sequence 
variant was detected: Pro635Leu. This mutation was heterozygous on both DNA 
and RNA level in one patient and not found in 97 healthy controls. It is located in 
the middle of the linker region of POLG, which is involved in binding the accessory
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subunit POLG2. The homology-based tools PolyPhen (Polymorphism Phenotyping, 
http://genetics.bwh.harvard.edu/pph/index.html)22 and SIFT (Sorting Intolerant 
From Tolerant, http://sift.jcvi.org/)23 were applied to indicate the functional impact 
of the missense mutation. Both PolyPhen and SIFT predicted the mutation to be 
deleterious (with a PSIC, Position-Specific Independent Counts, score difference 
of 2.342 and a score of 0.04, respectively), but the reliability of the predictions is 
decreased due to the limited number of sequences represented at that position. 
Additional research, among which family history to assess the possibility of 
autosomal dominant inheritance, MLPA and mtDNA depletion/deletion screening, 
is called for to determine the significance of this mutation. Subsequently, the effect 
of the mutation on POLG functions such as catalytic activity, DNA binding ability 
and interaction with the accessory subunit could be analyzed.24 Pro635Leu is a 
neutral sequence variant or a deleterious mutation, either dominant or recessive, 
with in the latter case either an intronic mutation on the other POLG allele, the 
absence of (part of) the other allele, or a mutation in a related gene such as the 
mtDNA helicase, resulting in digenic disease.25
No mutations were found in POLG2 in our patient group. To date, two 
mutations in POLG2 have been described to cause mitochondrial disease, in 
particular progressive external ophthalmoplegia (PEO).26,27
The POLG mutation history illustrates the importance of critical evaluation 
of mutation reports as the mode of inheritance and clinical relevance cannot 
always be established accurately without analysis of multiple families, and even 
then the role of certain mutations remains unclear, as is the case for above­
mentioned Asn468Asp and Gly517Val mutations. Therefore, mutations should be 
revisited and if necessary reclassified in the light of new findings until they are 
fully characterized, especially in such a fast moving field with over 150 mutations 
discovered in just a decade. Much is still to be learned about the currently known 
POLG and POLG2 mutations and those awaiting identification.
M itochondrial translation factors
Up to date, three out of nine mitochondrial translation factors have been implicated 
in human mitochondrial disease. The first two mutations in mitochondrial 
translation factors, GFM1 and TSFM, were detected at our center but in different 
patient cohorts than the one that is subject of this thesis (TSFM: see chapter 4).2 
Subsequently, the first mutation in TUFM and additional mutations in GFM1 were 
identified.2829
All nine mitochondrial translation factors that have been characterized -  MTIF2, 
MTIF3, TSFM, TUFM, GFM1, GFM2, MTRF1, MTRF1L and MRRF -  were screened for 
mutations in our patient group. One patient harbored the Arg333Trp mutation in 
elongation factor mtEFTs (TSFM) that was published earlier (see chapter 4 for the
Chapter
9
197
Chapter 9
Chapter
9
first report and see the discussion section of chapter 5 for a note on the finding 
in the current patient cohort). This mutation caused severe mitochondrial disease 
leading to death within the first few months after birth in three unrelated patients. 
The phenotypic expression of the mutation was remarkably different between 
patients. Furthermore, we identified a new mutation in elongation factor mtEFG1 
(GFM1) and demonstrated its role in the combined OXPHOS deficiency and 
mitochondrial translation defect that ultimately resulted in fatal mitochondrial 
encephalopathy in one patient (chapter 5). In stark contrast to previously described 
GFM1 cases, decreased enzyme activities were detected only in fibroblasts and 
not in muscle tissue of this patient, underscoring that comprehensive biochemical 
investigation is critical in the diagnosis of mitochondrial disease.
The reports on mutations in mitochondrial translation factors emphasize the 
heterogeneity and complexity of mitochondrial disorders: a) an identical mutation, 
e.g. Arg333Trp in TSFM, can result in strikingly different clinical presentations in 
individual patients; b) tissues are selectively affected despite ubiquitous expression 
of the translation factors; c) in which tissues the biochemical defect manifests 
itself can differ between patients with distinct mutations in the same gene, e.g. 
GFM1. Currently, one can primarily speculate on the causes for the biochemical 
and clinical variability associated with mutations in mitochondrial translation 
factors. Even though the core mitochondrial protein synthesis machinery has been 
characterized (see chapter 2), much remains to be unraveled concerning details 
of the mechanisms of mitochondrial translation, the exact function of some of the 
proteins involved, and especially regulation of the entire system. Antonicka et al 
showed that tissue-specific differences exist not only in the basal mitochondrial 
translation machinery, but also in its response to dysfunction.28 The efficiency of 
mitochondrial translation partly depends on congruous ratios of the translation 
elongation factors (mtEFTs, mtEFTu and mtEFG1) and these relative ratios differ 
between tissues. In line with this, over-expression of certain translation elongation 
factors can be beneficial in patient cells but can be detrimental to mitochondrial 
translation in control cells. Furthermore, the residual level of mutant protein was 
found to parallel the severity of the OXPHOS deficiency caused by compound 
heterozygous GFM1 mutations, suggesting it as the major factor in the tissue 
specificity of the biochemical and clinical phenotypes.28 The differences in 
mtEFG1 protein expression are likely the result of post-transcriptional regulatory 
mechanisms as mRNA steady-state levels did not correlate with protein levels 
in the various tissues. Moreover, changes in the translation factor ratios, for 
instance through transcriptional upregulation of mtEFTu in heart tissue of a 
patient with mutations in GFM1, can occur in response to dysfunction of part 
of the mitochondrial translation apparatus. Such adaptive mechanisms appear 
to function differently between tissues and plausibly also between patients,
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thereby contributing to the observed biochemical and clinical variability. It would 
be interesting to investigate whether similar observations as the ones reported 
by Antonicka et al would be made in patients with other GFM1 mutations and 
with TSFM and TUFM mutations. Therefore, the levels of all OXPHOS complexes 
and translation elongation factors as well as the effect of over-expression of 
the elongation factors on these levels and on the rate of mitochondrial protein 
synthesis should be determined in multiple patient tissues. This could shed more 
light on, for instance, whether heart indeed uniquely possesses compensatory 
mechanisms to avoid deleterious effects on mitochondrial translation when one 
of the proteins involved in this process is impaired, as speculated by Antonicka 
et al, or whether this was a patient-, mutation- or gene-specific response. The 
last option seems most probable since mutations in TSFM and MRPS22 have 
subsequently been associated with hypertrophic cardiomyopathy (chapters 4 
and 8), whereas two other GFM1 cases again did not show any signs of heart 
involvement (chapter 5).29 Other explanations for the biochemical and clinical 
variability, besides differences in (compensatory changes in) translation factor 
ratios, could be the presence of genetic modifiers and threshold effects. 
Genetic modifiers are likely to play a role in the variation among individuals 
with mitochondrial translation defects, however, they will be difficult to identify 
because usually large numbers of patients are needed to obtain reliable results. 
The term threshold effect refers to the finding that genetic defects are manifested 
only when a threshold value is exceeded.30 These threshold levels vary between 
individuals, e.g. due to dissimilarities in OXPHOS capacity related to mtDNA 
haplotypes.31 Threshold effects also differ between tissues within an individual 
and can occur at various levels: transcription, translation, enzyme complex, 
biochemical, and cellular, finally resulting in the phenotypic threshold effect. 
Differences between tissues are based on quantitative properties of the basal 
mitochondrial machineries and adaptive mechanisms that are at hand, which 
together lead to distinct threshold values beyond which pathology ensues. For 
example, if the basal OXPHOS or mitochondrial translation system, which both 
have been shown to vary quantitatively between tissues, contains an excess of 
a protein, this excess could be used as a reserve to compensate for a deficit 
in that particular system (of either the same protein or another component). 
Consequently, the threshold value for the amount of mutant protein above which 
deleterious effects arise would be higher in a tissue with reserves present in 
that system. To illustrate, over-expression of mtEFTu has been shown to rescue 
a mtEFTs defect (chapter 4), and interestingly, over-expression of mtEFTu or 
mtEFG2 can partially suppress a mitochondrial translation deficit due to a mtDNA 
mutation (m.3243A>G, in tRNALeu).32 Thus, the rate of mitochondrial respiration 
or translation can be maintained when the activity of an OXPHOS complex,
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translation factor or tRNA is diminished. There are numerous threshold effects, 
for both mtDNA and nDNA mutations,30 with many of them poorly understood 
or perhaps still unknown. Further research is required to better comprehend 
the molecular bases of the various mitochondrial threshold effects and thereby 
improve our knowledge on the complex regulation of mitochondrial translation. 
Model organisms such as the long-lived Caenorhabditis elegans mitochondrial 
mutants could be used to study the compensatory pathways that are activated to 
delay human mitochondrial disease appearance.33
So far, no pathogenic mutations have been identified in factors involved in 
the initiation or termination phase of mitochondrial protein synthesis. During the 
mutational screen in our patient cohort, we came across one sequence variant 
in mitochondrial initiation factor MTIF2 and two sequence variants in ribosome 
recycling factor MRRF. All three variations were heterozygous and not detected in 
100 control samples. Table 1 shows predictions of the functional consequence of 
the substitutions. It additionally lists a rare polymorphism (Ser695Gly, rs34174245) 
that is located at the same position as our MTIF2 sequence variant (Ser695Cys).
Table 1. Predictions of functional impact of substitutions in MTIF2 and MRRF
Gene Substitution (Genbank Polyphen SIFT
Accession number) PSIC score 
difference
Predicted effect Score Predicted effect
MTIF2 Ser695Cys
(NP_001005369.1)
1.764 Possibly
damaging
0.04 Affect protein 
function
Ser695Gly
(NP_001005369.1)
0.025 Benign 0.46 Tolerated
MRRF Thr70Ile
(NP_620132.1)
1.553 Possibly
damaging
0.23 Tolerated
Pro141Ser
(NP_620132.1)
1.288 Benign 0.06 Tolerated
Both prediction methods, Polyphen and SIFT, clearly designate polymorphism 
Ser695Gly in MTIF2 as a benign variant and Ser695Cys as a possibly pathogenic 
mutation. Notably, the patient harboring this mutation has additional heterozygous 
changes in POLG2, MRPS14 and MRPS22, which suggests digenic disease. This 
is considered to be unlikely, though, because of the silent nature of the other 
changes. Based on sequence homology and physical properties of the amino 
acids, the substitutions in MRRF are predicted not to affect protein function, 
albeit the slight inconsistency of the two prediction methods. Furthermore, the 
heterozygous Pro141Ser mutation was found in a patient born of consanguineous 
parents, making it a less plausible cause for the patient's mitochondrial disorder. 
The pathogenicity of substitutions Ser695Cys (MTIF2) and Thr70Ile (MRRF) could
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be elucidated by screening family members for the presence of the change and 
investigating the effects of over-expression of the wild-type proteins in patient 
cells. Unless deleterious mutations in mitochondrial translation initiation or 
termination factors are incompatible with life, they are good candidates for 
involvement in mitochondrial translation defects.
M itochondrial ribosom al proteins
Of the more than 80 mitochondrial ribosomal proteins (MRPs) currently known, 
mutations have been found in merely two of them: MRPS16 and MRPS22.34,35 In 
principle, all MRPs are candidate genes for mitochondrial disorders. To facilitate 
the selection of which MRPs to screen for mutations first, we performed extensive 
homology searches to reconstruct the evolutionary history of the mitochondrial 
ribosomal proteome across different eukaryotic lineages (chapter 6). MRPs could 
thereafter be prioritized based on their location and function in the mitochondrial 
ribosome (mitoribosome) and the outcome of yeast knock-out studies, if this 
information was available, as well as on their evolutionary conservation. What is 
more, two new human MRPs were detected in this comparative genomics analysis: 
CHCHD1 and METT11D1, orthologs of yeast mitoribosomal small subunit proteins 
MRP10 and RSM22, respectively. These novel MRPs as well as MRPS12, MRPS14, 
MRPS16, MRPS22, MRPL11, MRPL12 and MRPL45 were subsequently screened for 
mutations in our patient cohort. This revealed three possibly pathogenic and not 
previously reported sequence variations in MRPS14, MRPS22 and MRPL11.
Chapter 8 reports the mutation in MRPS22 and evinces its pathogenicity by 
transfection of patient cells with wild-type MRPS22. This study confirms that not 
only well-conserved core proteins, such as MRPS16, but also phylogenetically 
less conserved proteins, such as MRPS22, can be implicated in disease. Essential 
genes are generally more evolutionary conserved than non-essential genes and 
consequently, well-conserved proteins are obvious candidates for involvement 
in disease. Nevertheless, supernumerary proteins, which typically do not show 
a wide phylogenetic distribution, are functionally important, as has clearly been 
shown by knock-out studies and mutational reports. When prioritizing proteins 
for their involvement in mitochondrial disease, one should therefore be careful 
when using evolutionary conservation as a criterion.
Table 2 lists predictions of the functional impact of the substitutions 
detected in MRPS14 and MRPL11. Both PolyPhen and SIFT predict the change 
in MRPS14 not to be deleterious, even though the properties of glycine and 
arginine are considerably dissimilar. This discrepancy may be attributed to the 
low conservation level of this position, making the predictions less reliable. The 
substitution is located in the mitochondrial targeting sequence and could thus 
affect targeting of the protein to the mitochondrion. Mitochondrial translation
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was found to be impaired in patient fibroblasts. However, this sequence variant 
was heterozygous in a patient born of consanguineous parents, making it a less 
plausible cause for the patient's mitochondrial disorder. To ascertain its functional 
importance, additional research is necessary, starting with investigation of control 
DNAs to determine whether this concerns a polymorphism. The sequence variant 
in MRPL11 is evidently predicted to affect protein function and was absent from 
99 control samples. Nonetheless, the mutation was heterozygous on both DNA 
and RNA level and did not result in a clear disruption of mitochondrial translation. 
Introduction of wild-type MRPL11 cDNA into patient cells could shed more light 
on the pathogenicity of this mutation. No mutations were found in our patient 
cohort in the other MRP genes that were analyzed (see chapter 7 for the report 
on CHCHD1 and METT11D1).
Table 2. Predictions of functional impact of substitutions in MRPS14 and MRPL11
Gene Substitution (Genbank Polyphen SIFT
Accession number) PSIC score 
difference
Predicted effect Score Predicted effect
MRPS14 Gly7Arg 1.478 Benign 0.35 Tolerated
(NP_071383.1)
MRPL11 Arg142Cys 2.165 Probably 0.00 Affect protein
(NP_057134.1) damaging function
Recently, two additional components of the mitoribosome were identified, 
bringing the total number of human MRPs on 83. Richter et al convincingly 
showed that ICT1 is actually an integral component of the human mitoribosome, 
unlike the other members of the release factor family to which ICT1 belongs.36 It 
is thought to be essential for hydrolysis of prematurely terminated peptidyl-tRNA 
species in stalled mitoribosomes, releasing the mitoribosome for recycling. The 
other members of the mitochondrial release factor family are mtRF1a and mtRF1, 
both suggested to be class I release factors, and C12orf65. Notably, C12orf65 
mutations were detected in patients with encephalopathy and were demonstrated 
to be responsible for the OXPHOS system and mitochondrial translation defects.37 
Although the specific role of C12orf65 in mitochondrial protein synthesis has 
not yet been elucidated, Antonicka et al speculate that it functions in recycling 
abortive peptidyl-tRNAs, which would explain why over-expression of ICT1 can 
partially rescue the C12orf65 defect. The other newly found MRP is ERAL1, a 
constituent of the small subunit.38 Knock-down of ERAL1 leads to impairments in 
small subunit assembly, mitochondrial translation and cell growth. In addition to 
functions in mitoribosome assembly and mitochondrial translation, ERAL1 is also 
posited to be involved in other processes, including mitochondrial transcription
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through association with nucleoid proteins. Furthermore, recent experimental 
data confirmed that NOA1 is an indispensible GTPase specifically required for 
mitochondrial protein synthesis, probably through a role in mitoribosome 
biogenesis.39 NOA1 deficiency was shown to be lethal in mid-gestation in mice, 
which was accompanied by a severe developmental defect and malfunctioning 
of mitochondrial translation and all OXPHOS enzymes except for complex
II. Interestingly, NOA1 knock-out also hampered mitochondria-dependent 
apoptosis. This is not surprising given that NOA1 interacts with, among other 
MRPs, MRPS29 or DAP3 (Death-Associated Protein 3),40 which is an integral part 
of the mitoribosome and involved in programmed cell death.41 These findings 
illustrate that our understanding of the mitochondrial translation system is still far 
from complete and that this system and its relationships to other pathways are 
probably much more complex than previously anticipated.
Other candidate genes
Summarizing, in our cohort of 33 patients with combined OXPHOS complex I,
III and IV deficiencies, the causative genetic defect was detected in 4 patients 
(12%) in the mitochondrial genome and also in 4 patients (12%) in the nuclear 
genome. Of these patients in whom the genetic cause was elucidated, half 
harbored mutations that were known and half had mutations that were not 
reported previously. MtDNA mutations thus appear to account for mitochondrial 
disease in 12% of patients with combined complex I, III and IV deficits, whereas 
the remaining 88% is consequently due to nDNA mutations. Since a nuclear gene 
defect was identified in merely 12% of all cases, 76% of patient disease currently 
remains unresolved, disregarding the possibly deleterious mutations that were 
found in some of these cases. In conclusion, hardly one quarter of patients with 
combined complex I, III and IV deficiencies are genetically diagnosed using the 
current strategy.
The presently unresolved cases of combined OXPHOS deficiencies in our 
patient cohort are due to either new mutations in known mitochondrial disease 
genes or, which is likely the larger contributor, mutations in genes that have 
not yet been linked with mitochondrial disease. Many candidate genes exist 
for mitochondrial disorders in general and combined OXPHOS deficiencies in 
particular. When multiple OXPHOS enzymes are affected, the genetic defect is 
presumed not to be located in genes encoding OXPHOS subunits but rather in 
genes needed for mtDNA maintenance, mitochondrial transcription (including 
transcript processing), mitochondrial translation, import of nDNA-encoded 
proteins into the mitochondrion, quality control, processing of mitochondrial 
proteins, insertion of OXPHOS components into the inner membrane, 
mitochondrial membrane biogenesis, or assembly of OXPHOS supercomplexes
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(see Chapter 2 for more details). When OXPHOS complex II activities are normal, 
the genetic defect should be sought mainly in the first three gene classes as the 
others theoretically influence all OXPHOS complexes.
Several candidate genes, in addition to the ones mentioned in the sections 
above, were screened for mutations in the current study: two genes that code for 
presumed nucleoid proteins (NIPSNAP1 and GBAS, chapter 7), 7 transcription 
factors (POLRMT, TFAM, TFB1M, TFB2M, MTERF1, MTERFD1 and MTERFD3), and 
OXA1L, which facilitates the insertion of proteins from the mitochondrial matrix 
into the inner membrane. Unfortunately, no pathogenic sequence variations were 
found in any of these genes in our patient cohort. This could be attributed to 
1) erroneous inclusion of patients in the cohort, 2) the genes not being good 
candidates for combined complex I, III and IV deficiencies, 3) the genetic defect 
not being perceived, or 4) the multitude of other genes that could theoretically 
harbor the disease-causing mutation and the scarcity of mutations in most 
disease genes. These points, except for number 2, of course also apply to the 
genes screened before. First of all, patient selection. In several patients that were 
included in the cohort, not all OXPHOS enzyme activities were measured. Complex
II was missing in most of these cases, although a normal activity of this enzyme 
is actually an inclusion criterion. In some other patients, complex II was (slightly) 
decreased. Its diminished activity could simply be secondary to the combined 
OXPHOS deficiency via disturbance of supercomplex formation, however, many 
supercomplexes appear to not contain complex II.42,43 Furthermore, conflicting 
results were obtained in three patients: when repeating the measurements, 
normal activities of (nearly) all complexes were found. Considering the above, 
it is not unlikely that some patients were erroneously included in the study. 
And as mentioned before, there is still a small chance that the mitochondrial 
genome harbors the deleterious mutation since heteroplasmic mtDNA mutations 
might have been overlooked. Secondly, let us evaluate whether the candidate 
genes were selected appropriately. The potential roles of NIPSNAP1 and GBAS 
in mtDNA maintenance have not yet been substantiated by functional studies. 
NIPSNAP1 has been suggested to be essential for OXPHOS complex I based 
on a large-scale proteomics and bioinformatics study44 and more specifically 
to be required for complex I assembly using protein correlation profiling.45 The 
involvement of GBAS in ATP production has recently been confirmed via knock­
down experiments, however, the enzyme activities of complexes I and IV were 
not affected by GBAS knock-down and so the exact role of GBAS in oxidative 
phosphorylation remains to be ascertained.46 Consequently, NIPSNAP1 and 
GBAS are possible but not definite candidate genes. Although the mechanisms 
of mitochondrial transcription -  transcription termination in particular -  have 
not been fully elucidated, the transcription machinery components that were
204
General discussion and future perspectives
analyzed for mutations are evidently needed to maintain adequate transcript 
levels and are thus good candidates for association with combined OXPHOS 
deficiencies.47 The potential function of MTERFD2, which was not included in 
our screen, in transcription termination still awaits determination. Most of the 
knowledge on OXA1L is based on studies in yeast. Knock-down of OXA1L in 
human cells disrupted the assembly and activity of OXPHOS complexes I and
V but surprisingly did not adversely affect complexes III and IV.48 Furthermore, 
since OXA1L mediates membrane insertion of not only proteins synthesized in 
the mitochondrion but also nuclear-encoded proteins, OXA1L might not be the 
best candidate for the current patient cohort, considering the normal activities of 
complex II. Explanation 3 -  that the defect is located in a gene that was subjected 
to mutational analysis, but that this defect did not get identified -  is a reasonable 
cause for the seemingly absence of mutations. Using standard PCR and DNA 
sequencing methods, heterozygous deletions of (part of) a gene can be missed. 
This can be overcome by performing MLPA for all genes.21 In addition, besides 
the splicing signals at the exon-intron boundaries, which are usually included 
in the mutational screen of a gene, an extensive array of intronic and exonic 
splicing enhancer and suppressor elements are necessary for proper splicing.4950 
Intriguingly, 15% up to 60% of disease-causing mutations are estimated to disrupt 
splicing. Sequencing of the open reading frame and exon-intron boundaries 
is not sufficient to exclude deleterious mutations in a gene as mutations in 
intronic splicing signals are thereby missed. Furthermore, synonymous and non- 
synonymous mutations can have severe effects on the structure of the encoded 
protein when they inactivate an exonic splicing enhancer (ESE), which will result 
in exon skipping and thus a profound effect on protein level. Therefore, when 
predicting the effect of an exonic mutation, one should always assess the possible 
consequences on pre-mRNA processing, either by computational prediction 
or better yet by RT-PCR analysis. Lastly, we fail to identify the disease-causing 
mutation in more than half of patients with mitochondrial disorders partly as a 
result of the vast number of genes required for mitochondrial function. There is a 
large degree of genetic heterogeneity among patients, each mutation accounting 
for disease in often not more than a few families. Additionally, due to the lack of 
a clear genotype-phenotype correlation in most cases, which candidate genes to 
investigate in a patient is not always easily determined and generally many genes 
need to be analyzed before a genetic diagnosis can be made. Moreover, as our 
comprehension of the genes related to the function of mitochondria is far from 
complete, a substantial number of patients remain without a molecular diagnosis 
merely because we are not aware of the role in oxidative phosphorylation for the 
gene in which they harbor mutations. Before discussing the evidently needed 
expansion of our knowledge of the genes associated with mitochondrial function,
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the candidate genes for combined OXPHOS deficiencies that are presently known 
will be further considered.
As previously indicated, all genes necessary for mtDNA maintenance, 
mitochondrial transcription (including transcript processing) and mitochondrial 
translation are the most likely candidates for involvement in combined complex I,
III and IV deficits. These include all genes that were screened in the current study, 
except for OXA1L, as well as the many other genes related to these processes 
(see Chapter 2). The list of candidate genes continues to grow as the functions 
of more and more genes are being elucidated. The above-mentioned newly 
identified components of the mitochondrial translation machinery are good 
examples.37,36,38,39 Several other genes that were recently demonstrated to play a 
role in mitochondrial protein synthesis will be highlighted below (see also Table 
3). First of all, mitochondrial methyltransferase HEMK1 was shown to methylate 
a glutamine residue in the region of translation termination factor MTRF1L 
that interacts with the mitoribosomal peptidyl transferase center.51 It is thereby 
advantageous for mitochondrial translation, especially when cells are exposed 
to stress. Secondly, during mitochondrial translation initiation, N-terminal 
formylation occurs. Downstream processing of nascent mitochondrial translation 
products involves a peptide deformylase (PDF) that removes the formyl group 
and a methionine aminopeptidase (METAP1D) that subsequently excises the 
initial methionine residue.52 Inhibition of PDF caused disruption of mitochondrial 
protein synthesis, OXPHOS assembly and ATP production,53 and similar results are 
expected for METAP1D dysfunction. Third, 5S rRNA forms an essential part of the 
large (mito)ribosomal subunit in many organisms. Nuclear-encoded 5S rRNA was 
found to be present in human mitochondria,54 however, it has only been detected 
in cytoplasmic ribosomes and not in mitoribosomes. Part of the cytoplasmic 5S 
rRNA molecules are imported into human mitochondria and their mitochondrial 
levels are comparable with the predicted average number of mitoribosomes.55 
The precise location and function of 5S rRNA inside mitochondria remains unclear, 
but the significance for mitochondrial translation was demonstrated by silencing 
the gene coding for thiosulfate sulfurtransferase (rhodanese), which is required 
for import of 5S rRNA.56 A change in rhodanese expression caused proportional 
changes in 5S rRNA import as well as in mitochondrial translation rates.
Notwithstanding the fast pace at which the intricacies of mitochondrial 
biology and disease are being unraveled, many areas still remain obscure or even 
unexplored. There is a great need to unequivocally identify all requisite factors and 
to better understand the regulation and interrelations of all processes ultimately 
related to oxidative phosphorylation.
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Table 3. Recently identified candidate genes for combined complex I, III and IV deficiencies
Gene Protein (Predicted) function
ICT1 Peptidyl-tRNA hydrolase Mitoribosomal large subunit protein; hydrolysis
ICT1, mitochondrial of prematurely terminated peptidyl-tRNA species
56 f r0 21 C Probable peptide chain 
release factor C12orf65, 
mitochondrial
Recycling abortive peptidyl-tRNAs
ERAL1 GTP-binding protein Mitoribosomal small subunit protein; involvement
era homolog in transcription through association with nucleoid 
proteins
C4orf14 Mitochondrial nitric 
oxide synthase (NOA1)
Mitoribosome biogenesis; apoptosis
HEMK1 HemK methyltransferase Methylation of translation termination factor
family member 1 MTRF1L
PDF Peptide deformylase Removal of the formyl group from the initiating
(mitochondrial) methionine of nascent peptides
METAP1D Methionine aminopeptidase Removal of the initial methionine residue
type 1D (mitochondrial) of nascent peptides
TST Thiosulfate sulfurtransferase 
(rhodanese)
Import of 5S rRNA into mitochondria
F u t u r e  p e r s p e c t i v e s
This thesis demonstrates that locating the disease-causing mutation in patients 
with combined OXPHOS complex I, III and IV deficiencies remains a complicated 
and laborious undertaking in many cases. The current approach yielded up till now 
elucidation of the genetic defect in 8 out of 33 patients, including 4 novel mutations. 
It allows for focus on the most promising genes and for a rapid reaction to reports 
on newly identified candidate genes. However, there are several negative aspects, 
making it not the favored approach for future research. First of all, our patient cohort 
was rather heterogeneous: patients with deficiencies in either fibroblasts or muscle 
tissue or in both, with often not all enzyme activities being measured. Besides 
more stringent selection criteria for the OXPHOS enzyme activities, analysis of the 
mitochondrial translation rate -  which was performed in approximately half of the 
present cohort, either to direct mutational analysis or to indicate the pathogenicity 
of a mutation -  could be used as an additional selection step. Thereby, a better 
focus on deficiencies originating from mitochondrial translation defects could be 
achieved and thus the number of candidate genes could be limited. On the other 
hand, implementation of this extra criterion could turn out problematic because of 
the need for multiple controls per translation assay and/or repeated assays to be
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able to properly assign the ambiguous cases. In addition, it would surely lead to 
exclusion of patients that do harbor mutations in genes implicated in mitochondrial 
translation since, for instance, tRNA mutations do not always result in a clearly 
measurable translation defect.5758 Further drawbacks of the approach that was used 
for this thesis are the facts that it is quite time-consuming and that a relatively small 
number of cases gets resolved. This is due to the multitude of candidate genes for 
combined OXPHOS defects (with many yet to be identified), the paucity of common 
mutations in most of these genes, the poor genotype-phenotype relationships 
(complicating the selection of genes for mutational analysis), and the inability to 
detect copy number variations and intronic mutations (except for those bordering 
exons). Linkage analysis or homozygosity mapping could facilitate disease-gene 
discovery, as demonstrated in chapter 8, but usually homozygosity mapping is 
not an option because of the lack of consanguineous families in Northern Europe. 
And lastly, perhaps the major disadvantage is that uncharacterized genes that may 
function in OXPHOS will not be identified via this research strategy.
The elucidation of the complete human genome and the considerable 
progress in high-throughput DNA sequencing platforms open up new avenues 
for future research into the molecular genetic origins of mitochondrial diseases. 
Next-generation sequencing technologies permit more rapid and cost-effective 
sequencing of larger DNA volumes in comparison with the commonly used 
Sanger method59,60 and thus overcome many drawbacks of the research strategy 
used for this thesis. They have proven effective by detecting defects in genes not 
previously predicted to be involved in disease pathology.6162 Despite the major 
advances in this field in recent years, there still remains much to be accomplished. 
Most importantly, further cost reductions and improvements in bioinformatics 
tools63 that can cope with and interpret the huge quantities of sequence data are 
needed for high-throughput sequencing to become a feasible option for routine 
mutation detection. Targeted sequencing, e.g. of all protein-coding regions or 
exomes,64 markedly curtails costs and the amount of data generated compared 
with whole-genome sequencing. Eventually, these powerful sequencing 
technologies will enable complete genome sequencing as a standard approach 
to disease-gene discovery. The key hurdle will then be the interpretation of 
data: the great natural variation within the human population makes it difficult 
to establish which of the many mutations in an individual patient is causative. 
Large-scale DNA sequencing will thus shift the focus from prioritizing candidate 
genes for sequencing to prioritizing sequence variants for functional follow-up. 
In the coming couple of decades, the traditional strategies to uncover nuclear 
OXPHOS disease genes -  i.e. sequencing candidate genes sequentially by the 
Sanger method, if possible based on data from linkage analysis or homozygosity 
mapping -  are anticipated to become obsolete. The accumulating data obtained
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in the increasing number of high-throughput sequencing projects should permit 
better differentiation between benign and deleterious variations. Additionally, 
advances in the field of systems biology will be of great value. Systems biology 
has enabled the development of catalogs that integrate data from multiple 
sources to systematically characterize the complement of proteins that comprise 
the mitochondrial proteome.65 Currently, the most comprehensive mitochondrial 
proteome databases are MitoCarta and MitoMiner, with the latter containing a 
total of 3025 human proteins predicted to be located in the mitochondrion.4466 
These compendia, together with either next-generation sequencing platforms 
or the present-day mapping methods, provide powerful tools for novel disease 
gene identification. Furthermore, integration of information available on disease 
genes, clinical features and biological pathways could reveal new candidate genes 
for OXPHOS disorders and facilitate the discovery of new pathways underlying 
their pathogenesis,65 ultimately leading to a more thorough understanding of 
the enigmatic genetic, biochemical and clinical diversity of disorders due to 
mitochondrial dysfunction. Several other strategies that offer great potential to 
further our insights into the molecular mechanisms of mitochondrial disease 
are the following: 1) comparative mitochondrial proteomics, i.e. identification 
of differentially expressed mitochondrial proteins in patient material,67 2) using 
evolutionary data of multiple species to predict new disease genes and functional 
links between human mitochondrial proteins,68 3) computational expression 
screening, which uses a compilation of microarray data to find uncharacterized 
genes that could be involved in a certain pathway based on co-expression.69
The recent technological developments and our rapidly expanding knowledge 
of the genetic defects and pathogenic mechanisms underlying mitochondrial 
disorders will undoubtedly improve our diagnostic capabilities for these often 
devastating diseases. Whole mitochondrial genome screening can now easily 
and reliably be performed using a microarray-based analysis, the MitoChip.70 
However, microarray chips for the detection of nuclear gene mutations will not 
be very valuable because of the great and ever-expanding numbers of nuclear 
genes involved in OXPHOS deficiencies and mutations in these genes, demanding 
constant updating of the chips. Moreover, most mutations are present in just a 
small subset of patients. Instead, whole-exome sequencing will likely become the 
genetic diagnostic method of choice in the not too distant future. In addition to 
being successfully applied to OXPHOS disorders in research settings,71 whole- 
exome sequencing presently is a feasible option for diagnostics when merely the 
variations in genes known to be implicated in the particular OXPHOS deficiency 
are considered. As soon as bioinformatics tools are optimized and more sequence 
data are gathered to facilitate downstream filtering and interpretation of gene 
variants, also novel causative genes can be discovered by routine diagnostic whole-
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exome sequencing. Consequently, the percentage of patients that receive a genetic 
diagnosis will increase, which will aid prevention of mitochondrial disease through 
genetic counseling and prenatal diagnosis. This is of great importance as most 
cases of mitochondrial disease are currently untreatable, besides relieving certain 
symptoms, despite the impressive progress made in the field of mitochondrial 
biology and disease. Existing treatments (e.g. exercise training and coenzyme 
Q supplementation) and novel therapeutic strategies (e.g. gene therapy and 
pharmacological induction of mitochondrial biogenesis) are being explored for their 
applicability and effectiveness.7273 Although genetic-based therapies are far from 
being ready for clinical practice, some show promise.74 To illustrate, mitochondrial 
translation defects caused by mutations in tRNAs could be corrected by importing 
yeast or cytosolic tRNAs into mitochondria.757677 Nevertheless, many hurdles are 
to be overcome and shifting heteroplasmy towards wild-type mtDNA appears an 
option easier to attain for mtDNA mutations than gene therapy.7879 A promising 
approach to treating nuclear as well as mitochondrial gene defects, including 
those leading to combined OXPHOS deficiencies, is promotion of mitochondrial 
biogenesis through activation of the peroxisome proliferator-activated receptor 
(PPAR)/PPARy  coactivator-1a (PGC-1a) pathway.8081 This pathway regulates 
energy metabolism by controlling expression levels of numerous genes involved 
in mitochondrial respiration and biogenesis. Increasing expression of PGC-1a, e.g. 
via the PPAR agonist bezafibrate (a widely used hypolipidemic drug), improved 
respiratory function in both control cells and cells with OXPHOS deficiencies.
These are exciting times for patients, medical practitioners and scientists 
dealing with mitochondrial disorders now that our deeper understanding of 
these errors of metabolism is bringing us closer to the development of effective 
therapies. Future research will surely yield the much-needed further insights into 
the intricate and somewhat enigmatic processes fundamental to proper OXPHOS 
system function. This will hopefully shed more light on relations between 
mitochondrial disease genotype and phenotype, among others. Additional 
factors involved in the critical step of mitochondrial protein synthesis are bound 
to be uncovered. Moreover, the currently known nuclear gene defects underlying 
combined OXPHOS deficiencies are quite likely just the tip of the iceberg. 
This thesis is a contribution to the field devoted to unraveling the etiology of 
mitochondrial disorders -  combined OXPHOS complex I, III and IV deficiencies in 
particular -  and exemplifies the challenge this endeavor presents.
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S u m m a r y
Mitochondrial disorders are a heterogeneous group of often multisystemic and 
early fatal errors of metabolism, and are amongst the most common inherited 
human diseases. These disorders are generally caused by defects in the main 
energy-generating system, the oxidative phosphorylation (OXPHOS) system. It 
comprises five multisubunit enzyme complexes coded for by both the nuclear (n) 
and the mitochondrial (mt) genomes; only complex II is encoded entirely by the 
nDNA. Due to the multitude of proteins and intricacy of the processes required 
for a properly functioning OXPHOS system, identifying the genetic defect that 
underlies OXPHOS impairment is a daunting task, especially in the case of 
combined OXPHOS deficiencies. Whenever the activities of multiple enzymes are 
diminished, the molecular cause is presumed not to be located in genes encoding 
OXPHOS subunits but rather in genes implicated in processes such as mtDNA 
maintenance, mitochondrial transcription and mitochondrial translation. Chapter 
2 of this thesis gives an extensive overview of these processes, highlighting proteins 
involved in the biogenesis or maintenance of multiple OXPHOS complexes and 
implicated in mitochondrial disorders. To date, numerous mutations associated 
with combined OXPHOS deficits have been reported -  most in mtDNA, but 
the number of nDNA mutations is increasing rapidly -  yet many cases remain 
unresolved.
The main objective of the research presented in this thesis was to discover 
new nuclear gene defects that cause combined OXPHOS complex I, III and IV 
deficiencies, with the focus on deficiencies originating from mitochondrial 
translation impairments. This could consequently improve diagnostic possibilities, 
our understanding of underlying disease mechanisms, and hopefully curative 
therapy in the future. For this purpose, we assembled a cohort of 33 patients 
with decreased enzyme activities of complex I, III and IV -  and normal complex
II activities -  in fibroblasts and/or muscle tissue. Mutations in the mtDNA were 
excluded by sequencing the entire mitochondrial genome, when available in 
affected tissue. Subsequently, nuclear genes were screened for mutations: 1) genes 
known to be implicated in combined complex I, III and IV deficiencies, namely 
the genes coding for polymerase gamma (POLG and POLG2), mitochondrial 
translation factors mtEFTs, mtEFTu and mtEFG1, and mitochondrial ribosomal 
proteins (MRPs) MRPS16 and MRPS22; 2) candidate genes for combined OXPHOS 
deficits, namely the genes encoding the 6 remaining mitochondrial translation 
factors, 7 more MRPs, 2 potential mtDNA maintenance proteins, mitochondrial 
inner membrane transport protein OXA1L, and 7 mitochondrial transcription 
factors. Additionally, the rate of mitochondrial protein synthesis was determined
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in 18 patients. The results were used either to direct mutational analysis or to 
indicate the pathogenicity of a mutation. Furthermore, homozygosity mapping 
was performed for 7 patients. This aided in the detection of the genetic defect in 
one patient (see chapter 8), but it was uninformative in the other cases.
MtDNA sequencing in our patient cohort revealed pathogenic tRNA mutations 
in four patients, including novel mutations in tRNAArg (m.10450A>G) and tRNATrp 
(m.5556G>A). Chapter 3 demonstrates that these latter two mutations affect 
the conformation and steady-state levels of the tRNAs, causing mitochondrial 
translation impairment and consequently combined OXPHOS deficiencies. 
The fact that the tRNATrp mutation was previously listed as a polymorphism 
underscores the importance of functional studies in defining the pathogenicity 
of tRNA mutations. Furthermore, the findings emphasize the rapid progress that 
is still being made in the identification of mitochondrial tRNA mutations and that 
such mutations are important contributors to mitochondrial disease.
Mutation analysis of a total of 30 nuclear genes yielded deleterious mutations 
(including two new mutations) in four genes previously reported to be implicated 
in combined OXPHOS deficits -  POLG, TSFM, GFM1 and MRPS22-  as well as several 
sequence variants with presently slightly ambiguous functional significance.
With over 150 pathogenic mutations, POLG is a major locus for a wide range 
of mitochondrial disorders. The most common POLG mutation, Ala467Thr, was 
found compound heterozygous with Gly848Ser in one of our patients.
Up to date, three out of nine mitochondrial translation factors -  all involved in 
the elongation phase -  have been associated with human mitochondrial disease. 
The previously described Arg333Trp mutation in elongation factor mtEFTs (TSFM) 
was detected in one patient (see chapter 4 for the first report and see the 
discussion section of chapter 5 for a note on the finding in the current patient 
cohort). The combined OXPHOS system and mitochondrial translation defects 
could be rescued by over-expression of either mtEFTs or mtEFTu. In control cells, 
on the contrary, over-expressing either elongation factor resulted in a dominant 
negative effect. This can be explained by the observation that the relative ratios 
of all three translation elongation factors, which are finely tuned and differ 
between tissues, are critical determinants of translation efficiency. Furthermore, 
we discovered a novel mutation in elongation factor mtEFG1 (GFM1), Arg250Trp, 
and demonstrated its role in the malfunctioning of the OXPHOS system and 
mitochondrial protein synthesis in one patient (chapter 5). In stark contrast to 
previously reported GFM1 cases, decreased enzyme activities were detected only 
in fibroblasts and not in muscle tissue of this patient, stressing that comprehensive 
biochemical investigation is critical in the diagnosis of mitochondrial disease. 
These and other reports on mutations in mitochondrial translation factors
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emphasize the heterogeneity and complexity of mitochondrial disorders: a) 
an identical mutation, e.g. Arg333Trp in TSFM, can result in strikingly different 
clinical presentations in individual patients; b) tissues are selectively affected 
despite ubiquitous expression of the translation factors; c) in which tissues the 
biochemical defect manifests itself can differ between patients with distinct 
mutations in the same gene, e.g. GFM1. Currently, one can primarily speculate on 
the causes for the biochemical and clinical variability associated with mutations 
in mitochondrial translation factors. Even though the core mitochondrial protein 
synthesis machinery has been characterized, much remains to be unraveled 
concerning details of the mechanisms of mitochondrial translation, the exact 
function of some of the proteins involved, and especially regulation of the entire 
system. Moreover, additional proteins involved in mitochondrial translation, such 
as MRPs, are still being uncovered.
Of the more than 80 MRPs presently known, mutations have been found in 
merely two of them: MRPS16 and MRPS22. In principle, all MRPs are candidate genes 
for mitochondrial disorders. To facilitate the selection of which MRPs to screen for 
mutations first, we performed extensive homology searches to reconstruct the 
evolutionary history of the mitochondrial ribosomal proteome across different 
eukaryotic lineages (chapter 6). What is more, two new human MRPs were 
detected in this comparative genomics analysis: CHCHD1 and METT11D1. These 
two MRPs, together with two other candidate genes that were selected based 
on their potential function in mtDNA maintenance (NIPSNAP1 and GBAS), were 
screened for mutations in our group of patients with OXPHOS complex I, III 
and IV deficiencies. Chapter 7 contains the results of this study, i.e. many non- 
pathogenic sequence variations. Sequence analysis of 7 additional MRP genes 
(MRPS12, MRPS14, MRPS16, MRPS22, MRPL11, MRPL12 and MRPL45) revealed 
a new mutation in MRPS22. Its pathogenic role in the patient's mitochondrial 
disorder is reported in chapter 8. Evidently, MRPS22 is indispensable for 
effective mitochondrial protein synthesis, even though it is evolutionary not well 
conserved. Thus, supernumerary proteins such as MRPS22, lacking homologs in 
bacteria and other lower species, should not be disregarded during investigations 
of mitochondrial disorders.
Finally, chapter 9 reflects on all results obtained and discusses directions for future 
research with respect to combined OXPHOS complex I, III and IV deficiencies. 
This thesis demonstrates that locating the disease-causing mutation in patients 
with combined complex I, III and IV deficits remains a complicated and laborious 
undertaking in many cases, despite the substantial progress in this area. The 
current approach yielded up till now elucidation of the genetic defect in 8 out 
of 33 patients, including 4 novel mutations. MtDNA mutations accounted for
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mitochondrial disease in 12% of patients, whereas the residual 88% consequently 
harbor nDNA mutations. Future research using high-throughput DNA sequencing 
platforms will undoubtedly provide the much-needed further insights into the 
intricate and somewhat enigmatic processes fundamental to proper OXPHOS 
system function. Moreover, many more disease genes are expected and required 
to be found to explain the numerous as yet unsolved cases. The currently known 
nuclear gene defects underlying combined OXPHOS deficiencies are quite likely 
just the tip of the iceberg.
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S a m e n v a t t i n g
Mitochondriële aandoeningen zijn een heterogene groep van veelal multisysteem 
en vroeg fatale energiestofwisselingsziekten, en zijn een van de meest frequente 
erfelijke humane ziekten. Deze aandoeningen worden doorgaans veroorzaakt 
door defecten in het belangrijkste energiegenererende systeem, het oxidatieve 
fosforyleringssysteem (OXFOS systeem). Dit systeem bestaat uit vijf multisubunit 
enzymcomplexen die gecodeerd worden door zowel het nucleaire (n) als het 
mitochondriële (mt) genoom; alleen complex II wordt volledig gecodeerd door het 
nDNA. Het enorme aantal eiwitten en de gecompliceerdheid van de processen die 
benodigd zijn voor het goed functioneren van het OXFOS systeem bemoeilijken 
de opsporing van het genetische defect dat ten grondslag ligt aan een verstoring 
van het OXFOS systeem, in het bijzonder in het geval van gecombineerde OXFOS 
deficiënties. Wanneer de activiteiten van meerdere enzymen verlaagd zijn, wordt 
verondersteld dat de moleculaire oorzaak niet gelegen is in genen die coderen 
voor OXFOS subunits maar juist in genen die betrokken zijn bij processen als 
mtDNA onderhoud, mitochondriële transcriptie en mitochondriële translatie. 
Hoofdstuk 2 van dit proefschrift geeft een uitgebreid overzicht van deze 
processen, waarbij de nadruk gelegd wordt op eiwitten die vereist zijn voor de 
biogenese of het in stand houden van meerdere OXFOS complexen en welke 
geassocieerd worden met mitochondriële ziekten. Tot op heden zijn er talrijke 
mutaties in verband gebracht met gecombineerde OXFOS deficiënties -  de 
meeste in het mtDNA, maar het aantal nDNA mutaties neemt snel toe -  doch 
vele gevallen blijven onopgelost.
De voornaamste doelstelling van het onderzoek dat beschreven wordt in 
dit proefschrift was het identificeren van nieuwe nucleaire gendefecten die 
gecombineerde OXFOS complex I, III en IV deficiënties veroorzaken, met 
daarbij de focus leggend op deficiënties die voortkomen uit een stoornis in de 
mitochondriële translatie. Dit zou de diagnostische mogelijkheden, ons begrip 
van de onderliggende ziektemechanismen, en hopelijk toekomstige curatieve 
behandelingsstrategieën kunnen bevorderen. Met dit doel voor ogen hebben 
we een cohort van 33 patiënten samengesteld met verlaagde enzymactiviteiten 
van complex I, III en IV -  en normale complex II activiteiten -  in fibroblasten 
en/of spierweefsel. Mutaties in het mtDNA zijn uitgesloten door het volledige 
mitochondriële genoom te sequencen, wanneer beschikbaar in aangedaan 
weefsel. Vervolgens zijn nucleaire genen gescreend op mutaties: 1) genen die 
bekend zijn betrokken te zijn bij gecombineerde complex I, III en IV tekorten, 
namelijk de genen die coderen voor polymerase gamma (POLG en POLG2), 
mitochondriële translatiefactoren mtEFTs, mtEFTu en mtEFG1, en mitochondriële
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ribosomale eiwitten (MRP's) MRPS16 en MRPS22; 2) kandidaatgenen voor 
gecombineerde OXFOS deficiënties, namelijk de genen die coderen voor de
6 resterende mitochondriële translatiefactoren, 7 andere MRP's, 2 potentiële 
mtDNA nucleoid eiwitten, mitochondrieel binnenmembraan transporteiwit 
OXA1L, en 7 mitochondriële transcriptiefactoren. Bovendien is de snelheid van 
de eiwitsynthese in de mitochondriën bepaald bij 18 patiënten. De resultaten 
werden gebruikt of om richting te geven aan de screening van nucleaire genen of 
om de pathogeniteit van een mutatie aan te tonen. Voorts is er voor 7 patiënten 
homozygosity mapping uitgevoerd. Dit droeg bij tot de vondst van het genetische 
defect in één patiënt (zie hoofdstuk 8), maar in de overige gevallen waren de 
resultaten niet van nut.
Het sequencen van mtDNA in ons patiëntencohort bracht bij vier patiënten 
pathogene tRNA mutaties aan het licht, waaronder nieuwe mutaties in tRNAArg 
(m.10450A>G) en tRNATrp (m.5556G>A). Hoofdstuk 3 bewijst dat deze twee 
mutaties de conformatie en steady-state niveaus van de tRNA's negatief 
beïnvloeden, hetgeen gebreken in de mitochondriële translatie en daardoor 
gecombineerde OXFOS deficiënties tot gevolg heeft. Het feit dat de tRNATrp 
mutatie tevoren als polymorfisme vermeld stond benadrukt dat functionele 
studies belangrijk zijn bij het karakteriseren van de pathogeniteit van tRNA 
mutaties. De bevindingen onderstrepen de snelle vooruitgang die nog steeds 
geboekt wordt in de opsporing van mitochondriële tRNA mutaties en dat zulke 
mutaties een aanzienlijke bijdrage leveren aan mitochondriële aandoeningen.
Middels mutatieanalyse vanin totaal 30nucleairegenenzijnziekteverwekkende 
mutaties (inclusief twee nieuwe mutaties) gedetecteerd in vier genen die eerder 
in verband gebracht waren met gecombineerde OXFOS tekorten -  POLG, TSFM, 
GFM1 en MRPS22 -  evenals verscheidene sequentievarianten waarvan de 
functionele betekenis momenteel enigszins onduidelijk is.
Met meer dan 150 pathogene mutaties is POLG een locus die van groot belang 
is voor een breed scala aan mitochondriële ziekten. De meest voorkomende POLG 
mutatie, Ala467Thr, werd compound heterozygoot met Gly848Ser aangetroffen in 
één van onze patiënten.
Tot dusver zijn drie van de negen mitochondriële translatiefactoren -  alle drie 
betrokken bij de elongatiefase -  in verband gebracht met humane mitochondriële 
syndromen. De reeds beschreven Arg333Trp mutatie in elongatiefactor mtEFTs 
(TSFM) werd gedetecteerd in één patiënt (zie hoofdstuk 4 voor de eerste 
publicatie en zie de discussie sectie van hoofdstuk 5 voor een aantekening 
over de bevinding in het huidige patiëntencohort). De gecombineerde OXFOS 
systeem en mitochondriële eiwitsynthese defecten konden hersteld worden door 
overexpressie van ofwel mtEFTs ofwel mtEFTu. In controle cellen daarentegen
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resulteerde overexpressie van ieder van beide elongatiefactoren in een dominant 
negatief effect. Dit kan verklaard worden met de observatie dat de relatieve ratio's 
van alle drie de translatie elongatiefactoren, welke nauwkeurig afgestemd zijn en 
variëren tussen weefsels, kritische determinanten zijn van de translatie efficiëntie. 
Tevens hebben we een nieuwe mutatie, Arg250Trp, in elongatiefactor mtEFG1 
(GFM1) ontdekt in één patiënt en de rol in de disfunctie van het OXFOS systeem 
en de mitochondriële translatie aangetoond (hoofdstuk 5). In schril contrast met 
eerder gerapporteerde GFM1 gevallen werden verlaagde enzymwaarden alleen 
waargenomen in fibroblasten en niet in spierweefsel van deze patiënt, hetgeen 
benadrukt dat uitvoerig biochemisch onderzoek cruciaal is bij het stellen van de 
diagnose voor mitochondriële ziekten. Deze en andere publicaties over mutaties 
in mitochondriële translatiefactoren maken wederom duidelijk hoe heterogeen 
en complex mitochondriële aandoeningen zijn: a) een identieke mutatie, bv. 
Arg333Trp in TSFM, kan zeer uiteenlopende klinische fenotypes teweeg brengen in 
afzonderlijke patiënten; b) weefsels zijn selectief aangedaan ondanks de ubiquitaire 
expressie van de translatiefactoren; c) in welke weefsels het biochemische defect 
tot uiting komt kan verschillen tussen patiënten met diverse mutaties in hetzelfde 
gen, bv. GFM1. Momenteel kan men voor het merendeel slechts speculeren 
over de oorzaken van de biochemische en klinische variabiliteit ten gevolge van 
mutaties in mitochondriële translatiefactoren. Alhoewel de basiscomponenten 
van de mitochondriële eiwitsynthese machinerie gekarakteriseerd zijn, moet 
er nog veel opgehelderd worden omtrent de details van de mitochondriële 
translatie mechanismen, de exacte functie van bepaalde betrokken eiwitten en 
in het bijzonder de regulering van het hele systeem. Daarnaast worden er nog 
altijd additionele eiwitten die benodigd zijn voor mitochondriële translatie, zoals 
MRP's, geïdentificeerd.
Van de meer dan 80 thans bekende MRP's zijn er slechts in twee mutaties 
gevonden: MRPS16 en MRPS22. In principe zijn alle MRP's kandidaatgenen 
voor mitochondriële ziekten. Om de selectie van MRP's voor mutatieanalyse 
te vergemakkelijken, hebben we omvangrijke homologie zoekopdrachten 
uitgevoerd om de evolutionaire geschiedenis van het mitochondriële ribosomale 
proteoom over verscheidene eukaryote geslachten te reconstrueren (hoofdstuk 
6). Bovendien werden twee nieuwe humane MRP's aan het licht gebracht in deze 
vergelijkende genomics analyse: CHCHD1 en METT11D1. Deze twee MRP's zijn 
samen met twee andere kandidaatgenen (NIPSNAP1 en GBAS), welke werden 
geselecteerd op basis van hun vermeende functie in mtDNA onderhoud, 
gescreend op mutaties in onze groep van patiënten met OXFOS complex I, III en
IV deficiënties. Hoofdstuk 7 bevat de resultaten van deze studie, d.w.z. veel niet­
pathogene sequentievariaties. Sequentieanalyse van 7 additionele MRP genen 
(MRPS12, MRPS14, MRPS16, MRPS22, MRPL11, MRPL12 en MRPL45) onthulde een
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nieuwe mutatie in MRPS22. De pathogene rol van de mutatie in de mitochondriële 
aandoening van de patiënt wordt beschreven in hoofdstuk 8. MRPS22 is 
klaarblijkelijk onmisbaar voor effectieve mitochondriële eiwitsynthese, ook al is 
het eiwit evolutionair niet goed geconserveerd. Dus boventallige eiwitten zoals 
MRPS22, waarvoor homologen in bacteriën en andere lagere soorten ontbreken, 
zouden niet buiten beschouwing gelaten moeten worden tijdens onderzoek naar 
mitochondriële ziekten.
Tot slot reflecteert hoofdstuk 9 op de verkregen resultaten en bespreekt de 
richting van toekomstig onderzoek naar gecombineerde OXFOS complex 
I, III en IV deficiënties. Dit proefschrift toont aan dat het lokaliseren van de 
ziekteveroorzakende mutatie bij patiënten met gecombineerde complex I,
III en IV tekorten in veel gevallen nog immer een ingewikkelde en moeizame 
onderneming is, ondanks de aanzienlijke vooruitgang op dit gebied. De huidige 
aanpak zorgde tot nu toe voor opheldering van het genetische defect bij 8 van de 
33 patiënten, inclusief 4 nieuwe mutaties. MtDNA mutaties waren verantwoordelijk 
voor mitochondriële ziekte in 12% van de patiënten, terwijl de resterende 88% 
dientengevolge nDNA mutaties herbergen. Toekomstig onderzoek middels high- 
throughput DNA sequencing platforms zal ons ongetwijfeld de broodnodige 
verdere inzichten bieden in de complexe en enigszins raadselachtige processen 
die ten grondslag liggen aan het adequaat functioneren van het OXFOS systeem. 
Tevens verwacht en dient men beduidend meer ziektegenen te vinden om de 
talrijke nog onopgeloste zaken te kunnen verklaren. De nucleaire gendefecten 
die vooralsnog gerelateerd zijn aan gecombineerde OXFOS deficiënties zijn zeer 
waarschijnlijk slechts het topje van de ijsberg.
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S a m e n v a t t i n g  v o o r  l e k e n
Achtergrondinform atie
Energie en mitochondriën
Zonder energie is er geen leven mogelijk. Voor al onze acties, van rennen tot 
slapen, voor de opbouw en het onderhoud van het lichaam en voor de normale 
werking van weefsels en organen is energie nodig. Deze energie verkrijgen we 
uit onze voeding door middel van vele stofwisselingsreacties, waarin enzymen de 
voedingsstoffen verwerken en omzetten in energie. De energie wordt opgeslagen 
in de vorm van het molecuul ATP. Verreweg de meeste ATP wordt geproduceerd 
in de mitochondriën, ook wel de 'energiecentrales' van de cel genoemd. Dit 
zijn organellen ('celorganen') die voorkomen in vrijwel elke cel van ons lichaam. 
Het aantal mitochondriën is afhankelijk van de energiebehoefte van de cel en 
loopt uiteen van enkele tot meer dan duizend per cel. Mitochondriën bestaan 
uit een binnen- en een buitenmembraan, met binnenin de zogenaamde matrix. 
In de binnenmembraan, welke sterk geplooid is, bevindt zich het oxidatieve 
fosforyleringssysteem (OXFOS systeem). Oxidatieve fosforylering vormt de laatste 
schakel in het stofwisselingsproces en levert de hoogste opbrengst aan ATP
Mitochondriële ziekten
Wanneer de energieproductie verstoord is, kan dit leiden tot energiestofwisselings- 
ziekten ofwel mitochondriële ziekten. De meeste patiënten met een mitochondriële 
ziekte hebben een defect in een of meerdere enzymcomplexen van het OXFOS 
systeem. Een van de gevolgen is een tekort aan energie, waardoor voornamelijk 
weefsels en organen met een hoge energiebehoefte, zoals hart, hersenen en 
spieren, niet optimaal kunnen functioneren. Maar aangezien mitochondriën 
in nagenoeg alle cellen aanwezig zijn, kan een stoornis hierin elk deel van het 
lichaam aantasten. De leeftijd waarop een mitochondriële aandoening zich 
openbaart, de symptomen die hierbij optreden en het verloop van de ziekte 
variëren sterk tussen patiënten, ook tussen patiënten met eenzelfde defect. Deze 
vaak ernstige en eveneens frequente aandoeningen (met ongeveer één nieuw 
geval per week in Nederland) zijn over het algemeen helaas nog niet te genezen. 
Symptoombestrijding en het voorkomen van nieuwe gevallen, door prenatale 
diagnose en erfelijkheidsadvisering, zijn daarom van groot belang.
Vorming van het OXFOS systeem
De oorzaak van mitochondriële ziekten ligt in het erfelijke materiaal van het 
lichaam, het DNA. Bij de vorming en werking van mitochondriën zijn een paar 
duizend genen betrokken. Het merendeel van deze genen ligt op het nucleaire 
genoom (het DNA in de celkern, het nDNA), maar de mitochondriën zelf bezitten
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ook DNA. Dit mitochondriële DNA (mtDNA) bevat slechts 37 genen, welke 
coderen (de genetische informatie bevatten) voor 2 rRNA's, 22 tRNA's en 13 
mRNA's (zie Figuur 1). Het DNA van een gen wordt omgezet in ribosomaal (r), 
transfer (t) of messenger (m) RNA, afhankelijk van het type gen; dit proces heet 
transcriptie. Vervolgens wordt het mRNA molecuul vertaald naar een eiwit, ook 
wel eiwitsynthese of translatie genoemd. Voor dit proces zijn onder meer rRNA en 
tRNA moleculen benodigd. Het OXFOS systeem bestaat uit vijf enzymcomplexen: 
complex I tot en met IV van de ademhalings- of electronentransportketen en 
complex V (ATP synthase). Ieder van deze complexen bestaat uit meerdere 
eiwitten die samen als enzym functioneren. In de mitochondriën worden met 
behulp van het mtDNA en de mitochondriële transcriptie- en translatiesystemen 
13 eiwitten gemaakt voor de bouw van de complexen I, III, IV en V. De genetische 
informatie voor de overige 76 eiwitten van de complexen I-V van het OXFOS 
systeem en alle andere eiwitten die aanwezig zijn in mitochondriën ligt op het 
nDNA; deze eiwitten worden in het cytosol (celvloeistof) gemaakt en daarna naar 
het mitochondrion getransporteerd.
Figuur 1. Vorming van het OXFOS systeem (een bewerking van Florentz et al. 2003 Cell Mol Life Sci). 
Het mitochondriële genoom codeert voor 2 rRNA's, 22 tRNA's en 13 mRNA's (in groen). Het nucleaire 
genoom codeert voor alle overige eiwitten die in het mitochondrion voorkomen, waaronder eiwitten 
van het OXFOS systeem en eiwitten die betrokken zijn bij de mitochondriële transcriptie en translatie 
(in paars).
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Oorzaken van OXFOS deficiënties
Een afwijking in de genetische informatie, in de celkern of het mitochondrion, 
kan ervoor zorgen dat het OXFOS systeem niet goed werkt met uiteindelijk 
een mitochondriële aandoening tot gevolg. Wanneer slechts één van de 
enzymcomplexen van het OXFOS systeem een verlaagde activiteit vertoont, 
zogenoemde geïsoleerde deficiënties of tekorten, is er meestal iets mis met 
een bouwsteen of met een eiwit dat alle onderdelen samenvoegt tot één 
geheel. Wanneer meerdere OXFOS complexen zijn aangetast, zogenoemde 
gecombineerde deficiënties, is de situatie gecompliceerder. Talrijke processen zijn 
noodzakelijk voor de vorming van de vijf complexen van het OXFOS systeem, 
zoals de aanmaak van de afzonderlijke bouwstenen, het transport van deze 
eiwitcomponenten naar het mitochondrion, de plaatsing in het binnenmembraan 
en de assemblage tot enzymcomplexen. Hierbij zijn honderden eiwitten en 
andere stoffen betrokken en een fout in de genetische code voor ieder van deze 
elementen kan resulteren in een gecombineerde OXFOS deficiëntie. Hoofdstuk 2 
van dit proefschrift geeft een uitgebreid overzicht van al deze processen. Hierbij 
is de nadruk gelegd op eiwitten die vereist zijn voor de vorming of het in stand 
houden van meerdere OXFOS complexen en welke geassocieerd worden met 
mitochondriële ziekten. Tot op heden zijn tal van mutaties (foutjes in het DNA) 
in verband gebracht met gecombineerde OXFOS tekorten. De meeste van deze 
afwijkingen zijn gevonden in het mtDNA, maar het aantal nDNA mutaties neemt 
snel toe. Toch kan bij veel patiënten de genetische oorzaak van hun ziekte nog 
niet worden ontdekt.
Mijn prom otieonderzoek
Doelstelling en aanpak
De voornaamste doelstelling van het onderzoek dat beschreven wordt in 
dit proefschrift was het opsporen van nieuwe nucleaire gendefecten die 
gecombineerde OXFOS deficiënties veroorzaken, om zo ons begrip van de 
onderliggende ziektemechanismen, de diagnostische mogelijkheden en hopelijk 
toekomstige curatieve behandelingsstrategieën te kunnen bevorderen. De focus 
van het onderzoek is gelegd op gecombineerde tekorten van de complexen I, III en 
IV, welke kunnen voortkomen uit een stoornis in de mitochondriële eiwitsynthese. 
Wanneer de enzymcomplexen I, III en IV niet optimaal functioneren, maar 
complex II wel een normale activiteit heeft, kan er verondersteld worden dat er 
een afwijking is in één van de processen betrokken bij de vorming van eiwitten in 
het mitochondrion. Complex II bestaat namelijk volledig uit eiwitten die door het 
nDNA gecodeerd worden, terwijl de overige vier complexen voor hun bouwstenen 
afhankelijk zijn van het nDNA én het mtDNA. Een normale activiteit van complex II 
duidt er dus op dat de aanmaak van eiwitten in het cytosol en het transport naar het
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mitochondrion correct verlopen. In het geval van gecombineerde complex I, III en
IV deficiënties moet daarom het mankement gezocht worden in processen als het 
onderhoud van het mitochondriële genoom, de mitochondriële transcriptie (van 
DNA naar RNA) en de mitochondriële translatie (van RNA naar eiwit). Complex
V wordt hier overigens buiten beschouwing gelaten, aangezien dit enzym in 
weinig patiënten wordt gemeten. Met bovenstaande doel voor ogen hebben we 
een groep van 33 patiënten samengesteld met verlaagde enzymactiviteiten van 
OXFOS complexen I, III en IV -  en normale complex II activiteiten -  in huidcellen 
en/of spierweefsel. Mutaties in het mtDNA zijn uitgesloten door het complete 
mitochondriële genoom te sequencen bij deze patiënten. Sequencen is een 
methode voor het bepalen van de DNA sequentie, de volgorde van nucleotiden 
ofwel bouwstenen van het DNA. Vervolgens zijn een totaal van 30 nucleaire 
genen gescreend op mutaties. Hieronder waren zowel genen waarin afwijkingen 
gevonden waren bij andere patiënten met gecombineerde OXFOS deficiënties als 
genen waarbij dit niet het geval was, maar waarvan men op basis van hun functie 
een rol in gecombineerde OXFOS tekorten verwacht. Bovendien is de snelheid 
van eiwitsynthese in de mitochondriën bepaald bij 18 patiënten. De resultaten 
werden gebruikt om richting te geven aan de screening van nucleaire genen of 
om vast te stellen of een bepaald gendefect effect had op de mitochondriële 
eiwitsynthese. Voorts is er voor 7 patiënten homozygosity mapping uitgevoerd. 
Deze methode berust op het feit dat patiënten van ouders met een hoge graad 
van bloedverwantschap vaak dezelfde mutatie op beide chromosomen hebben, 
welke de ouders van een gezamenlijke voorouder hebben geërfd. De stukken 
DNA rondom de mutatie zijn dan ook identiek en kunnen we zichtbaar maken 
met deze techniek. Homozygosity mapping droeg bij tot de vondst van het 
genetische defect in één patiënt (zie hoofdstuk 8), maar in de overige gevallen 
waren de resultaten niet van nut.
Resultaten
Mitochondrieel DNA
S Het sequencen van het mtDNA in onze patiëntengroep bracht bij vier patiënten ziekteveroorzakende veranderingen in tRNA genen aan het licht, waaronder nieuwe 
mutaties in tRNAArg en tRNATrp. Deze tRNA's dragen respectievelijk de aminozuren 
arginine (Arg) en tryptofaan (Trp) bij zich, die ze tijdens het translatieproces 
afleveren om toegevoegd te worden aan de groeiende aminozuurketen (die 
zich later vouwt tot een eiwit). Hoofdstuk 3 bewijst dat de mutaties in deze 
twee tRNA genen de structuur van en gehalte aan de tRNA moleculen negatief 
beïnvloeden, hetgeen gebreken in de mitochondriële eiwitsynthese en daardoor 
gecombineerde OXFOS deficiënties tot gevolg heeft. Het feit dat de tRNATrp 
mutatie tevoren als polymorfisme vermeld stond -  een polymorfisme is een vaker
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voorkomende genafwijking die niet tot ziekte leidt -  benadrukt dat functionele 
studies belangrijk zijn bij het karakteriseren van de gevolgen van tRNA mutaties 
voor de cel en de patiënt. De bevindingen onderstrepen de snelle vooruitgang 
die nog steeds geboekt wordt in de opsporing van mitochondriële tRNA mutaties 
en dat zulke mutaties een aanzienlijke bijdrage leveren aan mitochondriële 
aandoeningen.
Nucleair DNA
Middels mutatieanalyse van in totaal 30 nucleaire genen zijn ziekteverwekkende 
mutaties (inclusief twee nieuwe mutaties) gedetecteerd in vier genen die eerder 
in verband gebracht waren met gecombineerde OXFOS tekorten -  POLG, mtEFTs, 
mtEFG1 en MRPS22 -  evenals verscheidene veranderingen in de DNA sequentie 
waarvan de functionele betekenis momenteel enigszins onduidelijk is. Hieronder 
zullen de mutaties in deze vier genen en andere belangrijke bevindingen 
besproken worden.
Met meer dan 150 ziekteveroorzakende mutaties is POLG een gen dat van 
groot belang is voor een breed scala aan mitochondriële ziekten. De twee genen 
POLG en POLG2 coderen samen voor het enzym polymerase gamma, wat zorgt 
voor de replicatie (verdubbeling) en het in stand houden van het mitochondriële 
genoom. De meest voorkomende POLG mutatie werd samen met een andere 
mutatie aangetroffen in één van onze patiënten.
Tot dusver zijn drie van de negen mitochondriële translatiefactoren (eiwitten 
die een belangrijke rol spelen in de eiwitsynthese in mitochondriën) gerelateerd 
aan mitochondriële aandoeningen. Er zijn drie soorten translatiefactoren die elk 
bij een bepaalde fase van de translatie betrokken zijn: initiatie-, elongatie- en 
terminatiefactoren. Een reeds gepubliceerde mutatie in elongatiefactor mtEFTs 
werd gedetecteerd in één patiënt (zie hoofdstuk 4 voor de eerste publicatie 
en zie de discussie sectie van hoofdstuk 5 voor een aantekening over de 
bevinding in de huidige patiëntengroep). Om te bewijzen dat deze mutatie leidt 
tot een mitochondrieel translatiedefect en een gecombineerde OXFOS systeem 
deficiëntie bij de patiënt, hebben we viruscellen die elongatiefactor mtEFTs 
produceren in gekweekte patiëntcellen gebracht. Op deze manier konden de 
stoornissen grotendeels hersteld worden. In controle cellen daarentegen had 
deze zogenaamde overexpressie van elongatiefactor mtEFTs een negatief effect 
op de mitochondriële eiwitsynthese. Dit komt doordat de relatieve ratio's van 
alle drie de bestaande elongatiefactoren, welke variëren tussen weefsels, van 
groot belang zijn voor de efficiëntie van de eiwitsynthese. Tevens hebben we een 
nieuwe mutatie in elongatiefactor mtEFG1 ontdekt in één patiënt en de rol in de 
disfunctie van het OXFOS systeem en de mitochondriële translatie aangetoond 
(hoofdstuk 5). In schril contrast met eerder gerapporteerde gevallen met een
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afwijking in mtEFG1, werden verlaagde enzymwaarden alleen waargenomen in 
huidcellen en niet in spierweefsel van deze patiënt. Dit benadrukt dat uitvoerig 
biochemisch onderzoek, bij voorkeur in meer dan één weefseltype, naar het 
functioneren van het OXFOS systeem cruciaal is bij het stellen van de diagnose 
voor mitochondriële ziekten. Deze en andere publicaties over mutaties in 
mitochondriële translatiefactoren maken wederom duidelijk hoe gevarieerd en 
complex mitochondriële aandoeningen zijn. Zo zijn er de volgende situaties te 
noemen: a) een identieke mutatie, bv. die in mtEFTs, kan zeer uiteenlopende 
klinische verschijningsvormen teweeg brengen in afzonderlijke patiënten; b) 
weefsels zijn selectief aangedaan ondanks dat de translatiefactoren in alle 
cellen aangemaakt worden; c) in welke weefsels de deficiëntie van het OXFOS 
systeem tot uiting komt kan verschillen tussen patiënten met diverse mutaties 
in hetzelfde gen, bv. mtEFG1. Momenteel kan men voor het merendeel slechts 
speculeren over de oorzaken van de biochemische en klinische variabiliteit 
ten gevolge van mutaties in mitochondriële translatiefactoren. Hoewel de 
basiscomponenten van de mitochondriële eiwitsynthese machinerie bekend zijn, 
moet er nog veel opgehelderd worden omtrent de details van de mitochondriële 
translatie mechanismen, de exacte functie van bepaalde betrokken eiwitten 
en in het bijzonder de regulering van het hele systeem. Daarnaast worden er 
nog altijd additionele eiwitten die benodigd zijn voor mitochondriële translatie 
geïdentificeerd.
Tot op heden zijn er meer dan 80 mitochondriële ribosomale eiwitten 
(MRP's) bekend. Deze eiwitten vormen samen met de twee mitochondriële rRNA 
moleculen het mitochondriële ribosoom, een groot complex dat essentieel is 
voor de eiwitsynthese. Vooralsnog zijn in slechts twee MRP's mutaties gevonden: 
MRPS16 en MRPS22. In principe zou elk van de MRP's aan de basis kunnen liggen 
van een mitochondriële ziekte. Om de selectie van MRP's voor mutatieanalyse te 
vergemakkelijken, hebben we de evolutionaire geschiedenis van de mitochondriële 
ribosomale eiwitten gereconstrueerd (hoofdstuk 6). Er is bepaald welke MRP's in 
welke organismen, van eencelligen tot de mens, aanwezig zijn. Vervolgens kon een 
prioritering aangebracht worden voor het screenen van de MRP's op mutaties aan 
de hand van hun evolutionaire conservering en andere beschikbare informatie. 
Evolutionaire conservering betekent dat een gen behouden is gebleven in de loop 
van de evolutionaire ontwikkeling. Genen die evolutionair goed geconserveerd 
zijn, en dus voorkomen in veel verschillende organismen, zijn vaak van bijzonder 
belang en afwijkingen in zulke genen worden daarom verwacht tot ziekte te leiden. 
Dit onderzoek bracht bovendien twee nieuwe humane MRP's aan het licht. Deze 
twee MRP's zijn samen met twee andere genen, welke werden geselecteerd op 
basis van hun vermeende functie in mtDNA onderhoud, gescreend op mutaties in 
onze groep van patiënten met OXFOS complex I, III en IV deficiënties. Hoofdstuk
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7 bevat de resultaten van deze studie, dat wil zeggen veel DNA veranderingen 
die geen ziekte veroorzaken. Sequentieanalyse van 7 additionele MRP genen 
onthulde een nieuwe mutatie in MRPS22. De ziekteverwekkende rol van deze 
mutatie in de mitochondriële aandoening van de patiënt wordt beschreven in 
hoofdstuk 8. MRPS22 is klaarblijkelijk onmisbaar voor effectieve mitochondriële 
eiwitsynthese, ook al is het eiwit evolutionair niet goed geconserveerd. Dus 
eiwitten zoals MRPS22, waarvoor overeenkomstige eiwitten in bacteriën en 
andere lagere soorten ontbreken, zouden niet buiten beschouwing gelaten 
moeten worden tijdens onderzoek naar mitochondriële ziekten.
Conclusies
Tot slot reflecteert hoofdstuk 9 op de verkregen resultaten en bespreekt de 
richting van toekomstig onderzoek naar gecombineerde OXFOS complex 
I, III en IV deficiënties. Dit proefschrift toont aan dat het lokaliseren van de 
ziekteveroorzakende mutatie bij patiënten met gecombineerde complex I, III en IV 
tekorten in veel gevallen nog immer een ingewikkelde en moeizame onderneming 
is, ondanks de aanzienlijke vooruitgang op dit gebied. De huidige aanpak zorgde 
tot nu toe voor opheldering van het genetische defect bij 8 van de 33 patiënten, 
inclusief 4 nieuwe mutaties. MtDNA mutaties waren verantwoordelijk voor 
mitochondriële ziekte in 12% van de patiënten, terwijl de resterende 88% derhalve 
nDNA mutaties herbergen. Toekomstig onderzoek middels grootschalige DNA 
sequencing technieken zal ons ongetwijfeld de broodnodige verdere inzichten 
bieden in de complexe en enigszins raadselachtige processen die ten grondslag 
liggen aan het adequaat functioneren van het OXFOS systeem. Tevens verwacht en 
dient men beduidend meer ziektegenen te vinden om de talrijke nog onopgeloste 
zaken te kunnen verklaren. De nucleaire gendefecten die tot dusver gerelateerd 
zijn aan gecombineerde OXFOS deficiënties zijn zeer waarschijnlijk slechts het 
topje van de ijsberg.
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The only people with whom 
you should try to get even are 
those who have helped you. 
John E. Southard
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